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Recomeça… 
Se puderes, 
Sem angústia e sem pressa. 
E os passos que deres, 
Nesse caminho duro 
Do futuro, 
Dá-os em liberdade. 
Enquanto não alcances 
Não descanses. 
De nenhum fruto queiras só metade. 
E, nunca saciado, 
Vai colhendo 
Ilusões sucessivas no pomar 
E vendo 
Acordado, 
O logro da aventura. 
És homem, não te esqueças! 
Só é tua a loucura 
Onde, com lucidez, te reconheças. 
 
Miguel Torga, Diário XIII 
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Abstract 
Magnetic hyperthermia (MHT) therapy is a cancer treatment that takes advantage of 
the ability of magnetic nanoparticles (MNPs) to produce heat when exposed to an 
alternating magnetic field (AMF). The use of targeted (functionalized) MNPs for MHT has 
been explored, but generally with limited efficiency. In many cases, a combination with 
chemotherapeutic agents was suggested to improve MHT outcome (and vice-versa). The 
use of MHT to treat glioblastoma multiforme (GBM, a very aggressive type of brain 
tumour) has been approved by the European Medicines Agency. Yet, the improvement on 
the overall survival of GBM patients, although significant, is insufficient, and death is still 
the most probable outcome within less than 2 years after diagnosis. The overexpression 
of the chemokine receptor, CXCR4, in a range of cancer cells, namely, GBM and 
leukaemia, among others, has been related to tumour development, growth and 
metastasis, making CXCR4 an appealing target for cancer diagnosis and treatment. 
Particularly, CXCR4-targeted MNPs have been tested for cancer diagnosis, but still have 
not been tested for cancer treatment. With this in mind, it was our purpose to functionalize 
MNPs with anti-CXCR4 antibodies (targeted particles) to produce highly efficient cytotoxic 
MHT in cancer cells, while minimizing the toxicity in normal cells. 
We optimized the conditions for the functionalization of the MNPs with anti-CXCR4 
by testing direct covalent binding of antibodies to poly(acrylic acid)-coated MNPs, or by 
affinity binding of antibodies to proteins (streptavidin (STR) or protein A (PA)) covalently 
immobilized on the MNPs surface (STR– or PA–MNPs). Our results demonstrated 
successful covalent binding of proteins to the MNPs, a process that depended on the 
concentration of coupling agents and protein. STR and PA on the MNPs allowed the 
affinity immobilization of antibodies, showing the linker protein functionality was not 
compromised during conjugation. However, PA–MNPs maintained higher stability, 
probably due to the oriented binding of the antibody. Thus, PA–MNPs further 
functionalized with anti-CXCR4 antibodies were selected to set-up the conditions for MHT 
treatments. These MNPs proved to be insufficient for obtaining efficient temperature rise 
in MHT studies, so bigger particles (MPs) with the same linker protein were selected for 
the targeted MHT experiments. 
The studies on Jurkat cells showed that a purely CXCR4-targeted approach 
underperformed in the MHT studies, resulting in limited toxicity in cancer cells. The 
efficiency of this approach was then improved by providing cells with a boost of magnetic 
material of a non-targeted origin (SPIONs). The cells internalized a sufficient amount of 
SPIONs to increase the magnetic material, boosting the heating during an optimized AMF 
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application of 1 h. This way, remarkable decreases in cell viability were observed, 
following two distinct death pathways depending on the temperature conditions during the 
MHT treatment. When a necrotic pathway was followed, a long-lasting, null cell viability 
was maintained, while for the apoptotic samples a slight recovery was observed, 
supporting a more efficient outcome for the necrotic route. This strategy was subsequently 
applied to a GBM in vitro model, adjusting the magnetic content with SPIONs due to lower 
surface expression of CXCR4. Again, the MHT treatment established herein resulted in 
long-lasting, null cell viability, and only features of a necrotic signature were observed. 
Furthermore, the developed strategy proved safe for normal cells, as demonstrated by 
control experiments on normal cells from human kidney, HK-2 cell line.  
Overall, the combination of targeted and non-targeted nanoparticles for MHT resulted 
in remarkable toxicity in cancer cells, while keeping normal cells nearly undamaged. This 
strategy is a rare example of efficient MHT in a mono-therapeutic context, proving 
interesting and promising for future in vivo studies. 
Keywords: magnetic hyperthermia, CXCR4, cancer treatment, targeted-
nanoparticles 
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Resumo 
A hipertermia magnética (MHT) é um tratamento anticancerígeno que explora a 
produção de calor por nanopartículas magnéticas (MNPs) expostas a um campo 
magnético alternado (AMF). A utilização de MNPs direcionadas (funcionalizadas) em 
MHT tem sido estudada, mas geralmente tem eficácia limitada. Em muitos casos, a 
combinação com agentes quimioterapêuticos foi sugerida como forma de melhorar o 
efeito da MHT (e vice-versa). O uso de MHT para o tratamento do glioblastoma 
multiforme (GBM, um tipo de tumor do cérebro muito agressivo) foi aprovado pela 
Agência Europeia do Medicamento. Ainda assim, a melhoria da sobrevida dos pacientes 
com GBM não é suficiente, e a morte, em menos de 2 anos após o diagnóstico, ainda é o 
desfecho mais provável. A sobre-expressão do recetor de quimiocinas, CXCR4, em 
vários tipos de tumores, nomeadamente GBM e leucemia, entre outros, foi associada a 
desenvolvimento e crescimento tumoral e, ainda, a metastização, fazendo do CXCR4 um 
alvo apelativo para o diagnóstico e tratamento do cancro. Em particular, MNPs 
direcionadas para o CXCR4 foram testadas em diagnóstico do cancro, mas não para o 
tratamento de tumores. Sendo assim, foi nosso objetivo funcionalizar MNPs com 
anticorpos anti-CXCR4 (partículas direcionadas) para produzir MHT citotóxica, de 
elevada eficácia em células tumorais, com toxicidade mínima em células normais.  
As condições de funcionalização das MNPs com anticorpos anti-CXCR4 foram 
otimizadas testando a ligação covalente de anticorpos a MNPs revestidas com ácido 
poliacrílico, ou por química de afinidade entre os anticorpos e as proteínas (streptavidina 
(STR) ou Proteína A (PA)) imobilizadas covalentemente à superfície das MNPs. Os 
resultados demonstraram que a ligação covalente de proteínas às MNPs foi bem 
sucedida, num processo dependente das concentrações de reagentes de acoplamento e 
de proteína. A STR e a PA das MNPs permitiram a imobilização de anticorpos por 
afinidade, demonstrando que a funcionalidade da proteína de ligação não foi 
comprometida durante o processo de imobilização. No entanto, as PA–MNPs mantiveram 
maior estabilidade, provavelmente devido à ligação orientada do anticorpo à PA. 
Portanto, as PA–MNPs funcionalizadas com anticorpos anti-CXCR4 foram selecionadas 
para estabelecer as condições para os estudos de MHT. Estas MNPs não conduziram a 
um aquecimento suficiente nesses estudos pelo que, consequentemente, selecionamos 
MNPs maiores com a mesma proteína de ligação para os estudos subsequentes de MHT 
direcionada.  
Os estudos em células Jurkat demonstraram que uma estratégia puramente 
direcionada para o CXCR4 não funcionou nos testes de MHT, resultando em toxicidade 
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limitada em células cancerígenas. A eficácia desta estratégia foi, portanto, incrementada 
utilizando um impulso de material magnético de origem não-direcionada (SPIONs). As 
células internalizaram quantidade suficiente de SPIONs para aumentar o seu material 
magnético, impulsionando o aquecimento durante uma aplicação do AMF optimizador, 
durante 1 h. Como consequência, foram observados decréscimos notáveis na viabilidade 
celular, seguindo duas vias de morte celular distintas, de acordo com as condições de 
temperatura atingidas durante o tratamento de MHT. Enquanto a morte celular por 
necrose conduziu a uma viabilidade celular nula e prolongada, para as amostras 
apoptóticas, foi observada uma pequena recuperação, o que sugere maior eficácia para a 
morte por necrose. Esta estratégia foi subsequentemente aplicada a um modelo in vitro 
de GBM, ajustando o conteúdo magnético com SPIONs devido à menor expressão de 
CXCR4 neste modelo. Da mesma forma, o tratamento de MHT desenvolvido neste 
trabalho, resultou em viabilidade celular nula e prolongada, observando-se apenas 
características de necrose. Adicionalmente, a estratégia desenvolvida provou ser segura 
para células normais, como se demonstra com os testes em células normais de rim 
humano, HK-2. 
No geral, a combinação de MNPs direcionadas e não-direcionadas para MHT 
resultou numa toxicidade extraordinária em células cancerígenas, mantendo as células 
normais praticamente sem danos. Esta estratégia constitui um raro exemplo de MHT 
eficaz num contexto de mono-terapia, interessante e promissora para futuros estudos in 
vivo. 
Palavras-chave: hipertermia magnética, CXCR4, tratamento do cancro, 
nanopartículas direcionadas 
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This thesis is divided in four chapters: 
 
Chapter I – General Introduction and Main Objectives the Thesis  
In this chapter, general concepts that are important for the understanding of the work 
in magnetic hyperthermia are explained. Some cancer facts are provided and the in vitro 
models selected for the experimental part are described. A number of in vitro, in vivo, and 
clinical studies are discussed to provide an insight on the current knowledge and the main 
needs on this topic.  
The main objectives of the thesis are described at the end of this section.  
 
Chapter II – Experimental Section, Results and Partial Discussions 
The manuscripts produced under the scope of this dissertation, either submitted or 
not, are presented in this chapter. 
 
Chapter III – Integrated Discussion and Conclusions 
This chapter provides an integrative discussion of the main results obtained, and their 
relevance within the framework of magnetic hyperthermia for cancer treatment. 
The final part of this chapter includes the main conclusions that may be drawn from 
the studies included in this dissertation. 
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General Introduction 
Plenty of the currently on-going scientific research in the field of medicine is devoted 
to cancer, namely its prevention, detection and treatment. Notwithstanding the small 
progress observed in the past decade, cancer has escalated to one of the leading causes 
of death worldwide, being one of the most important and dreadful contemporary problems 
of mankind. Cancer treatments are sometimes very difficult to endure due to the elevated 
incidence of important and debilitating secondary effects. Therefore, further efforts are 
needed to fight this complex disease in a more efficient and less toxic way. Innovative 
treatments have been recently proposed to treat cancer, among them magnetically-
induced hyperthermia, which employs the heating ability of magnetic nanoparticles under 
the influence of an alternating magnetic field to kill cancer cells. The use of targeted 
strategies, i.e., therapies directed to cancer cells, offers the opportunity of minimizing the 
side effects, which are common in conventional cancer therapies. In summary, directing 
magnetic nanoparticles to accumulate in tumours so that cancer cells can be “cooked” to 
death sounds promising and appealing. As a researcher, it is particularly gratifying to have 
the possibility of contributing, even slightly, to improve the current armoury to fight this 
devastating condition. 
In this section, the thematic of this work is introduced and the latest developments 
are described to better understand the motivation and the purpose of the work herein 
presented. 
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1. Cancer at a glance 
Cancer is a generic term referring to a group of diseases that can affect any part of 
our body, characterized by rapid and uncontrolled cell growth. Although the precise origin 
of cancer is yet to unveil, it generally arises from a single cell that suffers DNA damage 
(mutation), escapes the repair mechanisms and becomes abnormal, rapidly multiplying as 
abnormal cells. This transformation is dependent both on genetic and environmental 
causes (exposure to chemical, physical and biological carcinogens). Ageing is also a risk 
factor for developing cancer. Some types of cancer have a tendency to spread to other 
locations, a process called metastization. The presence of metastases is normally 
associated with worse prognosis. 
1.1. Cancer statistics 
The most recent worldwide data collection on cancer refers to the year 2012, and 
was performed by the International Agency for Cancer Research, the cancer agency of 
the World Health Organization, under the GLOBOCAN project (Ferlay et al. 2015). This 
project aimed at granting a contemporary estimation of cancer incidence, mortality and 
prevalence for 184 countries worldwide. Overall, in 2012 only, an estimated 14.1 million 
new cancer cases were diagnosed, and 8.2 million people died with cancer (Ferlay et al. 
2015). In the United States (US), cancer is the second leading cause of death, right after 
heart disease, eventually ranking first if considering the age group between 40 and 80 
years old (Siegel et al. 2015). Annual cases of cancer are expected to rise to over 22 
million by 2030 (Bray et al. 2012). These data suggest that advances in prevention, (early) 
diagnosis, and treatment of cancer are urgently needed to avoid such statistics to be 
maintained or even aggravated. 
According to GLOBOCAN estimations, lung cancer was the most frequent and 
deadly type of cancer worldwide (Ferlay et al. 2015) —if considering women only, or, 
interestingly, Europe only (Ferlay et al. 2013), breast cancer was the most common one. 
Notably, when considering the individual age groups, higher death rates are found for 
leukaemia and brain tumours, in particular in US patients aged below 20 (Siegel et al. 
2015). In this introductory section, leukaemia and glioblastoma multiforme (GBM, the most 
common and most aggressive brain cancer) will be especially addressed, as we believe 
that magnetically-induced hyperthermia may become an important asset to treat these 
types of cancer. 
 
General Introduction 
5 
1.2. Leukaemia 
Leukaemia is a group of cancers of the hematopoietic and lymphoid tissues that 
generally begins at the bone marrow, resulting in increased numbers of white blood cells. 
Considering the cell type of origin, there are lymphoid and myeloid types of leukaemia. 
While lymphoid leukaemia affects cells committed to lymphoid lineages (namely T-
lymphocytes, B-lymphocytes, and natural killer cells), the myeloid type affects cells 
committed to myeloid lineages (namely megakaryocytes and erythrocytes, as well as 
granulocytes and macrophages). Depending on the speed of the onset of the disease, 
acute and chronic subtypes are described. Therefore, the majority of the leukaemia cases 
are categorized as Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia 
(AML), Chronic Lymphocytic Leukaemia (CLL) and Chronic Myeloid Leukaemia (CML). An 
overview of the haematopoiesis and the set points of each of these types of leukaemia are 
provided in Figure 1.  
 
 
Figure 1 - Leukaemia set points during haematopoiesis.  
Adapted from National Cancer Institute (https://www.cancer.gov/types/leukemia/patient/child-all-
treatment-pdq). 
 
Nearly 352,000 new leukaemia cases, and more than 265,000 deaths, were reported 
worldwide, in 2012 (Ferlay et al. 2015). Leukaemia is the most frequent type of cancer 
affecting children, with ALL at the top of the list. ALL is characterized by the 
overproduction of immature lymphocyte precursors, called lymphoblasts, which 
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accumulate and prevent the development of normal B- or T-lymphocytes (B-ALL or T-ALL, 
respectively). These blasts normally represent 1–2 % of bone marrow cells, but in ALL 
patients this percentage raises to more than 20 % and blasts are also found in peripheral 
blood, or even invading other organs, as a result of their uncontrolled proliferation. 
1.2.1. Available ALL therapies 
Modern ALL therapy uses high-dose chemotherapy, allogeneic haematopoietic stem-
cell transplantation (HSCT) and targeted therapies, and comprises three phases: 
remission-induction (4–6 weeks), consolidation (20–30 weeks) and maintenance (2 years 
or longer) (Inaba et al. 2013). However, ALL has a wide biological heterogeneity, which 
leads to different treatment needs depending on the patient’s age and overall status, 
ALL’s immunophenotype, and genetic studies (Bassan and Hoelzer 2011). A variety of 
chemotherapeutic drugs can be used for ALL treatment, normally in combination (namely 
vincristine, asparaginase, daunorubicin, methotrexate, cytarabin, etoposide, some 
glucocorticoids, such as dexamethasone or prednisone), under a number of different 
protocols (Inaba et al. 2013). Allogeneic HSCT is considered for patients with very high 
risk ALL. It refers to the use of haematopoietic pluripotent stem-cells collected from 
compatible healthy donors that are transplanted to the patient, normally after 
chemotherapy has destroyed the immune system (Bassan and Hoelzer 2011). For some 
ALL subtypes, targeted therapies with tyrosine-kynase inhibitors, such as imatinib or 
nilotinib, may be useful. Surgery, radiation and monoclonal antibodies may be interesting 
approaches in special cases. 
Higher incidence of ALL is reported in children (6 in each 10 cases), but an estimated 
80 % of deaths from ALL occur in adults (4 in each 5 deaths), showing the need for more 
efficient approaches to eradicate ALL. 
1.2.2. Jurkat cells as an in vitro model of T-cell leukaemia 
Around 1500 models of leukaemia are available for in vitro studies, 600 of which are 
well characterized and have been considered robust in vitro models (Drexler et al. 2000, 
MacLeod and Drexler 2008). In particular, Jurkat cell line (clone E6-1, ATCC® TIB-152) 
is one of the most frequently used acute lymphoblastic leukaemia model for mechanistic 
studies. This immortalized cell line was collected and maintained from the peripheral 
blood of a 14-year old boy relapsing from T-ALL (Schneider et al. 1977). Its easy 
manipulation and evident response in the context of apoptosis, for example, makes it an 
appealing model for many types of studies, such as the staining with the early apoptosis 
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marker, Annexin-V, for flow cytometry (Martin et al. 1995). Figure 2 shows microscopy 
images of Jurkat cells at different cell densities. 
  
Figure 2 - Bright field images of Jurkat cells at low (left) and high (right) cellular density.  
The circles and arrows highlight the cell agglomerates formed when cells multiply to high density.  
 
The mechanisms of action and the therapeutic effects on ALL of many 
chemotherapeutic agents have been studied in vitro using Jurkat cells. As an example, a 
study by da Silva et al. has shown that methotrexate, doxorubicin, daunorubicin and 
vincristine, many of which are currently used in ALL treatment, induced pronounced 
apoptotic cell death in Jurkat cells (da Silva et al. 1996). The same study demonstrated 
lack of efficiency of 6-mercaptopurine and prednisolone for ALL treatment. More recently, 
lapatinib—an inhibitor of the tyrosine-kinase activity of the epidermal growth factor 
receptor (EGFR) family members, which has been approved in 2007 by the Food and 
Drug Administration (FDA) for the treatment of breast cancer—has been tested in Jurkat 
cells, demonstrating its potential to be used in leukaemia therapy (Chen et al. 2016b). 
Another example is the recent suggestion of Articulatin-D, a ribosome-inactivating protein 
extracted from the mistletoe (Viscum articulatum), as a promising agent for leukaemia 
treatment (Mishra et al. 2016). The studies performed in Jurkat cells and, in parallel, in 
peripheral blood mononuclear cells demonstrated selective cytotoxicity in cancer cells 
(Mishra et al. 2016). These recent studies highlight the present reliability on Jurkat cells as 
suitable in vitro models of ALL.  
1.3. Glioblastoma multiforme 
The cancers of the brain and the central nervous system (CNS) accounted for around 
256,000 new cases worldwide (1.8 % of total new cases), nearly 74 % of which resulted in 
death in 2012 (Ferlay et al. 2015). These numbers show that, even though their incidence 
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rate is low, these cancers have a very high mortality rate. Amongst the various types of 
brain tumours, glioblastoma multiforme (GBM, Figure 3), also called glioblastoma, stands 
out as the most frequent and most malignant type of primary brain tumours. They are also 
known as high-grade (i.e. fast-growing; grade IV) astrocytomas as they arise from star-
shaped cells called astrocytes. The presence of necrotic cells and increased blood flow 
(angiogenesis) around the tumour are key histological features of GBM (ABTA 2016). 
GBM’s malignancy is related to their ability to metastasize inside the brain, but these 
tumours rarely spread outside the CNS. Although a small amount of GBM can be called 
secondary, as they develop from less malignant (grades II or III) astrocytoma forms, most 
GBM (90–95 %) are called primary or de novo as they are diagnosed without a known 
less malignant precursor lesion. These types are also associated with different age 
groups: while secondary glioblastomas predominate in patients aged under 45, primary 
glioblastomas are more frequent in patients aged over 55 (ABTA 2016).  
  
Figure 3 - Glioblastoma multiforme: schematic representation and magnetic resonance 
imaging.  
The red arrows indicate the tumour mass, appearing red in the schematic representation and 
appearing as black masses in the magnetic resonance imaging. Adapted from 
http://mayfieldclinic.com/PE-Glioma.htm 
 
1.3.1. Clinically available glioblastoma therapies 
The high malignancy and fast-growth of GBM demand a very aggressive treatment 
approach, generally combining resection surgery, radiation and chemotherapy as first line 
treatment (Stupp et al. 2005, Weller et al. 2014).  
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Surgery is a fundamental element in the management of GBM treatment, both for 
diagnostic (biopsy) and therapeutic purposes. Maximal resection of the tumour mass, 
specially its core that can be resistant to radiation and chemotherapy, helps diminishing 
the incidence of symptoms arising from the presence of the tumour, but generally a 
complete resection is not possible due to the tentacle-shaped cells composing it (Weller et 
al. 2014). Chemotherapy, radiation and immunotherapy are then used, combined or not, 
to control the growth of the remaining tumour cells (ABTA 2014). 
Radiotherapy is directed to the tumour and surrounding area, and it can be boosted 
with localized radiation, which is more protective of normal cells. It generally lasts for 5–6 
weeks (5 a week) (Stupp et al. 2005).  
The most used chemotherapeutic agent to treat GBM is temozolomide (TMZ). Since 
2005, the standard treatment combines a 6-week course of TMZ with radiation therapy, 
followed by TMZ alone for 6–12 cycles (Stupp et al. 2005). Other alkylating agents have 
been approved for the treatment of GBM, namely Carmustine (1,3-Bis(2-chloroethyl)-1-
nitrosourea), and Lomustine (N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea). Patients 
whose tumours display O-6-methylguanine-DNA methyltransferase (MGMT) promoter 
methylation have better prognosis, as they are more responsive to these alkylating agents 
(Hegi et al. 2005). Because chemotherapeutic agents can affect normal cells as well, 
chemotherapy is normally associated to high incidence of adverse effects. 
Other innovative therapies have been proposed for the treatment of GBM, namely 
immunotherapy and magnetic hyperthermia (see Section 2), a therapy that has been 
certified in the European Union to treat glioblastoma with NanoTherm® Therapy 
(MagForce 2016a). Phase II clinical trials showed a 7.2–8.6 month increase in overall 
survival of GBM patients (Maier-Hauff et al. 2011). 
Despite the plethora of combined treatments for GBM, the prognosis for this type of 
cancer remains very unfavourable. Median survival of adult patients with GBM treated 
with concurrent TMZ and radiation therapy is about 14.6 months; the two-year median 
survival rate is 27 %. Overall five-year survival is 10 % (Stupp et al. 2009). These 
numbers confirm the urgent need for new and more efficient treatments for GBM. 
1.3.2. LN229 cells as an in vitro model of glioblastoma 
A number of glioblastoma cell lines from human origin are available, which can be 
grown in 2D or 3D configuration, for in vitro studies on the physiology, the diagnosis and 
the therapy of this aggressive type of brain cancer (Grotzer et al. 2016). Despite the 
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advantages of in vitro 3D cultures, the 2D models still represent a good starting point for 
therapeutic studies due to their affordable price, easiness of handling, and compatibility 
with high throughput screening (Das et al. 2015). The advantages and disadvantages of 
2D and 3D in vitro cultures are summarized in Table 1. 
Table 1 - Advantages and limitations of 2D and 3D in vitro cell culture 
In vitro 
culture 
method 
Advantages Limitations 
2D 
Easiness of culturing; 
Good viability levels; 
Easiness of imaging; 
Suitable for endpoint assays; 
Highly suitable with high throughput screening; 
Affordable when compared with other systems; 
Significant availability of 2D data. 
Lack of cell–cell and cell–stroma interactions;  
Lack of histological morphology of tumour of origin; 
Do not replicate heterogeneity seen in tumour 
regions; 
Different genetic makeup from the original tissue. 
3D 
Oxygen and nutrient gradient of tumours; 
Cell–cell and cell–stroma interactions; 
Histological morphology different from the 
tumour of origin; 
Hypoxia-induced cell cycle alterations 
reflecting microregions of tumours; 
High throughput-compatible 3D culture plates 
available. 
Assays are laborious; 
Requires higher drug concentrations compared with 
2D cultures; 
Requires advanced imaging systems; 
Relatively expensive compared with 2D cultures; 
High throughput screening compatibility still under 
development. 
Adapted from (Das et al. 2015) 
 
In particular, the LN229 cell line (ATCC® CRL-2611™) was first established in 1979 
from cells collected from a 60 year-old female patient with right frontal parieto-occipital 
GBM. This adherent, highly tumorigenic, cell line is commonly used in studies involving 
apoptosis, and is capable of growing in 2D or 3D configuration (Figure 4). The LN229 cell 
line has been genetically characterized and its resistance/ sensitivity to a number of 
chemotherapeutic drugs has been established (Weller et al. 1998). 
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Figure 4 - LN229 cells cultured in 2D or 3D configurations. 
a) Bright field microscopy image of a high-density monolayer of LN229 cells. b) a 48-h LN229 3D 
culture (spheroid). 
 
This cell line has been extensively used in previous reports as an in vitro model of 
GBM, in particular, in the search for therapeutic improvements to the current standard 
protocols for GBM treatment, which are highly fallible. For example, Combs et al. found 
that LN229 cells are highly resistant to radiation therapy alone, and higher therapeutic 
efficiency was observed for a combination of TMZ and cetuximab, an anti-EGFR antibody 
(Combs et al. 2007). This cell surface receptor was found to be overexpressed in many 
GBM samples collected from patients (Shinojima et al. 2003). More recently, Elhag et al. 
demonstrated that the effects of TMZ in LN229 cells could be potentiated by silibinin, a 
hepatoprotective drug, via down-regulation of the inhibitor of apoptosis, survivin (Elhag et 
al. 2015). Another interesting study used nanoparticles as nanocarriers, serving as 
transfection agents, of an antisense microRNA to silence the microRNA21, an oncogene 
overexpressed in many cancer cells. The resulting knockdown of microRNA21 in LN229 
cells significantly potentiated TMZ effect in this cell line (Ananta et al. 2015). 
1.4. CXCR4 expression and cancer 
The ability of cells to migrate directionally is often moved by the secretion of small 
molecules (chemokines) that bind to a subset of G-protein-coupled receptors at the cell 
membrane (chemokine receptors), a process called chemotaxis. One of such receptors, 
CXCR4, is a seven transmembrane protein that is endogenously activated by the stromal 
cell-derived factor-1 (SDF-1 or CXCL12), which can rapidly induce receptor endocytosis to 
initiate the signalling cascade (Signoret et al. 1997). The CXCR4 has been initially 
described as a co-receptor for CD4-independent HIV infection (Endres et al. 1996, Feng 
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et al. 1996). Further studies established an important role for the CXCL12/CXCR4 axis in 
haematopoiesis, leukocyte chemotaxis and cerebellar development (Zou et al. 1998).  
The CXCR4 antagonist, AMD3100, also known as Plerixafor, has been clinically 
tested as a stem cell mobilizer, in combination with granulocyte-colony-stimulating factor, 
after chemotherapy in lymphoma or multiple myeloma patients, with good results and low 
toxicity (Jagirdar et al. 2015). Later, CXCR4 was found to be overexpressed in many 
types of cancer, such as leukaemia (Mohle et al. 1998), GBM (Sehgal et al. 1998), breast 
cancer (Muller et al. 2001) and prostate cancer (Taichman et al. 2002), among others. In 
this sense, CXCR4 overexpression is related with increased tumour aggressiveness, 
proliferation, metastization and, consequently, bad prognosis (reviewed in (Zlotnik 2006, 
Domanska et al. 2013)). CXCR4 has consequently been proposed as a potential target for 
ALL (de Lourdes Perim et al. 2015) and GBM treatment (Terasaki et al. 2011). A recent 
work reports the use of AMD3100 as part of the therapeutic regimen of a 66-year old 
patient diagnosed with GBM that has been in clinical and radiological remission 
30 months from initiating the adjuvant treatment (Rios et al. 2016). 
The leukaemia and glioblastoma in vitro models previously described, i.e., Jurkat and 
LN229 cells, express different levels of CXCR4, as assessed by western blotting using a 
monoclonal anti-human-CXCR4 antibody (Figure 5). When compared to another GBM cell 
line, U87MG (ATCC® HTB-114™), LN229 cells display intermediate levels of that 
chemokine receptor while Jurkat cells exhibit the highest levels of CXCR4, in line with a 
previous study (Huang et al. 2014). The discrepancy in CXCR4 expression between 
suspension and adherent cell lines has been previously discussed (Huang et al. 2014). 
The exposed facts confirm the suitability of those cell lines for in vitro studies in the scope 
of CXCR4 targeting for leukaemia and GBM treatment. 
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Figure 5 - CXCR4 expression in two human glioblastoma cell lines, LN229 and U87MG, 
assessed by western blot.  
The dashed line represents CXCR4 expression in the positive control, Jurkat cell line. 
 
2. Magnetic hyperthermia for cancer treatment 
“Quæ medicamenta non sanant, ferrum sanat; quæ ferrum non sanat, ignis sanat; 
quæ vero ignis non sanat, insanabilia reputari oportet.” – Hippocrates 
“Those diseases which medicines do not cure, the knife cures; those which the knife 
cannot cure, fire cures; and those which fire cannot cure, are to be reckoned wholly 
incurable.” 
2.1. Introducing the (magnetic) hyperthermia concept 
The term “hyperthermia” refers to the local, regional, or generalized increase in body 
temperature (T). This concept has been put in practice centuries ago by the ancient 
civilizations and has been applied for cancer treatment since the 19th century (Moyer and 
Delman 2008). Cancer cells are known to be more sensitive than normal cells to elevated 
T, in the range of 41–43 ºC, due to their faster cellular division rate, entering a 
programmed cell death mode (apoptosis) (Hervault and Thanh 2014). Although the 
cellular targets of hyperthermia are not yet fully understood, it is known that it affects the 
membranes, the cytoskeleton, protein synthesis and, even, DNA repair (reviewed in 
(Hildebrandt et al. 2002)). Some genes were found overexpressed after hyperthermia 
treatment, namely the heat-shock protein (HSP) family, a situation known to generate 
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thermo-resistance, also called thermo-tolerance, that results in impaired cell death 
through hyperthermia. At a T below 42 ºC, tumour blood flow is increased, which may be 
useful for the simultaneous delivery of chemotherapeutic agents, enhancing their anti-
tumour effect (Wust et al. 2002). Furthermore, increased blood flow results in increased 
oxygenation, a factor known to enhance radiosensitivity (Maier-Hauff et al. 2011). At a T 
above 42 ºC the tumour’s blood flow decreases, while increasing in the normal tissues, 
which leads to lower dissipation rate and, therefore, faster T rise in tumours, compared to 
normal tissues (Song 1984). In the case of thermoablation, when the T rises above 46 ºC, 
the cell death mode changes to a necrotic cell death (generally accompanied by 
inflammation), which may affect normal cells, as well (Hildebrandt et al. 2002). 
Since the late 1950s, magnetic implants have been proposed for cancer treatment, 
as thermo-seeds, under an alternating magnetic field (AMF), a process called magnetic 
hyperthermia (MHT) (Gilchrist et al. 1957). Later, in 1979, Gordon et al. were the first to 
introduce the concept of “intracellular” MHT by using dextran-coated magnetite submicron 
particles, which were internalized by cancer cells in vivo, to increase the T of tumours 
submitted to a strong AMF (Gordon et al. 1979). These authors suggested that cell 
membranes efficiently act as thermal insulators, preventing the heat generated by the 
internalized particles from dissipating to the surroundings. This concept, therefore, implied 
that, when an external magnetic field is applied, the heat generated by a single particle 
inside a cell could effectively kill it.  
The first clinical trials on MHT were undertaken in Japan, in the 1990s, by Kobayashi 
and Kida, in malignant glioma patients locally implanted with a FePt metal alloy, reporting 
encouraging results, in particular for the generally considered unresectable tumours 
(Kobayashi and Kida 1990). More recently, many MHT studies have been performed 
using magnetic nanoparticles (MNPs) as magnetic heaters, testing different sizes, 
coatings, targeting systems, cancer cells, and AMF parameters to reach the best protocol 
to induce cancer-cell death. Andreas Jordan and co-workers have reported consistent and 
pioneering studies, performing in vitro, in vivo, and clinical studies on MHT for cancer 
treatment. He founded the company MagForce Nanotechnologies AG, which currently 
detains an European Medicines Agency (EMA) approval for using and testing MHT as 
cancer treatment (NanoTherm™ therapy), in particular primary and recurrent GBM 
(MagForce 2016a). So far, the results collected from phase II clinical trials were promising 
and indicated a significant 8-month prolongation of patient life (Maier-Hauff et al. 2011). 
More studies were conducted to test MHT’s efficacy and safety for the treatment of 
prostate cancer (Johannsen et al. 2007). Figure 6 shows a schematic representation of 
magnetic hyperthermia treatment. 
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Figure 6 – Schematic representation of a magnetically-induced hyperthermia treatment 
using magnetic nanoparticles.  
The MNPs may be injected directly into the tumour or intravenously, with the possibility of being 
magnetically or biologically guided to the tumour. The application of an alternating magnetic field 
generates heat that kills tumours cells, shrinking or eradicating the tumour. Adapted from (Andrade 
et al. 2011) 
 
Although MHT is mostly used for cancer treatment, some other interesting 
applications have been recently suggested, namely the treatment and control of bacterial 
(Chen et al. 2016a), fungal (Chudzik et al. 2016) and parasitic (Grazu et al. 2012) 
infections, or as a disruptor of β-amyloid protein aggregates that trigger Alzheimer’s 
disease (Loynachan et al. 2015). A search in Pubmed.gov under the keywords “magnetic 
hyperthermia cancer” showed that around 2100 reports have been published since its 
introduction in 1950, nearly half of which in the past six years (since 2010). Therefore, 
MHT for cancer treatment has been experiencing increased interest by the scientific 
community in recent years. This fact was particularly promoted by the expansion and 
growth of nanotechnology era, through the development of new and efficient materials for 
MHT, followed by its application to in vitro, in vivo and clinical studies. 
2.2. Magnetic nanoparticles for MHT  
The magnetic properties of some naturally occurring materials, such as loderstone, 
have been noticed thousands of years ago due to their rare ability to attract iron. These 
rocks, also called magnetes or magnetis back then, because they were extracted in a 
region named Magnesia, are mainly composed of magnetite (Fe3O4) and maghemite (-
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Fe2O3). Their natural orientation towards the earth’s geographical poles led to their use as 
direction tools, that later gave rise to the compass (Du Trémolet de Lacheisserie 2005). 
The magnetic properties of the materials arise from their basic building blocks, the 
atoms, through the magnetic fields (named magnetic moments) eventually produced by 
the movement of their unpaired electrons in response to an applied magnetic field (Du 
Trémolet de Lacheisserie 2005). In this sense, diamagnetic materials—frequently known 
as non-magnetic—have all their electrons in pairs, so their atoms possess no permanent 
magnetic moment, resulting in very low magnetic susceptibility (<0), which is defined as 
the magnetization in response to a magnetic field (Pamme 2006). Copper, silver and gold 
are examples of diamagnetic materials. Paramagnetic materials, like oxygen and platinum 
salts, have unpaired electrons that align with the external magnetic field direction, 
therefore, exhibiting positive susceptibility values (>0) (Pamme 2006). Once the 
magnetic field is removed, neither diamagnetic nor paramagnetic materials retain any 
magnetic properties. On the other hand, ferromagnetic materials (e.g. iron, cobalt and 
nickel), also called ferromagnets, have unpaired electrons that tend to align with the 
external magnetic field direction, generating a large magnetic susceptibility (»0) and, 
therefore, being strongly attracted to magnetic fields and becoming magnetized (Pamme 
2006). This magnetization of ferromagnets is retained once the magnetic field is removed, 
therefore behaving like permanent magnets. Their strong magnetic properties are also a 
consequence of the presence of domain regions in the ferromagnetic materials separated 
by boundaries called domain walls (multi-domain materials), which ensure keeping an 
overall lower energy state. As the volume of the material decreases, it may reach a critical 
diameter below which it becomes unfavourable to keep the domain walls, and single-
domain particles are created (Dutz and Hergt 2013). Whenever the size of the magnetic 
particles falls between 1 and 100 nm at least in one dimension, they are called MNPs.  
Specifically, MNPs made of ferri- (Fe3+) or ferro- (Fe2+) magnetic materials below a 
critical size value (typically ~10–20 nm diameter) may exhibit, at room temperature, an 
unique magnetic property known as superparamagnetism (Bedanta and Kleemann 2009); 
this critical diameter varies between different materials. When exposed to an external 
magnetic field, the atomic magnetic moments of superparamagnetic iron oxide 
nanoparticles (SPIONs) align along the field direction, achieving high susceptibility (Lu et 
al. 2007). Once the magnetic field is removed, SPIONs behave like a non-magnetic 
material exhibiting no magnetic memory (i.e., no remanence), which minimizes the 
interactions between any two MNPs, yielding stable colloidal dispersions (Pamme 2006). 
SPIONs are, therefore, preferable materials for a number of applications in the biomedical 
General Introduction 
17 
field, namely for tumour imaging, magnetic targeting, targeted drug-delivery, 
magnetofection, and MHT (Zhao et al. 2013). Some nanoparticle clusters (multi-core 
nanoparticles) cannot be described by a specific behaviour, rather sharing characteristics 
of both ferrimagnetic and superparamagnetic nanoparticles, being also interesting 
materials for MHT induction (Dutz and Hergt 2014). 
2.2.1. Requirements for biomedical applications  
The main requirements for the biomedical application of MNP preparations are low 
toxicity, ability to escape the reticulo-endothelial system (RES) and low protein adsorption 
(Yang et al. 2012). Therefore, when optimizing iron oxide nanoparticles (IONPs) for their 
use in biomedical applications, some issues need to be addressed namely their size, 
stability in biofluids (tendency for aggregation and protein corona formation), possible 
toxicity, pharmacokinetics and pharmacodynamics within the body (Yang et al. 2012), as 
well as the specificity for target tissues.  
Size 
The size of the MNPs is an important factor to consider for in vivo or clinical studies. 
MNPs sized above 200 nm are rapidly taken up by the RES and accumulate in the liver 
and spleen; on the other hand, MNPs sized below 6 nm are filtered by the kidney 
(Bychkova et al. 2012). Furthermore, there are natural differences between the 
neovasculature of tumours (defective and leaky) and that from normal tissues, which lead 
to increased supply of nutrients and oxygen to the tumour site. While tumour vasculature 
fenestrations can be hundreds of nanometres in size, normal vessels openings’ are 
generally less than 10 nm (Iyer et al. 2006). This phenomenon has practical implications 
as nanoparticles sized above 10 nm can extravasate and accumulate in the tumour, but 
not in the normal tissues. Also, the slow venous return and lower lymphatic clearance 
characteristic of tumours, favour MNPs’ retention in the tumour (Stylianopoulos 2013). 
This extensive leakage and low clearance are known as the enhanced permeability and 
retention (EPR) effect, characteristic of many solid tumours (Iyer et al. 2006).  
At a cellular level, the upper size limit consensually considered for nanoparticle 
uptake through endocytosis is 500 nm (Rejman et al. 2004, Bychkova et al. 2012). As 
already mentioned, nanoparticles sized above 200 nm are generally uptaken by 
specialized cells of the RES through phagocytosis, a specific type of endocytosis 
(Saptarshi et al. 2013). 
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Surface coating stabilization 
Apart from their unusual electronic, optical and magnetic properties, the usefulness of 
nanoparticles predominantly arises from their small size and large surface area (Yang et 
al. 2012). In the case of bare IONPs, these characteristics, along with their metallic 
composition, contribute to a high degree of chemical instability and reactivity to air, 
resulting in surface oxidation and, consequently, loss of magnetism (Wu et al. 2015). This 
issue may be surpassed by providing the IONPs with a coating layer that limits the access 
of oxygen to the highly reactive core surface. In this sense, a core-shell type of 
nanoparticles is the most common one, whereby a highly reactive iron oxide core is 
protected by an organic (e.g. polymer) or inorganic (e.g. silica, carbon, gold) shell (Figure 
7). Alternatively, IONPs can be dispersed or embedded in an organic/ inorganic matrix 
forming composites where the nanoparticles are fixed in space (Lu et al. 2007). 
  
Figure 7 - Schematic representation of a core-shell iron oxide nanoparticle.  
The iron oxide magnetic core is embedded in a coating layer that provides the IONPs with 
protection, stability, biocompatibility and the possibility of functionalization with targeting ligands 
(e.g. antibodies), while affecting their biodistribution profile. 
 
The most studied protective coatings, so far, are silica or polymers, in particular, 
poly(ethylene glycol) (PEG) and dextran (and its derivatives). Other polymers include 
poly(acrylic acid) (PAA), alginate and chitosan, among others (Yoffe et al. 2013). Different 
coating materials are described in detail in a recent review by Wu et.al (Wu et al. 2015). 
Besides being an important step towards lower IONP degradability, surface coating also 
brings other advantages such as increased colloidal stability and biocompatibility (Figure 
7). Furthermore, in an in vivo context, the chosen coating can minimize opsonisation, 
affecting the circulation half-life of nanoparticles and, consequently, their biodistribution. 
Such effects can be observed when using PEGylated nanoparticles (Albanese et al. 2012). 
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The selected coatings provide the nanoparticles with different surface charges that 
vary depending on the medium’s pH (Vilas-Boas et al. 2015). Studies suggest that surface 
charge may also influence nanoparticle’s uptake, with positively charged nanoparticles 
being more internalized than negatively charged ones, while neutral nanoparticles were 
not internalized (Villanueva et al. 2009, Bychkova et al. 2012). These different 
internalization rates result in higher toxicity of the positively charged nanoparticles and 
lower toxicity, as well as prolonged half-life, of negatively charged ones; neutral 
nanoparticles are considered the most biocompatible. 
Specific coatings also provide the IONPs with reactive groups (e.g. carboxylic groups 
that stabilize the particles by electrostatic repulsion) that allow particle functionalization or 
conjugation with biomolecules, such as proteins, to actively pinpoint specific tissues or 
biological targets (Yoffe et al. 2013). The term “functionalization” is sometimes used 
meaning “surface coating” [e.g. (Wu et al. 2008)] but, in this work, “surface coating” and 
“functionalization” refer to different layers of the IONPs (Figure 7). 
Conjugation with biomolecules 
A targeted use of IONPs in cancer diagnosis and treatment is generally preferred and 
desirable in order to diminish or avoid the possible side effects on healthy body tissues. 
While the EPR effect is considered a passive targeting strategy, the active targeting is a 
strategy that requires a ligand (conjugated to the MNP) directed to a cell-surface receptor, 
which in many cases results in efficient internalization of targeted MNPs by receptor-
mediated endocytosis (Pirollo and Chang 2008). Active targeting can be controlled by the 
use of safe and stable surface coatings and by providing the IONPs with targeting 
molecules such as proteins, like streptavidin (STR) or antibodies [e.g., anti-EGFR, 
Herceptin], or peptides, DNA or RNA (Sperling and Parak 2010). Although STR is not a 
targeting molecule to be used in cancer recognition it may be used as an intermediate for 
high affinity binding of antibodies, similarly to staphylococcal Protein A (PA) (Martins et al. 
2012).  
There are a number of strategies to achieve nanoparticle conjugation, depending on 
the chemical functional group present on the IONPs, generally carboxylic (–COOH) or 
amine (–NH2) groups. Among them, one of the most widely used is the so-called EDC 
crosslinking chemistry. It consists of a water-soluble carbodiimide (1-ethyl-3-(-3-
dimethylaminopropyl) carbodiimide hydrochloride, EDC) that activates the carboxylic 
groups (generally from the IONPs) to an unstable intermediate that will react with the 
primary amine groups (generally from the protein to bind). The efficiency of this reaction is 
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increased in the presence of a chemical modification reagent, N-hydroxysulfosuccinimide 
(sulfo-NHS), that converts the activated carboxyl groups in amine-reactive NHS esters, 
more stable for bioconjugation with primary amines by means of a new amide bond 
(Sperling and Parak 2010). A schematic representation of the EDC-sulfo-NHS crosslinking 
reaction is provided in Figure 8. 
  
Figure 8 - Schematic representation of the EDC-sulfo-NHS crosslinking chemistry for IONPs 
functionalization with biomolecules.  
Adapted from (Sperling and Parak 2010) 
 
Tumour accumulation and internalization 
While it’s known that the functionalization, the surface coating, and the size of the 
nanoparticles play a role in their biodistribution and cell uptake, the different contribution 
of each factor is still not clear. Some studies using functionalized nanoparticles reached 
contrasting conclusions on the effect of the targeting biomolecule in tumour accumulation 
and cell uptake. For example, the use of Herceptin-conjugated PEGylated nanoparticles 
(ca. 100 nm), compared to non-targeted ones, did not result in more efficient accumulation 
in the tumour, but resulted in enhanced internalization by the tumour cells (Kirpotin et al. 
2006). These nanoparticles’ efficient accumulation has been ascribed to the presence of 
PEG as coating agent, which prolonged their circulation time, therefore, contributing for 
efficient tumour accumulation through the EPR effect (Pirollo and Chang 2008). On the 
other hand, a more recent study on the influence of size, targeting and PEGylation on the 
IONPs biodistribution and tumour accumulation in vivo, reported no influence of PEG on 
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tumour accumulation (NDong et al. 2015). Contrarily to the in vitro studies, where the 
cellular homing was mainly dependent on the targeting moiety, the key determinant factor 
for tumour accumulation of IONPs in vivo was the IONPs size. In fact, the 100 nm IONPs, 
both targeted and non-targeted, PEGylated and non-PEGylated, were similarly cleared 
from the blood and accumulated in the liver. On the other hand, the smaller IONPs (ca. 
30 nm) accumulated significantly more in the tumour than the 100 nm IONPs, an effect 
further enhanced by the presence of the targeting moiety (NDong et al. 2015). Another 
study suggested that targeted polymeric nanoparticles accumulated more in tumours 
overexpressing the cancer target, while for tumours with lower expression the effect was 
mainly dependent on the nanoparticle’s size (Lee et al. 2010). These conflicting results 
highlight the need for more studies to further establish the influence of these variables in 
the accumulation of nanoparticles in the tumour. 
Nanoparticle’s endocytosis is thought to be a two-step process that starts with 
nanoparticle’s adhesion to the cell surface followed by nanoparticles internalization 
(Lesniak et al. 2013). Besides the size limitation, the adhesion to cells and subsequent 
uptake of nanoparticles depends on the presence of targeting moiety, which may trigger 
receptor-mediated endocytosis (Pirollo and Chang 2008). The protein adsorption layer 
(known as protein corona) formed by the proteins in the medium where nanoparticles 
interact with cells (e.g. blood proteins in vivo, serum proteins in vitro) contributes for lower 
adhesion, consequently resulting in lower uptake. However, if a targeting moiety is 
present on the nanoparticles, the adhesion of the nanoparticles to the cells will fully 
depend on the target recognition (Lesniak et al. 2013). The adhesion of MNPs, particularly, 
can be improved by means of the external contribution of a static magnetic field, to 
magnetically concentrate the MNPs and promote MNPs internalization (magnetofection) 
(Prijic et al. 2012, Ma et al. 2015). 
2.2.2. How do MNPs produce heat under an AMF? 
The heat generation by MNPs exposed to an AMF, i.e., the conversion of 
electromagnetic to thermal energy, is governed by different mechanisms, depending, 
mainly, on the size of the MNPs used. For multi-domain IONPs (e.g. ferromagnets) 
submitted to AMF, heat production arises mainly from hysteresis losses, i.e., the energy 
dissipated during a magnetization cycle. The higher the saturation magnetization (Ms) of 
the MNPs, the bigger amount of heat is dissipated (Figure 9). When the AMF is removed, 
these MNPs behave as permanent magnets, keeping some magnetization (remanent 
magnetization), as opposed to SPIONs that display no remanent magnetization after AMF 
removal (Figure 9) (Hervault and Thanh 2014).  
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Figure 9 - Dependence of magnetization (M) on the applied magnetic field amplitude (H).  
a) Typical hysteresis loop of a multi-domain IONP, showing the area that represents the energy 
dissipated during a magnetization cycle, where Ms is the saturation magnetization and Mr is the 
remanent magnetization. b) Typical magnetization curve for SPION, showing the absence of 
remanent magnetization (Mr) when the AMF is removed. 
 
For single-domain MNPs (including SPIONs), heat generation is due to two different 
modes of relaxation losses known as Néel and Brownian relaxation. Néel relaxation 
derives from the orientation of the magnetic moments in the same direction as the applied 
AMF, for each field oscillation. Brownian relaxation comes from the friction of the whole 
particle’s rotation in its dispersing medium (Lee et al. 2015). Therefore, the contribution of 
each relaxation mode for heat dissipation will depend on the size and mobility of the 
MNPs: while Néel relaxation varies exponentially with the core volume, being more 
significant for small diameters, Brownian relaxation varies linearly with the viscosity of the 
solvent and the hydrodynamic volume of the MNPs (Khandhar et al. 2011). As an 
example, in tumour tissue, the internalization of MNPs by cancer cells prevents Brownian 
relaxation from occurring, so only Néel relaxation will contribute to heat generation (Dutz 
and Hergt 2014).  
The heating ability of different MNPs to be used for magnetic hyperthermia is 
commonly described by the specific absorption rate (SAR), also known as specific loss 
power, which is the quantification of power dissipation of magnetic nanomaterials under a 
specific AMF (W·g-1):  
ܵܣܴ ൌ ܥ݉ி௘
∆ܶ
∆ݐ  
being C the specific heat capacity of the sample, ݉ி௘ is the iron mass per unit volume, 
and ∆ܶ/∆ݐ the initial slope of the T vs. time curve (Hervault et al. 2016). SAR is affected 
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by a number of parameters, such as size, size distribution, chemical composition, 
concentration, and also frequency (݂) and amplitude (H) of the applied AMF. Clustering 
MNPs seems to improve their SAR with respect to the individual SPIONs composing the 
magnetic nanoclusters (MNCs) (Maity et al. 2011). The potential of MNPs to be used in 
hyperthermia applications is often defined by their SAR value. However, care must be 
taken while comparing SAR values due to the wide range of different equipment available 
for AMF application, and the diversified protocols for SAR quantification (Hervault and 
Thanh 2014). 
2.2.3. Use of iron oxide nanoparticles in the clinical context 
The use of IONPs in the clinical context is currently a reality, in particular as iron-
replacement therapies (e.g. Ferrisat, DexFerrum or Ferumoxytol). Other formulations have 
also been approved as imaging agents by the FDA or the EMA (e.g. Feridex I.V., Resovist, 
Combidex, among others), but the majority of them has, curiously, been discontinued in 
the US and European markets (Anselmo and Mitragotri 2016), as their diagnostic utility 
was not demonstrated in the pivotal studies (Wang 2015). Several clinical trials are 
currently ongoing, assessing MNP formulations for diagnosis or therapy in many different 
conditions. As an example, the FDA approved drug Ferumoxytol is being tested as an 
enhanced contrast agent for magnetic resonance imaging (MRI) in some types of cancer 
and multiple sclerosis (NIH 2015). 
2.3. In vitro MHT studies 
For the MNPs to be approved for in vivo or clinical trials their potentiality needs first to 
be tested in vitro, in cancer and/or normal cell models, to have an initial impression on the 
tolerability and toxicity of the MNPs and the selected AMF conditions. Accordingly, many 
reports in the literature refer to the use of MHT to kill cancer cells in vitro.  
Establishing comparisons between in vitro MHT studies can be a challenge due to 
the widely different conditions used by different authors, which in some cases is 
aggravated by the lack of information concerning a certain aspect of the procedure. 
Tables 2 and 3 compile examples of in vitro MHT studies, presenting the most relevant 
parameters that may have contributed for the observed outcome. Amongst them, we 
highlight the cell line that was tested, the IONPs’ characteristics (namely, the coating 
employed, the size, and initial concentration), the targeting system (if applicable), the AMF 
parameters, and the reported T reached. Different cell lines may have distinct 
susceptibilities to heat, meaning that similar T profiles may lead to varying outcomes in 
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unrelated cells. One major contributing factor for such differences may be the divergent 
induction of HSP synthesis amongst cell lines (Hildebrandt et al. 2002). As explained in 
section 2.2.1., the targeting moiety and the characteristics of the nanoparticles will have 
an impact on their interaction with cells (and subsequent internalization). The importance 
of the concentration of MNPs used for the MHT test is related to the possible secondary 
effects that may derive from it lately, in an in vivo context. The reached T is a vital element 
to be disclosed in an MHT study due to the obvious impact it may have in the observed 
outcome. Another parameter that is also important to refer is the time-point at which cell 
viability levels are assessed. In fact, evaluating cell viability levels right after MHT 
application may lead to deceiving results, particularly if high enough T has not been 
reached or maintained for enough time. The heat insult may cause a sudden deregulation 
in cellular metabolism, which can be recovered if the stimulus is removed and conditions 
are favourable (Hildebrandt et al. 2002). In this section, we will discuss and review some 
in vitro reports on MHT, using targeted or non-targeted nanoparticles, either in a mono-
therapeutic context or in combination with other therapies, primarily focusing on the 
observed outcome after MHT application. 
2.3.1. In vitro non-targeted MHT studies 
Many of the reports found in the literature concerning in vitro MHT refer to the use of 
either plain or surface-coated nanoparticles in many different cell lines. Table 2 compiles a 
number of these studies, specifying for each of them the parameters that mostly influence 
the observed outcome after MHT, which will be our primary focus. 
Amongst the selected reports on non-targeted in vitro MHT, some studies stand out 
due to the attained low cell viability levels. As an example, Qu et al. reported 10 % MCF-7 
(breast cancer) cell viability 24 h after using low concentrations of iron oxide nanoclusters 
doped with manganese and/or zinc ions for MHT. The observed low cytotoxicity in the 
absence of AMF and the elevated MHT efficiency show great potential for further in vivo 
studies using these magnetic nanoclusters (MNCs) (Qu et al. 2014). Sadhukha and co-
workers described similar MHT efficiencies (around 10 % cell viability) in breast (MDA-
MB-231) and lung (A549) cancer cell lines after a 30 min MHT treatment. The lower field 
amplitude used in this study, compared to the previous one, was compensated by a 
higher magnetite dose. Less prominent cell viability results were reported in the same 
study, whenever AMF was applied for shorter periods and lower T was reached 
(Sadhukha et al. 2013a). A study developed by Oh and co-workers used similar 
conditions: approximate amounts of magnetic material, comparable AMF conditions, and 
the same breast cancer model. Depending on the applied magnetic field amplitude, 
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distinct T was reached and, consequently, distinct cell death pathways were activated. 
While 42 °C led to an apoptotic pathway, reaching 52 ºC led to cell death through a 
necrotic pathway. Surprisingly, although a T of 52 ºC is expected to lead to complete cell 
death, both T resulted in similar cell viability levels (ca. 20 %) (Oh et al. 2016). A study by 
Guardia et al. describes the use of PEGylated nanocubes with very high SAR values to kill 
epidermoid carcinoma cells (KB cells) with a 1 h AMF application. The observed outcome 
strongly varied from 0–75 % cell viability, depending on the iron amount internalized by 
the cells, which further influenced the reached T. Complete cell death was reported when 
the T of 65 ºC was reached (Guardia et al. 2012), which may be a risky T to achieve in a 
clinical situation. A very interesting in vitro study addressed the influence of the tumour 
size, simulated by prostate cell clusters, on the efficiency of MHT (Hedayati et al. 2013). 
These authors concluded that a minimum of 250,000 cells, loaded with 200 pg of iron 
each, is required to reach 41.3 ºC, the lowest T that produced a cytotoxic effect. If 
translated to an in vivo situation, a minimum tumour size of 1 mm3 would be required for 
an efficient MHT treatment (Hedayati et al. 2013), which may imply the failure of MHT to 
treat microscopic tumours or metastasis. These observations are, in fact, in agreement 
with Rabin’s theoretical calculations that show that the “intracellular hyperthermia” concept 
firstly introduced by Gordon (Gordon et al. 1979) had no biophysical basis, as the cell 
membranes could not prevent heat conduction (Rabin 2002). Curiously, many of the 
reported studies do not refer to the concept of intracellular hyperthermia, in the sense that 
AMF is applied right after adding the magnetic materials to the cells. In fact, for the 
intracellular version of hyperthermia to be considered, a cells-plus-MNPs-incubation-time 
is necessary to allow particle’s internalization. Therefore, in these studies, the outcome is 
independent of the interaction of MNPs and cells (e.g. (Maity et al. 2011, Sadhukha et al. 
2013a, Qu et al. 2014, Ma et al. 2015, Oh et al. 2016)). 
A number of studies combine MHT with chemotherapy in a synergistic way. Alvarez-
Berrios et al. tested carboxymethyldextran-coated MNPs to perform MHT in breast (MDA-
MB-468), colorectal (Caco-2) and ovarian (A2780) cancer cells lines. Depending on the 
applied field amplitude, two different T were reached (43 or 45 ºC), consequently yielding 
two distinct outcomes. In particular, the breast cancer cell line seemed more resistant to 
the effects of heat. These authors, therefore, potentiated the MHT effects in combination 
with the proteasome inhibitor, bortezomib (Alvarez-Berrios et al. 2014). To explore the 
potentiality of IONPs as drug carriers, Quinto et al. synthesized phospholipid-PEG coated 
IONPs loaded with doxorubicin for combined MHT and chemotherapy in a human cervical 
cancer cell line (HeLa). They observed an additional decrease on cell viability from ca. 
55 % to ca. 30 %, still leaving some margin for improvement (Quinto et al. 2015). 
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Many other authors found lower MHT efficiency in a mono-therapeutic context but 
explored MHT effects in combination treatments. In this sense, Espinosa et al. developed 
MNPs that generate heat in response to AMF and to laser excitation, the so-called 
photothermal therapy (PTT). When performing only MHT, the samples reached 40 ºC, 
resulting in low MHT efficiency (75 % cell viability in a human ovarian cancer cell line, 
SKOV-3). This effect was potentiated by the bimodal approach that led to an 
enhancement of the treatment efficiency to only 15 % cell viability due to the higher T 
reached, 50 ºC (Espinosa et al. 2016). The same group had previously developed 
magnetic liposomes that are also responsive to photodynamic therapy (PDT) due to the 
inclusion of a photosensitizer agent. Both therapies resulted very effective either alone or 
in combination (Di Corato et al. 2015). Another example of double-effector MNPs was 
provided by Yoo et al. using MNPs that combine heating ability with enhanced ROS 
production. Cell viability decreased from 75 to 35 % when passing from mono-therapy to 
the combined approach (Yoo et al. 2012). In an interesting study, Yin and colleagues 
enhanced MHT efficiency by combining it with miRNA delivery to promote cell death 
through apoptosis. MNPs internalization was intensified by magnetofection, a 
magnetically-promoted incorporation of MNPs into cells. The AMF application resulted in 
an increase in T to 43 ºC, directly resulting in 60 % cell viability. This result was improved 
to 34 % cell viability in the combination therapy (Yin et al. 2014). Ma et al. observed that a 
static magnetic field can reduce the heating ability of MNPs under an AMF. By combining 
an alternating with a static magnetic field, these authors reduced the MHT effects in a 
surrounding area, while restricting the MHT effect to a specific area of interest. Although 
the reported MHT efficiencies in this in vitro study were modest, the proposed strategy 
shows great potential for in vivo applications (Ma et al. 2015). 
The in vitro studies discussed herein suggest that the MHT efficiency in a mono-
therapeutic context may be rather limited, therefore needing to be combined with other 
therapies to further enhance the treatment’s outcome.  
 
  
Table 2 - Conditions used, and outcome observed, in in vitro studies using magnetically-induced hyperthermia alone or combined with chemotherapeutic agents. 
Cell line 
MNPs Incubation 
time (h) 
[Fe] 
sample 
MNPs 
excess 
removal 
(Y/N) 
Magnetic field Reported 
T (ºC) 
% Cell viability 
(h after MHT) Obs. Reference Coating Size nm (technique) 
Initial conc. 
(g·L-1) 
F 
(kHz) 
H  
(kAm-1) 
Time 
(min)
A549 - 17.3±8.1 
(XRD) 
15 1 NR N 750 0.8 10 47 35 (0) LDH When using Pt-Fe-HAP for 
MHT=20% cell viability 
(Tseng et 
al. 2014) 
A549; MDA-
MB-231 
Myristic 
acid + 
pluronic 
F127 
12±3 (TEM); 
185 (DLS) 
1.5 (Fe3O4) 0 NA N 386 6 5, 15, 
30 
43–46 60, 30, 10, 
resp. (2) LDH 
Similar efficiency for both cell 
lines; no colonies formed two 
weeks after MHT 
(Sadhukha 
et al. 
2013a) 
DU-145 Starch 108 (DLS) 0.015, 
0.075, 0.1, 
0.15 (Fe) 
16–24 5, 70, 
105, 199 
pg/cell, 
resp. 
Y 150 88 30 37–49.1 <10 for T>43ºC 
(10–14 days) 
clonogenic 
survival assay 
PDL as facilitator of MNPs 
uptake; different reached T 
according to cell pellet size and 
iron/cell 
(Hedayati 
et al. 2013) 
HeLa Phospho 
lipid-PEG 
14 (TEM) 0.1 (Fe) 0 NA N 355 24 60 43–46 55 (24) MTT When using DOX-MNPs=32% 
cell viability 
(Quinto et 
al. 2015) 
Jurkat PMAO-
PEG 
12, 13 or 16 
(TEM); 
20 (DLS) 
0.49, 0.6 
and 0.6, 
resp. 
0.25 NA N 373 14 15 38.5, 39.8 
and 43.5, 
resp. 
50, 30 and 30, 
resp. (0.5) ATP 
levels 
If normalized to cells+MNP-AMF, 
cell viability= 40, 70 and 85%, 
resp. Optimization of MNP size to 
enhance MHT 
(Khandhar 
et al. 2012) 
KB Pullulan 
acetate 
10 (TEM); 
25.8±6.1 
(DLS) 
NR 0 NR N 100 10.4 20 45 or 47 45ºC=45, 
47ºC=20 (24) 
MTT 
L929 (normal) cell viability without 
AMF application=90% 
(Gao et al. 
2010) 
KB PEG 19±3 (TEM); 
37±11 (DLS) 
1 (Fe) 24 25–170 
pg/cell 
1.3–5.4 
g Fe/L 
Y 110 20 60 43 0–75 (NR) TB 2–4 g Fe/L to reach 40–
45ºC=50% cell viability; at 5 g 
Fe/L reach 65ºC=0% cell viability 
(Guardia et 
al. 2012) 
MCF-7 triethylene 
glycol: 
triethanol 
amine 
44 (TEM) 0.5 (Fe) 0 NA N 240 89 60 45 25 (48) MTT Nanoclusters also suitable for 
MRI in vivo; for the unclustered 
10nm MNPs=40% cell viability 
(Maity et 
al. 2011) 
MCF-7 MgO 75 (TEM) 2 mM 2 8 mM Y 765 20 15 41–45 NR MNPs cytotoxicity: 2mM=80% 
and 8mM=55% cell viability (SRB) 
(Chalkidou 
et al. 2011) 
MCF-7 Chitosan 20–30 
(TEM) 
1 0 NA N 267 24 120 44–45 60 (1) TB L929 (normal)=93% cell viability (Thorat et 
al. 2014) 
MCF-7; 
MCF-7/ADR 
mPEG−P
CL 
100 (TEM 
& DLS) 
0.2 (MNCs); 
0.1 (MNPs) 
0 NA N 114 115 15 NR 10 (24) MTT MnFe2O4/MNC vs. 
Mn0.6Zn0.4Fe2O4/MNC, both with 
similar MHT efficiencies, in both 
cell lines. Use low AMF exposure 
times 
(Qu et al. 
2014) 
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Table 2 - Conditions used, and outcome observed, in in vitro studies using magnetically-induced hyperthermia alone or combined with chemotherapeutic agents. 
Cell line 
MNPs Incubation 
time (h) 
[Fe] 
sample 
MNPs 
excess 
removal 
(Y/N) 
Magnetic field Reported 
T (ºC) 
% Cell viability 
(h after MHT) Obs. Reference Coating Size nm (technique) 
Initial conc. 
(g·L-1) 
F 
(kHz) 
H  
(kAm-1) 
Time 
(min)
MDA-MB-
231 
PEG bis 
(amine) 
15 (TEM) 0.2 5 NR N 500 37.4 60 43±1 75 (NR) WST-8 When using GdTx-MNPs for 
MHT=36% cell viability (GdTX as 
sensitizer to MHT) 
(Yoo et al. 
2012) 
MDA-MB-
231 
Chitosan 18 (TEM); 
90 (DLS) 
1.5 (Mn and 
Fe) 
0 NA N 307 50 (then 
to 20 or 
35) 
30 42 or 52, 
resp. 
22.5 and 18, 
resp. (24) 
Annexin-V/Pi 
24, 48 and 72h incubation with 
MNPs yielded 100, 112 and 146 
pg Fe/cell; for MHT42 apoptosis 
and for MHT52 necrosis 
(Oh et al. 
2016) 
MDA-MB-
468; Caco-
2; A2780 
Carboxy 
methyl 
dextran 
69±4 (TEM) 3.8 0 NA N 233 29.4 or 
34.7 
30 43 or 45, 
resp. 
MDA-MB-468 
43ºC=50, 
45ºC=30; Caco-2 
43ºC=35, 
45ºC=15; A2780 
43ºC=25, 45ºC=5 
(48) TB 
Reported enhanced effects of 
bortezomib in combination with 
MHT (cell viability lower than 20% 
in all cases). 
(Alvarez-
Berrios et 
al. 2014) 
SKOV-3 Liposomes 150 (TEM); 
200 (DLS) 
0.5–5 mM 
(Fe) 
1–4 20 
pg/cell 
(for the 
5mM Fe)
Y 700 24 30 NR 10 (12) 
AlamarBlue 
When combined with PDT=0% 
cell viability; missing MNP conc. 
of reported cell viability data 
(Di Corato 
et al. 2015) 
SKOV-3 Gallol-
PEG 
20 (TEM) 0.2 mM (Fe) 2 6 
pg/cell 
Y 520 20 10 38–40 75 (NR) 
AlamarBlue 
When combined with PTT=15% 
cell viability and T=50 ºC 
(Espinosa 
et al. 2016) 
SMMC-7721 - 17±2 (TEM) 1 0 NA N 50 34 40 42, 44 and 
44.3 
75.4, 61.5 and 
53.6 (24) MTT 
Application of a static magnetic 
field to limit the heating to a 
restricted area 
(Ma et al. 
2015) 
U87-
EGFRvIII 
PEI 77±11 (DLS) 0.01 5 NR Y 225 5 45 44.1 60 (24) MTS; 
80 in spheroids 
Magnetofection was used to 
facilitate MNPs uptake; if 
combined with let-7a 
miRNA=34% cell viability (45% in 
spheroids) 
(Yin et al. 
2014) 
 NA – not applicable; NR – not reported; resp. – respectively 
TEM – transmission electron microscopy; DLS – dynamic light scattering; XRD – x-ray diffraction; MNCs – magnetic nanoclusters; MNPs – magnetic nanoparticles; HAP – hydroxyapatite 
PEG – poly(ethylene glycol); PEI – poly(ethylenimine); PMAO - poly(maleic anhydride-alt-1-octadecene); mPEG-PCL - monomethoxy-terminated poly(ethylene glycol)-b -poly-(ε-caprolactone) 
Cell viability tests – TB – trypan blue exclusion; MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction; MTS - 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium reduction; SRB – sulforhodamine B binding; WST-8 - 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium reduction 
PDT – photodynamic therapy; PTT – photothermal therapy. 
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2.3.2. In vitro targeted MHT studies 
Molecular targeting, along with the surface-receptor expression levels, has been 
described as the main factor affecting MNPs binding to cells in an in vitro situation (NDong 
et al. 2015). The overexpression of some surface-receptors in cancer cells compared to 
normal cells allows differential interaction of MNPs directed to that receptor by means of 
an antibody, a peptide sequence, or a ligand protein, a concept known as active targeting. 
In this sense, the preferential accumulation (and possible internalization) of MNPs in 
cancer cells provides a robust strategy to kill cancer cells with minimal predicted effects in 
normal cells. Table 3 collects some features of in vitro studies directed to selected cancer 
targets. 
Liao et al. developed alginate-coated IONPs functionalized with D-Galactosamine (D-
Gal), to specifically target liver cancer cells. These authors observed enhanced MHT 
efficiency of targeted, compared to non-targeted, MNPs in HepG2 cells, decreasing cell 
viability levels from 60 %, with non-targeted, to an impressive 5 % with D-Gal-MNPs (Liao 
et al. 2015). Unfortunately, a correlation between the observed outcome and the T 
reached during MHT cannot be established due to lack of data concerning the observed T. 
Moreover, some doubts remain concerning this particular targeted strategy, as some 
studies report the asialoglycoprotein receptor, to which D-Gal binds to, to be widely 
expressed in normal hepatocytes (Shi et al. 2013). Similarly high MHT efficiency was 
observed in a study using very low MNPs’ concentration for MHT mediated by Luteinizing 
Hormone–Releasing Hormone (LHRH)-targeted MNPs (Taratula et al. 2013). In this case, 
the samples reached 44 ºC and a 5 % cell viability rate of ovarian cancer cells expressing 
the LHRH receptor was reported. Interestingly, significantly lower internalized iron amount 
was necessary in this study (ca. 15 pg Fe/cell), as opposed to the previous one (ca. 365 
pg Fe/cell) (Liao et al. 2015), to lead to such prominent effect. This fact can be a 
consequence of the different number of cells used in the experiments (5 higher in 
(Taratula et al. 2013)) and/or possible distinct surface expression levels of each receptor.  
The folate receptor is a promising target for cancer treatment as it appears to be 
overexpressed in many cancer types with limited expression in healthy tissues (Zwicke et 
al. 2012). Some groups have been investing in the development of MNPs functionalized 
with folate/ folic acid for actively targeted MHT in recent years (Sivakumar et al. 2013, 
Sadhasivam et al. 2015, Gupta et al. 2016). The reported outcomes were very distinct, 
ranging from 20–65 % cell viability levels, with no reference to the achieved T (Sivakumar 
et al. 2013, Gupta et al. 2016), which hampers comparisons and prevents conclusions 
regarding MHT efficiency. In any case, these authors found improvements to their strategy 
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when combined with chemotherapeutic drugs, either 5-fluouracyl (Sivakumar et al. 2013), 
or doxorubicin (Gupta et al. 2016). A study by Sadhasivam et al. describes a significant 
increase in lactase dehydrogenase (LDH) leakage, compatible with cell death, for ovarian 
cancer cells (HeLa) reaching 43–45 ºC after a 10-min AMF application (Sadhasivam et al. 
2015). Interestingly, normal fibroblasts were not affected under similar conditions. 
The human epidermal growth factor receptor 2 (HER2, also known as ERBB2) is an 
oncogene found to be overexpressed in nearly 20–30 % of the breast tumours. HER2+ 
breast cancers are recognised as more aggressive and more deadly, with improved 
prognosis since Trastuzumab, a blocking antibody, was introduced in the clinical context 
[reviewed in (Mitri et al. 2012)]. Therefore, targeting the HER2 receptor for MHT studies 
seems a promising approach that some research groups have been developing (Ito et al. 
2004, Zhang et al. 2011, Mi et al. 2012). These studies have used the same breast cancer 
cell model, SK-BR-3, known to overexpress the HER2 receptor, and tested MNPs with 
resembling sizes (100–150 nm), providing an opportunity for comparison. Widely distinct 
outcomes were reported, attaining 25–60 % cell viability, depending on the AMF 
conditions and T reached. While Zhang et al. reported keeping the T around 37 ºC by the 
application of an intermediate AMF power, leading to a modest decrease to 60 % cell 
viability (Zhang et al. 2011), Ito and co-workers’ study using lower AMF power, observed a 
T rise to 42.5 ºC consequently showing significantly higher efficiency (down to 25 % cell 
viability) (Ito et al. 2004). In the study performed by Mi et al. the concept of “targeting” may 
be controversial, because the excess of free MNPs was not removed prior to MHT (Mi et 
al. 2012). Therefore, in this particular situation, the MHT effect (30 % cell viability) cannot 
be solely attributed to the targeting strategy, as it depended not only on the bound MNPs 
but also on the ones that remained in suspension. It is, therefore, expectable that applying 
the same treatment to normal cells (i.e., with low or absent HER2 positivity) may lead to 
similar cytotoxic outcome. Unfortunately, this is not the only study in which there has been 
this misunderstanding. Although some studies provide information on the behaviour of 
normal cells exposed to similar MHT conditions (Sadhasivam et al. 2015, Thomas et al. 
2015), others fail to remove the excess of MNPs primarily incubated with cells without 
testing normal cells (Mi et al. 2012, Sivakumar et al. 2013, Kruse et al. 2014). This fact 
may have serious implications on the observed outcome that may, therefore, be 
fallaciously enhanced by the presence of MNPs that are not necessarily interacting with 
the cells. Thomas et al. targeted the CD44 receptor, in SCC7 murine cells, using 
hyaluronic-acid-conjugated MNPs. The T increase to 42 ºC during 10 min led to 
interesting MHT efficiency (30 % cell viability) while keeping normal (CD44 negative) cells 
undamaged (Thomas et al. 2015). Noteworthy for future studies, Kruse et al. used 
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CREKA—a tumour homing peptide—functionalized MNPs to target the fibrin-associated 
plasma proteins mostly present in the interstitial space within tumours. These authors 
reported additive effects when combining the chemotherapeutic agent, cysplatin (Kruse et 
al. 2014). 
Other interesting targets that have been tested for targeted MHT include the cancer 
stem cell marker, CD90 (Yang et al. 2016), the 3 integrin receptors (Shah et al. 2014), 
and EGFR (Domenech et al. 2013). Yang and co-workers used antibody-functionalized 
MNPs to target the CD90 receptor in cancer stem cells and to separate them from the 
CD90 negative counterparts using magnetic-activated cell sorting (MACS). The cells 
targeted with MNPs were then submitted to a 1-h AMF application leading to increased T 
(44 ºC) and 30 % cell viability. These authors suggested that these MNPs, reported as 
thermosensitive magnetoliposomes, are also suitable for MRI purposes (Yang et al. 2016). 
Shah and colleagues proposed targeting 3 integrin receptors in glioblastoma cells 
(U87MG) using MNPs functionalized with tumour homing peptide, iRGD (arginine-glycine-
aspartic acid). The MNPs’ uptake was enhanced using magnetofection and the MHT was 
proposed as a strategy to enhance the intracellular delivery of a mitochondria-targeting 
pro-apoptotic peptide. The reached T was not reported and cell viability levels decreased 
to 40 % in the combined treatment, which corresponds to a discrete increase of the effect 
obtained in the absence of MHT (Shah et al. 2014), leaving margin for some criticism on 
whether a “magnetic hyperthermia” effect was effectively observed. 
The EGFR is a well know target in many cancer treatment modalities, being the first 
cancer target against which monoclonal antibodies were developed, cetuximab and 
panitumumab, to be used in metastatic colorectal and head and neck cancer therapy 
(Martinelli et al. 2009). Domenech et al. have taken advantage of the overexpression of 
this receptor in breast cancer cells to test MNPs conjugated to its natural ligand, the 
epidermal growth factor (EGF), for MHT purposes. A 25 % decrease in cell viability was 
reported for cancer cells targeted with EGF-MNPs and submitted to an AMF for 1h, 
without significantly damaging normal cells that followed the same protocol. Temperature 
changes were not reported (Domenech et al. 2013). A previous study from the same 
group targeted EGFR using MNPs conjugated to an anti-EGFR antibody observing a 
prominent reduction of cell viability to 5 % after AMF application during 2 h. In this report, 
a T rise was not detected and the authors hypothesized the effects to be due to the 
rotation of the MNPs under the AMF that led to mechanical damage. Also noteworthy in 
this study, the targeted MNPs exhibited significant cytotoxicity even without AMF 
application (down to 40 % cell viability), which decreases the contribution of the AMF 
effect to the observed outcome (Creixell et al. 2011). 
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As for the non-targeted MHT in vitro studies, the targeted MHT strategies described 
herein showed limited treatment efficiency, which could be enhanced by a combination 
with chemotherapeutic drugs. In fact, for the only study performed in GBM cells, targeted-
MHT efficacy was limited to a 60 % reduction in cell viability. Noteworthy, studies in 
normal cells are lacking to assure the treatment’s selectivity and safety, as less than one 
third of the studies tested the same targeted strategy in normal (control) cell lines. 
 
 
  
Table 3 - Conditions used, and outcome observed, in in vitro studies using targeted magnetic hyperthermia alone or combined with chemotherapeutic agents 
Functionalization Cell line 
MNPs 
Incubation 
time (h) 
[Fe] 
sample 
MNPs 
excess 
removal 
(Y/N) 
Magnetic field 
Reported 
T (ºC) 
% Cell 
viability 
(h after 
MHT) 
Obs. Reference 
Coating Size (nm) 
Initial 
conc. 
(g·L-1) 
F 
(kHz) 
H 
(kAm-1)
Time 
(min)
Anti-CD90a Huh7 PEG 10–20 
(TEM); 
130±4.6 
0.34 (Fe) 1 NA Y 200 NR 60 44 30 (24) 
MTT 
Thermosensitive 
magnetoliposomes; CD90+ 
separated from CD90_ by 
MACS and then treated 
with MHT 
(Yang et al. 
2016) 
Anti-EGFRa MDA-MB-
468; MCF-
7 
Carboxy 
methyl 
dextran 
14±3 
(TEM); 
78±8 
(DLS) 
5.0 1, 6, 10 13–21 
pg/cell 
Y 233 37.5 120 ND 5 (120) 
TB 
T rise not detected; cell 
viability with EGF-
MNPs<40% 
(Creixell et al. 
2011) 
CREKAb A549 Dextran 5–13 
(TEM); 
 
3 
(Fe3O4) 
NA NA N 292 58 30 NR 40  
(48 & 72) 
Calcein-
AM 
Incubation suspended 
cells+NP; reported 
additive effects of cysplatin 
to 20% cell viability after 
72h 
(Kruse et al. 
2014) 
EGFa MDA-MB-
231 
Carboxy 
methyl 
dextran 
61±29 
(DLS) 
0.3 
(Fe3O4) 
2 1.75 
pg/cell 
Y 233 42 60 Kept below 
37 
75 (48) 
CellTiter-
Blue 
184-B5 (normal) cell 
viability unchanged. 
Reported the effects to 
derive from ROS 
production 
(Domenech et 
al. 2013) 
Folateb MCF-7; 
G1 
Carboxy 
methyl 
cellulose 
100–150 
(TEM); 
80–200 
(DLS) 
2 and 4 NA NA N 305 18 60 NR 20 (24) 
TB 
If combined with 5-FU=5% 
cell viability 
(Sivakumar et 
al. 2013) 
Folatea HeLa 
(FR+) 
PEG 84.9 
(TEM) 
0.5 1 0.3 gL-1 N 750 0.8 10 43–45 - Reported LDH values of 
0.76 compared to 0.45 for 
untreated control; human 
fibroblasts not affected 
(Sadhasivam 
et al. 2015) 
Folic acidb HeLa Poly 
acrylic 
acid 
8–10 
(TEM) 
2 24 ≈250 
pg/cell 
(24h inc. 
w/ 0.3 
gL-1) 
Y 265 27 10 NR 65 (24) 
SRB 
When using DOX loaded 
FA-MNPs=50% cell 
viability; DOX-FA-
MNPs+AMF=10% cell 
viability 
(Gupta et al. 
2016) 
Galactosea HepG2 Alginate 109.1–
146.9 
(HD) 
0.5 4 364.4 
pg/cell 
Y 780 19 20 NR 5 (18) 
MTT 
Only applicable for hepatic 
tumours 
(Liao et al. 
2015) 
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Table 3 - Conditions used, and outcome observed, in in vitro studies using targeted magnetic hyperthermia alone or combined with chemotherapeutic agents. 
Functionalization Cell line 
MNPs 
Incubation 
time (h) 
[Fe] 
sample 
MNPs 
excess 
removal 
(Y/N) 
Magnetic field 
Reported 
T (ºC) 
% Cell 
viability 
(h after 
MHT) 
Obs. Reference 
Coating Size (nm) 
Initial 
conc. 
(g·L-1) 
F 
(kHz) 
H 
(kAm-1)
Time 
(min)
Herceptina SK-BR-3 Dextran 138±7.6 
(DLS) 
28.6 pg 
Fe3O4/ 
cell 
4 16.5 pg 
Fe3O4/ 
cell 
Y 360 9.6 30 42.5 25 (24) 
TB 
Cell viability recovered 
after 5 days in culture. 
When AMF was repeated 
24h after, cell viability 
<10% after 5 days 
(Ito et al. 
2004) 
Herceptina SK-BR-3 Dextran ≈100 
(DLS) 
0.1 3 ≈28 
pg/cell 
Y 163 35.8 20 Kept below 
37 
60 (6) 
Live-dead 
kit 
HMEC (normal) cells 
>90% cell viability 
(Zhang et al. 
2011) 
Herceptinb SK-BR-3 PLA-
TPGS/ 
TPGS-
COOH 
155.2±0.
17 (DLS) 
0.86; 
(177ug 
Fe) 
24 NA N 240 42 20 or 
30 
NR 30 (12) 
MTT 
If combined with 
docetaxel=10% cell 
viability 
(Mi et al. 
2012) 
Hyaluronic acida SCC7 
(CD44+) 
None vs. 
PEG 
10–20 
(TEM); 
81–272 
(DLS) 
0.1 1 NA N 368 1 10 42 30 (24) 
MTS 
For SAR experiments, 
2g·L-1 reached 42ºC; 
CD44- cell viability 
unchanged 
(Thomas et al. 
2015) 
iRGDb U87-
EGFRvIII; 
MDA-MB-
231 
PEI+ 
PEG 
46.8±2.3 
(DLS) 
0.02 24 NR Y 300 5 45 NR 40 (48) 
MTS 
Magnetofection to facilitate 
MNPs uptake; MHT as 
enhancer of peptide 
therapeutics 
(Shah et al. 
2014) 
LHRH peptideb A2780/AD PMAO+ 
PEI+ 
PEG 
≈40 
(TEM) 
≈90 
(DLS) 
0.015 
(Fe) 
12 14.9 
pg/cell 
Y 393 33.5 30 44 5 (48) 
Calcein-
AM 
Similar cell viability 
achieved with DOX loaded 
LHRH-MNPs combined 
with MHT at 40ºC 
Taratula et al. 
2013) 
NA – not applicable; ND – not detected; NR – not reported;  
TEM – transmission electron microscopy; DLS – dynamic light scattering; MACS – magnetic-activated cell sorting; MNPs – magnetic nanoparticles 
LHRH – Luteinizing Hormone–Releasing Hormone 
PEG – poly(ethylene glycol); PEI – poly(ethylenimine); PMAO - poly(maleic anhydride-alt-1-octadecene); PLA-TPGS - poly(lactide)-D-a-tocopheryl poly(ethylene glycol) succinate; TPGS-COOH – carboxyl group-
terminated TPGS; 
Cell viability tests – TB – trypan blue exclusion; MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction; MTS - 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium reduction; SRB – sulforhodamine B binding 
aMonotherapeutic context 
bCombination with chemotherapeutic agents 
34 
General Introduction 
35 
2.4. In vivo MHT studies 
In vivo studies on MHT refer to the use of MNPs that are injected into in vivo animal 
models previously inoculated with tumorigenic cells, which grow into tumours in a few 
days. Besides the different types and configurations of MNPs used (individual or 
organized in clusters or sticks), and the different tumours to treat (origin, size), variations 
are also found in the route of administration, normally intratumoural (IT) or intravenous 
(IV) injection. The administration route leads to differential distribution and accumulation of 
the magnetic materials, and a balance needs to be found between the effective tumour 
treatment and the appearance of secondary effects due to particle accumulation in vital 
organs, such as the liver, spleen and lungs. A collection of the most relevant aspects of 
some in vivo studies is provided in Table 4. 
Andreas Jordan and co-workers successfully treated malignant rat gliomas using 
magnetic hyperthermia (Jordan et al. 2006). They administered aminosilane-coated MNPs 
by IT injection and controlled the applied AMF to produce an increase in tumour’s T to 43–
47 ºC, in two AMF applications. The reported outcomes varied from a 1.7 to a 4.5 
increase in the mean survival of the treated rats, respectively, depending on the reached 
intratumoural T. Interestingly, these authors tested, similarly and in parallel, dextran-
coated MNPs that spread into the surrounding tissue shortly after MNPs injection, leading 
to inefficient tumour heating. On the other hand, the authors claim the aminosilane MNPs 
to specifically interact with the tumour cells forming deposits that allow consecutive MHT 
treatments after MNPs injection (Jordan et al. 2006). Ohno et al. had previously reported 
similar results with the same in vivo model using carboxymethylcellulose-coated MNPs, 
organized in a thin stick-type, directly introduced in the tumour, also a glioma. An average 
3 increase in the mean rat’s survival was observed using a 3-cycle protocol reaching 
44.4 ºC (Ohno et al. 2002). Drake et al. also performed a 3-cycle protocol in an in vivo 
MHT study using dextran-coated MNPs in BALB/c mice bearing colon tumours. They 
observed a significant 80 % reduction in the tumour’s size by day 3 post-MHT, and a 
delay in tumour’s growth after this time-point. Unfortunately the reached T was not 
reported. 
Huang et al. successfully treated squamous cell carcinomas inoculated in NCr nude 
mice with a tumour ablation efficiency of 78–90 %, without reporting secondary effects. 
The intravenously injected PEGylated MNPs accumulated with a 16:1 tumour to non-
tumour surroundings ratio, and the application of high power AMF led to an increase in the 
tumours’ T to 60 ºC in 2 min (42 ºC in the muscle that accumulated MNPs). These authors 
defended that the rapid increase to an ablative T, compared to longer heating periods at 
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lower T, protects the tumour surroundings from heat dissipation, decreasing the 
probability of secondary effects (Huang and Hainfeld 2013). A major concern regarding IV 
injection strategies may be the high accumulation of MNPs in the liver (higher than the 
tumour), which limits the treatment of tumours located in the vicinity of this organ.  
Contrasting with the previous study that defended rapid tumour ablation, Yang et al. 
observed complete tumour elimination in 27 % of the MHT treated mice, 70 days after IT 
injection with non-targeted MNPs. Three AMF cycles were necessary to achieve this 
result. Notably, when using anti-CD90 targeted MNPs, instead of the non-targeted ones, a 
significant increase to 78 % complete tumour elimination was observed. The tumours in 
this study were formed from liver cancer stem cells (CD90+) isolated from a hepatocellular 
carcinoma cell line by MACS. Therefore, the authors claim MHT to be efficient in cancer 
stem cell elimination (Yang et al. 2016), showing that, if overall magnetic content would 
not be an issue for effective MHT (Hedayati et al. 2013), it would be useful for elimination 
of isolated cells that may spread from the tumour. Also using targeted MNPs, Baldi et al. 
used an EGFR-targeted nanocarrier for in vivo hyperthermia purposes and found a 1.7 
increased mean survival of the treated animals, after five successive IT injections and 
AMF application cycles (Baldi et al. 2014). Unfortunately, this study lacks statistical power 
due to the very small size of the animal groups. Sadhukha and co-workers also reported 
on the use of EGFR-targeted MNPs (using a peptide) with a very peculiar application: to 
be inhaled for the localized treatment of lung cancer with MHT. Bioluminescent tumours 
were generated, using luciferase-transfected-A549 cells, and tumour growth was followed 
through the luminescence signal. After inhalation, the MNPs were allowed to target and 
redistribute within the lungs, before a single MHT cycle was performed during 30 min, 
which resulted in a significant impairment in tumour growth rate (Sadhukha et al. 2013b). 
Although T and overall MNPs dosage details are not provided, this seems a very 
interesting and promising approach for the local treatment of lung cancer.  
The accumulation efficiency of passive vs. active targeting was compared by Xie et al. 
using PEG-phospholipid MNPs (either non-targeted or RGD-modified) as an in vivo 
theranostic agent, i.e., as a contrast agent for MRI and as a heating agent for MHT. 
Interestingly, they found that one single IV injection dose of MNPs does not result in 
accumulation of enough magnetic material to produce tumour heating. Therefore, 6 
repeated IV injections were performed followed by 15 MHT 30-min-sessions, which 
resulted in a delay in tumour growth. This discrete outcome is related to the insufficient 
tumoural heat reported, derived from poor MNPs accumulation within the tumour (Xie et al. 
2016). This fact can be related to the targeting strategy itself, which aims at the tumour 
vasculature instead of the tumour cells. This study provides a true example of the 
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difficulties encountered to reach satisfactory tumour accumulation of MNPs, after IV 
administration, so that enough heat is generated locally for an efficient MHT treatment. 
Other authors have previously reported on the challenges of effective MNPs’ delivery to 
the entire tumour with active targeting (Kirpotin et al. 2006, Pirollo and Chang 2008). 
The combination of MHT with other therapeutic strategies was also tested in and in 
vivo context. Yoo and co-workers conducted an experiment in nude mice bearing breast 
tumours submitted to a 30-min AMF application (1 cycle) that heated the tumours to 43 ºC. 
These authors found that, although the tumour’s size initially regressed after MHT, it 
would still regrow after some days because tumour elimination was not complete. 
Therefore, they developed MNPs combined with an agent that depletes the reducing 
metabolites in cancer cells, GdTX, predisposing them to the damaging effects of ROS, 
and leading to complete apoptotic tumour regression 8 days after MHT (Yoo et al. 2012). 
Combining MHT with gene therapy targeting α-fetoprotein in human liver carcinomas, 
Yuan et al. reported a more than 90 % reduction in the tumour size, relative to control, 28 
days after a 2-cycle MHT treatment that increased the tumour’s T to more than 42 ºC for 
nearly 50 min. Consistently with a synergistic effect, the combined therapy was 
significantly more efficient than each therapy independently (Yuan et al. 2014). Worth 
mentioning, although controlled tumour growth was possible in this study, complete 
tumour elimination was not found, which may result in tumour relapse at longer time-
points.  
A group from Japan was the first to describe anti-tumour immunity after magnetically-
induced hyperthermia treatment. They implanted two glioma tumours in opposite flanks of 
the same rat and injected magnetic cationic liposomes (MCLs) in only one of them. 
Twenty-eight days after the treatment, which caused the tumour’s T to increase to 45 ºC, 
both tumours had disappeared. They verified that the hyperthermia treatment to one of the 
tumours led to the recognition of tumour antigens by the rat’s immune system (Yanase et 
al. 1998). Later, Kawai et al. also described anti-tumour immunity in their attempts to treat 
prostate cancer induced in rats, also using MCLs. The 30 min-application of an AMF 
raised the intratumoural T to 45 ºC and inhibited tumour growth. They reported the 
presence of immunocytes in the tumours of treated rats, which may have been recruited 
by the release of HSP70 from the treated cells (Kawai et al. 2005). More recently, Toraya-
Brown and co-workers showed that the hyperthermia-induced immunologic response 
might be T dependent (Toraya-Brown et al. 2014). In fact, and in disagreement with the 
previous studies (Yanase et al. 1998, Kawai et al. 2005), when primary tumours were 
heated to 45 ºC for 20 min, although complete tumour destruction was observed, the 
secondary tumour continued to grow like in the control mice. On the other hand, heating 
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the primary tumour to 43 ºC for 30 min produced complete, or incomplete but significant—
depending on the type of tumour and mice—tumour elimination. At the same time, the 
secondary tumour’s growth rate decreased as a result of the intense immunostimulation, 
in particular CD8+ T-cells recruitment and activation (Toraya-Brown et al. 2014).  
In most of the in vivo studies described herein, MHT resulted in increased animal 
survival due to decreased tumour growth. This incomplete tumour regression seems to be 
related to inhomogeneous distribution of the MNPs after the IT injection. In agreement 
with the in vitro studies, combination of MHT with another treatment modalities resulted in 
enhanced efficacy. The few studies reporting complete tumour elimination corresponded 
to the cases in which temperatures equal to or above 45 ºC led to complete cell 
destruction.  
Only a fifth of the in vivo studies described in this review refer to the use of targeted 
MNPs, while only one seventh use the IV route for MNPs injection, evidencing the need 
for more in vivo studies addressing these issues. 
  
Table 4 - In vivo studies using passive or active targeted anti-cancer MHT 
Cell line 
(number of 
cells) 
In vivo 
model 
Initial 
tumour 
size 
MNPs MNPs 
inj. 
mode 
Magnetic field 
T (ºC) Outcome Obs. Reference 
Coating Size (nm)
Initial 
amount
Time 
after 
inj. 
F 
(kHz) 
H 
(kAm-1) 
Time 
(min)  Cycles 
Human breast 
cancer MDA-
MB-231 (NR) 
NR (nude 
mice) 
100 mm3 PEG bis 
(amine) 
15 
(TEM)
75 µg 
MNPs 
IT 0 500 37.4 30 1 43 Incomplete tumour 
regression day 8; tumour 
regrowth day 12 
When using GdTx-MNPs for 
MHT = tumour eliminated 
within 8 days 
(Yoo et al. 
2012) 
Human 
chronic 
myeloid 
leukaemia 
K562/A02 
(1107) 
BALB/c 
mice 
950±150 
mm3 
Oleic acid + 
Pluronic F-
127 
18.4±
1.8 
(TEM)
22 µg 
MCLs/g 
body 
weight 
IT 0 219 10.5–310 40 1 ~42 40 % decrease relative 
tumour volume 
If combined with DNR + 5-
BrTet=80 % decrease 
relative tumour volume and 
decreased P-gp expression 
(Ren et al. 
2012) 
Human 
epidermoid 
carcinoma 
A431 (5106) 
SCID 
female 
mice 
200–400 
mm3 
(calc.) 
PLGA-b-
PEG 
77.8±
2.1 
(DLS)
400–800 
µL of 4.5 
mg 
Fe3O4/mL, 
days 
16,17,18,
19,and 22
IT 0 173 25 30 5 5–6 inc. 1.7 inc. MS hEGFR-targeted MNPs; 
observed increased T in 
subsequent treatments; in 
vivo biodistribution after IV 
injection shows higher 
accumulation in the liver 
and lungs, than tumour 
(Baldi et al. 
2014) 
Human hepato 
carcinoma 
HepG2 (1106) 
BALB/c 
female 
mice 
50 mm3 PEI 20–30 
(TEM)
1 mg 
MNPs/ 
cm3 
tumour 
IT 0 230 NR 60 2 42–44 ~70 % or ~92 % reduction 
tumour volume 28 days after 
MHT, resp. MHT and 
MHT+gene therapy 
Combination of MHT with 
gene therapy targeting -
fetoprotein in 
hepatocarcinoma 
(Yuan et al. 
2014) 
Human liver 
cancer stem 
cells Huh7 
CD90+ (2104) 
NOD/ 
SCID 
mice 
600 mm3 PEG 10–20 
(TEM)
; 
130±4
.6 
NR IT 24 h 200 NR 60 3 NR 27.3±9.8% complete tumour 
regression 70 days after 
injection 
When using Anti-CD90-
MNPs=78±19.1% complete 
tumour regression 70 days 
after injection; rectal 
T<40ºC 
(Yang et al. 
2016) 
Human lung 
squamous 
carcinoma 
A549-Luc 
(1106) 
Fox 
Chase 
SCID 
female 
mice 
0.5106 
photons/s 
Myristic acid 
+ pluronic 
F127 
369±3
4 
(DLS)
NR IH 7 
days 
386 6 30 1 NR Reduction in tumour growth 
rate over 1 month after MHT; 
reduced tumour weight 
No significant side effects; 
inhalation led to higher 
tumour MNPs accumulation 
than other organs 
(Sadhukha et 
al. 2013b) 
Mouse breast 
cancer 4T1 
(5106) 
BALB/c 
female 
mice 
50–80 
mm3 
(calc.) 
PEG 54.6 
(DLS)
630 µg 
Fe/g body 
weight 
(every 
other day)
IV (tail 
vein) 
30 
min 
390 2.6 30 15 Passive: 
38.7–
42.5; 
Active: 
39.6–44.1
59 % apoptotic cells; delayed 
tumour growth 
Passive vs. active targeting 
(3 integrin –targeted 
MNCs); studied 
bioaccumulation in the main 
organs; combined MRI and 
MHT; no obvious toxicity 
(Xie et al. 
2016) 
Mouse colon 
carcinoma CT-
26 (1106) 
BALB/c 
mice 
200–300 
mg (calc.)
Dextran 13.2±
3.1 
(TEM)
0.2 mL of 
16 gL-1 
IT 0 52 20 30 3 NR Day 3: reduced size by 20 %; 
day 10: 500 mg 
Day 3: CT doubled size; day 
10: CT 1500 mg 
(Drake et al. 
2007) 
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Cell line 
(number of 
cells) 
In vivo 
model 
Initial 
tumour 
size 
MNPs MNPs 
inj. 
mode 
Magnetic field 
T (ºC) Outcome Obs. Reference 
Coating Size (nm)
Initial 
amount
Time 
after 
inj. 
F 
(kHz) 
H 
(kAm-1) 
Time 
(min)  Cycles 
Mouse colon 
carcinoma CT-
26 (1105) or 
mouse 
melanoma 
B16F10 
(1.25105) 
BALB/c or 
C57BL/6 
mice 
56 mm 
(2 
tumours/
mouse) 
BNF-Starch 100 
(TEM)
140 µg Fe ID 0 167.5 36–44 20 or 
30 
1 42.5–43 
for 30 
min; 
44.5–45 
for 20 min
43ºC = Complete elimination 
of treated CT26 tumour in 
BALB/c in 5 days + untreated 
tumour grew slower than CT; 
incomplete elimination of 
treated B16 tumour in 
C57BL/6 + untreated tumour 
grew slower than CT; 45ºC = 
complete elimination of 
treated B16 tumour in 
C57BL/6 + no effect in the 
untreated tumour 
Hyperthermia-induced 
immunologic response at 43 
but not at 45ºC; 
immunologic response was 
not observed for Lewis lung 
carcinoma tumours, even at 
43ºC; rectum T=35.5–37ºC 
(Toraya-
Brown et al. 
2014) 
Mouse 
squamous cell 
carcinoma 
SCC7 (2105) 
NCr nude 
mice 
150 
mm3 
PEG 11.3±
2.3 
(TEM) 
23.8±
0.1 
(DLS)
1.7 g 
Fe/Kg 
body 
weight 
IV 
(tail 
vein) 
24 h 980 38 2 1 60 Complete tumour ablation in 
78–90 % cases 
Muscle w/ MNPs T=42ºC; 
Muscle w/o MNPs T= 36ºC; 
Liver uptake > tumour’s; 
16:1 MNP ration tumour to 
non-tumour 
(Huang and 
Hainfeld 
2013) 
Rat prostate 
cancer PLS10 
(1106) 
F-344 
Fisher 
male rats 
5–6 mm Lipid 
membranea 
10 nm 
(TEM)
2 g MCLs IT 30 
min 
118 30.6 30 1 45 Suppressed tumour growth; 
no disappearance 
Rectum T=38ºC; reported 
anti-tumour immunity (CD4, 
CD8 activation) 
(Kawai et al. 
2005) 
Rat glioma 
RG-2 (1105) 
F-344 
Fisher 
male rats 
3–4 mm Aminosilane 15 
(TEM)
20 µL of 2 
mol Fe/L 
IT 0 100 18 max 40 2 43–47 1.7–4.5 inc. MS, depending 
on T 
Rectum T=36–37ºC (Jordan et al. 
2006) 
Rat glioma T-9 
(1107) 
F-344 
Fisher 
female 
rats 
13–18 
mm 
Lipid 
membranea 
10 3 mg 
Fe3O4 
IT 24 h 118 30.6 30 3 43 89 % complete treated 
tumours regression + 
complete regression of 
untreated tumours; no 
tumour regrowth during 3 
months 
2 tumours implanted per rat, 
only one received MCL and 
AMF, both disappeared. 
Long-lasting anti-tumour 
immunity was reported; 
rectum and other tumour 
T=35–37ºC 
(Yanase et al. 
1998) 
Rat glioma T-9 
(5106) 
F-344 
Fisher 
female 
rats 
NR 
(eighth 
day) 
Carboxy-
methyl 
cellulose 
NA 3.3 mg 
Fe3O4 
IT 24 h 89 30 30 3 44.4 3 inc. MS (44.2±10.9 vs. 
14.4±1.5 of the CT) 
Rectum T did not change; a 
variation of MNPs is used, 
named “stick-type 
magnetite” 
(Ohno et al. 
2002) 
aLipid membrane: N-(a-trimethylammonioacetyl) didodecyl-D-glutamate chloride, dilauroylphosphatidylcholine and dioleoylphosphatidylethanolamine at a molar ratio of 1:2:2   
NR – not reported; CT – control; -Luc – Luciferase transfected; TEM – transmission electron microscopy; DLS – dynamic light scattering; MACS – magnetic-activated cell sorting; MNPs – magnetic nanoparticles; MCLs – 
magnetite cationic liposomes; DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; LHRH – Luteinizing Hormone–Releasing Hormone 
PEG – poly(ethylene glycol); PEI – poly(ethylenimine); PLGA - poly(D,L-lactide-co-glycolide) 
Administration routes: IT – intratumoural; IV - intravenous; IH – inhalation; ID – intradermal 
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2.5. Clinical studies 
The first clinical trials testing MHT to treat cancer were performed in Japan in the 90’s, 
using metallic implants consisting of FePt alloys. The magnetic heaters were locally 
implanted into gliomas of 24 patients during surgery or stereotactically, and heated under 
a 240 kHz AMF, for 60 min, two to three times a week, in combination with external 
irradiation and, eventually, chemotherapy. The treatment efficiency depended on tumour 
localization with tumours located in the thalamus or the basal ganglia responding better 
(45.5 % of the cases) than the ones located in the cortical or subcortical region (23.1 % of 
the cases) (Kobayashi and Kida 1990). 
The subsequent clinical studies took place nearly fifteen years after, in Europe, under 
Jordan’s A. supervision, and already used MNPs as heat mediators (aminosilane-coated 
MNPs) for the treatment of locally recurrent prostate cancer or recurrent GBM (Johannsen 
et al. 2005, Johannsen et al. 2007, Maier-Hauff et al. 2007, Maier-Hauff et al. 2011). A 
study including 22 patients with many different types of solid tumours found some 
limitations in MHT application, namely the insufficient increase in T and inhomogeneous 
MNPs distribution. On the other hand, this study showed that the MNPs stay in the 
injection site for at least a month, what would allow repetition of the AMF application in 
cycles (Wust et al. 2006). In parallel, a phase I clinical trial studied the feasibility, toxicity 
and quality of life in 10 prostate cancer patients, with IT injected MNPs, weekly receiving 
an AMF cycle (100 kHz, 2–15 kA/m, 60 min) for six weeks (Johannsen et al. 2007). 
Hyperthermic to ablative intratumoural T were reached (up to 55 ºC), which sometimes 
resulted in heating of adjacent tissues up to 44 ºC causing some discomfort manageable 
with local cooling. The small number of participants in the study and the disparities 
between the patients’ characteristics prevented taking clear conclusions on the MHT 
outcome. Low systemic toxicity was observed and the quality of life was temporarily 
impaired during, and up to three months after, MHT. The authors concluded that, although 
feasible, the technique required further refinements, including a combination with 
radiotherapy, which was not addressed in this study (Johannsen et al. 2007). 
The first trial attesting the feasibility and tolerability of nanoparticle-induced MHT on 
recurrent GBM treatment included 14 patients that received 0.1–0.7 mL of MNPs 
intratumourally, and were subjected to 4–10 AMF cycles. The resulting intratumoural T 
consequently varied from 42.4–49.5 ºC, with minor or no side effects reported (Maier-
Hauff et al. 2007). Later, the efficacy and safety of MHT for GBM treatment was 
established, in combination with radiotherapy, in a complex study with 59 patients. The 
aminosilane-coated MNPs were instilled into the tumour, under neuro-navigational control, 
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along with a thermometry catheter to monitor intratumoural T. The amount of injected 
MNPs varied with the tumour size (assessed by computed tomography (CT) scan in the 
beginning of the study), and the median peak T reached 51.2 ºC. The MHT treatment, 
always combined with radiotherapy, resulted in a gain in the mean overall survival after 
recurrence of 7.2 months, and of 8.6 months in the mean overall survival after first 
diagnosis, both considered “remarkable” by the authors. Regrettably, forty-seven of the 59 
patients died within the course of the study. The reported adverse side effects were 
described as “moderate” and varied from sweating and general sensation of warmth, to 
tachycardia, headaches and convulsions (Maier-Hauff et al. 2011). Such complex studies, 
dealing with such limited patient prognosis, seem very difficult to accomplish.  
MagForce is currently developing another clinical trial in Germany to further establish 
the efficacy of MHT in GBM treatment (MagForce 2016b). There seems to be one more 
on-going clinical trial on MHT (“unknown” status, not verified in more than two years), 
which aims at studying the fate of MNPs after IT injection on prostate cancer patients with 
a previously planned surgery to remove their tumours (NIH 2014). The authors will use 
MRI and CT to assess MNPs location, and also histologically analyse the tumour 
specimens after surgery. In case the MNPs remain at the injection site, then the next step 
will be running a similar study in which the MHT treatment is actually performed as cancer 
therapy.  
No studies with targeted MNPs or IV injection of MNPs have been clinically 
developed, so far, leaving the door open for future improvements in MHT for cancer 
treatment.  
2.6. Final considerations 
The use of MHT for the treatment of cancer is currently a reality, in particular for GBM.  
While some of the in vitro studies discussed herein show very appealing results, 
testing new and refined materials for increased heating abilities and low cytotoxicity, 
others show limited efficacy suggesting that improvements can be made. The addressed 
targeted strategies, mainly studied in vitro, offer the possibility of autonomously directing 
the MNPs towards the tumour after an IV injection, a perspective that should be further 
refined in vivo. While directed strategies have been tested in a variety of tumours, 
targeted MHT strategies for leukaemia and GBM treatment, however, have not been 
explored so far, particularly targeting CXCR4. Most of the in vivo MHT studies have tested 
IT injection of MNPs. The IT vs. IV MNPs’ injection is possibly one of the most dividing 
issues for in vivo MHT testing, as a balance needs to be encountered between safety and 
General Introduction 
43 
efficiency. While the IT injection seems safer because of the limited access of MNPs to 
other tissues, questions arise concerning the (in)homogeneity of MNPs’ dispersion within 
the tumour, resulting in non-uniform T elevation throughout the tumour that may lead to 
inefficient outcome. On the other hand, the less explored IV injection appears as a more 
“natural” way by which active or passive targeting allow the MNPs to meet the tumours, 
independently of their size and location. However, the MNPs allocation to tissues other 
than the tumour, in particular the liver, spleen, kidney and lungs, must be regarded with 
caution. In any case, the results from some in vivo studies are exciting, in particular when 
the development of anti-tumour immunity contributed for the observed outcomes, 
providing an encouraging perspective for future clinical trials on targeted MHT. The 
current use of nanoparticle-induced MHT for GBM treatment is so far still limited to direct 
injection of non-targeted nanoparticles into the tumour mass, providing inhomogeneous 
MNP distribution, and consequent death from tumour regrowth.  
Notwithstanding the encouraging results obtained with the in vitro and, above all, in 
vivo studies, MHT for cancer treatment is still underexplored, particularly using directed 
strategies that may allow selective tumour targeting, with minor effects in normal cells.  
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Objectives of this thesis 
The use of MHT for cancer treatment is still far from reaching its full potential and a 
long path needs to be explored towards the achievement of an efficient anticancer 
strategy, with minimal expected side effects. The use of functionalized, targeted, 
nanomaterials is one improvement that can be made, but the dependence of treatment 
efficiency on the amount of magnetic material associated to cells is a difficult challenge. 
This dissertation aims at the development of a magnetically-mediated hyperthermia 
strategy using functionalized nanoparticles to target cancer cells. Specifically, the 
objectives of this thesis are: 
 To study and optimize magnetic nanoparticle’s functionalization with 
biomolecules; 
 To functionalize magnetic nanoparticles with antibodies against a surface 
receptor overexpressed in many types of cancer cells, the chemokine 
receptor CXCR4; 
 To study the interaction between magnetic nanoparticles functionalized with 
anti-CXCR4 antibodies and cancer vs. normal cells in vitro; 
 To optimize a magnetically-mediated hyperthermia strategy using anti-
CXCR4-functionalized nanoparticles to target cancer cells in vitro, with 
emphasis on cytotoxicity studies – the poof-of-concept;  
 To apply and tailor the developed strategy to distinct in vitro tumour models 
with different expression levels of the selected marker;  
 To ensure the safety of the MHT treatment developed in terms of cytotoxicity 
against normal cells. 
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Abbreviations 
AMF – alternating magnetic field 
BCA – bicinchoninic acid 
BSA – bovine serum albumin 
CD – circular dichroism 
CP – co-precipitation 
EDC – 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
Fab – antibody-binding fragment 
FBS – fetal bovine serum 
Fc – fragment crystallisable 
FITC – fluorescein isothiocyanate 
FTIR – Fourier Transformed Infrared spectroscopy 
HBSS +/+ – Hanks balanced saline solution w/ calcium and magnesium salts 
HT – hydrothermal 
IgG – immunoglobulin G 
IR – infrared 
LSCM – laser scanning confocal microscope 
MNP – magnetic nanoparticle 
MHT – magnetic hyperthermia 
NHS – N-hydroxysulfosuccinimide 
PA – Protein A 
PAA – poly(acrylic acid) 
pAb – polyclonal antibody 
PB – Presto Blue 
PS – protein solution 
RT – room temperature 
S – supernatant  
SA – sodium acetate 
SAR – specific absorption rate 
STR – streptavidin 
T – temperature 
W – wash 
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Abstract 
The use of functionalized nanomaterials in the biomedical field has gained significant 
importance in recent years, in particular with biomolecules that direct the nanomaterials to 
target tissues/cells. In this study, the functionalization of in house synthesized poly(acrylic 
acid)-coated magnetic nanoparticles (MNPs) was optimized for different model proteins, 
using the EDC-Sulfo-NHS crosslinking chemistry. The functionalization efficiency was 
quantified by protein quantification methods such as Bradford, UV-vis spectrometry and 
circular dichroism, and the interaction between the protein and the MNPs was examined 
by Fourier Transformed Infrared spectrometry. After the optimization, satisfactory 
coverage of the MNPs surface was achieved and the as-obtained Streptavidin- or 
Staphylococcal Protein A-functionalized MNPs (STR– or PA–MNPs, respectively) were 
further conjugated with an anti-CXCR4 antibody targeting tumour cells, and then used for 
magnetic hyperthermia experiments with cancer cells in vitro. The observed results 
depended on the MNPs concentration used for the studies, with the highest concentration 
of MNPs leading to more than 75 % reduction in cell viability. PA–MNPs displayed higher 
stability than STR–MNPs in terms of aggregation as shown by microscopy studies; the 
aggregation in these functionalized MNPs induced a higher increase in hyperthermia 
studies. 
From the obtained results, we may assume that successful immobilization of distinct 
proteins was observed, reaching satisfactory levels of biomolecules per MNP. The 
immobilized proteins retained functionality, as supported by the in vitro experiments on 
magnetic hyperthermia using cancer cells. 
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1. Introduction 
Magnetic nanoparticles (MNPs) are often covered by coating layers that protect the 
reactive metallic core and provide the MNPs with stability and biocompatibility, while being 
a source of chemical groups for additional functionalization (Wu et al. 2015). Amongst the 
variety of possible organic coatings, poly(acrylic acid) (PAA) has gained wide interest in 
the recent years, due to the extensive number of functional groups and the stability it 
confers, while considered biologically safe (Prijic et al. 2012, Iversen et al. 2013, Couto et 
al. 2015). 
The conjugation of MNPs with biomolecules is a challenging, yet very interesting, 
step that supplies the MNPs with recognition abilities, i.e., the possibility of identifying a 
specific target and binding to it. In most cases, the biomolecules used for MNPs 
functionalization are proteins (or peptides), including enzymes, antibodies, receptor-
ligands and affinity proteins [(such as streptavidin (STR), or protein A (PA)] (Minelli et al. 
2010). In particular, STR forms one of the strongest, non-covalent, biological bonds with 
biotin, with high affinity, specificity and stability. As a tetrameric protein, STR has four 
known binding sites for biotin. Therefore, when in solution, STR can bind up to 4 biotin 
molecules, but when immobilized in a surface, this number drops due to steric hindrance 
(Quevedo et al. 2016). Biotinylated antibodies can be effectively immobilized on MNPs 
coated with STR. This is one of the most used strategies for the generation of immuno-
targeted MNPs. 
The Staphylococcus aureus-derived PA is a 42 kDa protein known to bind the 
fragment crystallisable (Fc) region of antibodies (e.g. IgG), with varying affinities, 
depending on the host and, where applicable, the immunoglobulin’s subclass (Kronvall et 
al. 1970). Five possible binding sites of IgG to PA have been described (Moks et al. 1986), 
but steric hindrance between IgG molecules prevents more than 2 IgG to bind 1 PA 
simultaneously (Yang et al. 2003, Mu et al. 2015). Interestingly, this is an oriented binding 
through the Fc region of the antibody, leaving the antibody’s region of specific recognition 
(antibody-binding fragment, Fab) free to interact with its target. 
Functionalized MNPs have a wide range of applications in catalysis and in 
biomedicine, namely, for magnetic separation, magnetic drug delivery and magnetic 
hyperthermia (MHT) (Lu et al. 2007). MHT is a cancer treatment based on the heat 
produced by MNPs under an alternating magnetic field (AMF) (Banobre-Lopez et al. 2013). 
It is currently approved to treat a highly aggressive type of brain tumours, named 
glioblastoma, in combination with radiotherapy (MagForce 2016), but there’s margin for 
therapy improvement, namely by using targeted magnetic particles. Therefore, the use of 
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a selective moiety holding the MNPs capable of target recognition and binding, holds 
great potential for increased selectivity and safety of MHT for the treatment of cancer. 
In this study we evaluate diverse functionalization pathways with the final goal of 
immobilizing antibodies on the surface of MNPs for effective targeting of cancer cells in in 
vitro targeted MHT studies. 
 
2. Materials and methods 
Dulbecco’s Modified Eagle’s Medium – high glucose (DMEM), Roswell Park Memorial 
Institute medium (RPMI-1640), trypan blue solution, sodium pyruvate, sodium bicarbonate, 
penicillin (10,000 U/mL) and streptomycin (10,000 μg/mL), herein referred to as Pen-Strep, 
sodium acetate, bovine serum albumin (BSA), streptavidin (STR), Protein A (PA), were 
purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Fetal bovine serum (FBS) was 
purchased from HyClone UK, Ltd (Northumberland, England, UK). Pierce™ Coomassie 
Plus (Bradford) Assay Kit, Micro BCA™ Protein Assay Kit, Pierce™ Biotin-Fluorescein 
Conjugate (Biotin-FITC), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
(EDC), biotin-conjugated anti-Campylobacter polyclonal antibody, biotin-conjugated anti-
Salmonella polyclonal antibody and Sulfo-N-hydroxysulfosuccinimide (Sulfo-NHS) were 
purchased from ThermoFisher Scientific (Cambridge, UK). Biotinylated anti-human-
CXCR4 monoclonal antibody (clone 12G5), biotinylated mouse IgG2a (clone MOPC-173) 
and low endotoxin, azide-free anti-human-CXCR4 antibody (clone 12G5) were purchased 
from BioLegend Inc. (San Diego, CA, USA). 
2.1. Cell culture 
Human glioblastoma cells, LN229 (ATCC® CRL-2611™), and human acute 
lymphoblastic leukaemia cells, Jurkat (ATCC® TIB-152™), were purchased from the 
American Type Culture Collection (Manassas, VA, USA). These cell lines were grown in 
DMEM high glucose or RPMI-1640, respectively, both supplemented with 10 % FBS, 1 % 
Pen-Strep and maintained in a controlled atmosphere at 37 ºC and 5 % CO2. 
2.2. Specific absorption rate estimations 
The specific absorption rate (SAR) is the power absorbed per mass of magnetic 
material in watts per kilogram (in W/kg). Accurate measurement of SAR is essential for 
quantifying the heating efficiency of MNPs’ suspensions for applications in anti-cancer 
MHT. Three nanoparticle’s suspensions were tested to assess their magnetic 
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hyperthermia performance: PAA-CP (ca. 13 nm diameter core), PAA-HT-Na and PAA-HT 
(ca. 18 nm diameter core, in both cases). The samples were obtained using distinct 
synthesis methods: CP refers to “co-precipitation” while HT stands for “hydrothermal” 
method (Kolen’ko et al. 2014). The PAA-HT-Na sample was obtained using sodium 
hydroxide instead of ammonia (used for PAA-HT) as precipitation agent. 
The MHT performance of those samples was evaluated using an AMF of 869 kHz 
and 225 Oe (18 kA·m-1). MNPs were diluted in cell culture medium to the same final 
magnetite concentration (0.5 g·L-1) in a 1 mL sample volume. All samples were contained 
in a glass vial and placed at the mid-point of a water-cooled copper coil of a DM 100 
system (nB nanoScale Biomagnetics). Each sample’s temperature (T) was recorded using 
an optical-fibre-based thermometer. 
The SAR of each sample was calculated using the following equation: 
ܵܣܴ ൌ ܥ݉ܨ݁
∆ܶ
∆ݐ  
where ܥ is the heat capacity of water (4.184 J·K-1·g-1), ݉ܨ݁ is the mass (g) of iron in 
1 mL of sample, and ∆ܶ is the T variation in the ∆ݐ time interval.  
2.3. MNPs’ conjugation with proteins 
The selected MNPs’ formulation was washed using a permanent magnet to remove 
the excess of free PAA and recovered in the same volume of ultrapure water (Milli-Q®, 
Merck Millipore, Darmstadt, Germany). Subsequently, and according to the 
manufacturer’s instructions, EDC was added to the MNPs followed by equal volume of 
sulfo-NHS and the suspension was incubated for 15–30 min, at room temperature (RT), 
with agitation. The MNPs were then magnetically separated to remove the excess of EDC 
and sulfo-NHS, resuspended in the protein solution (PS), and incubated at 4 ºC, for 3 h, 
with agitation. The PS concentration corresponded to, at least, 5 the amount of protein 
calculated to fulfil the MNPs’ surface area (calculated for each protein as described in 
supplementary data). The MNPs were again magnetically separated, the supernatant (S) 
was collected to further quantify the free protein, and the MNPs were washed with the 
same volume of Milli-Q. A subsequent magnetic separation allowed the collection of this 
washing volume (W) and the MNPs were further resuspended in a 2 % dilution of bovine 
serum albumin (BSA) in ultrapure water. Whenever the magnetic separation of the MNPs 
was not possible due to low magnetic susceptibility, a centrifugation step was performed 
(12,000 g, 5 min). A schematic representation of sample’s collection for protein 
quantification is provided in Figure 1. 
Manuscript I 
57 
  
Figure 1 – Schematic representation of sample collection during MNPs functionalization 
with proteins, after the MNPs activation and stabilization with EDC-Sulfo-NHS. 
 
The parameters subjected to optimization were: 
EDC-Sulfo-NHS concentration: different concentrations of these reagents were 
tested (EDC = 12, 6, 1.2 and 0.6 g·L-1; Sulfo-NHS = 33, 16.5, 3.3 and 1.65 g·L-1); 
Protein coupling buffer: ultrapure water, sodium acetate (SA) pH=4.5 and SA pH=4; 
Tested proteins: BSA, STR, Protein A and polyclonal antibodies (anti-Campylobacter 
or anti-Salmonella). 
2.4. Protein quantification 
2.4.1. Coomassie Plus (Bradford)  
Ten microliters of the corresponding protein standard or sample were mixed with 
300 µL of Coomassie Plus reagent, in duplicates or triplicates, and incubated for 10 min, 
in the dark. The absorbance was measured at 595 nm using a microplate reader (Synergy 
H1, BioTek Instruments). The amount of protein immobilized on the MNPs was estimated 
by subtracting the amount of unbound protein (measured in S and W) from the measured 
starting amount of protein, PS. 
2.4.2. Micro-BCA 
Protein standards were prepared considering the linearity range of this assay (2 and 
40 µg·mL-1). Standards or diluted samples were incubated, in a 96-well microplate, with 
an equal volume of a mixture of the reagents A, B and C, according to the manufacturer’s 
instructions, for 2 h at 37 ºC. After cooling the microplate to RT, the absorbance was read 
at 562 nm using a microplate reader (Synergy H1, BioTek Instruments). As for the 
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Bradford assay, the amount of protein immobilized on the MNPs was estimated by 
subtracting the amount of unbound protein (measured in the supernatant S and washes 
W) from the measured starting amount of protein, PS.  
2.4.3. Absorbance at 280 nm 
This is a widely used protein quantification method due to its simplicity and the non-
destructive use of the samples. For this purpose, a NanoDrop 2000c (Thermo Scientific) 
spectrophotometer was used to read 2 µL of each sample, in duplicates. 
2.4.4. Circular dichroism 
Circular dichroism (CD) measurements followed a previously established protocol 
(Fears et al. 2013). Briefly, the collection of the UV absorbance and the CD spectra was 
performed simultaneously over the range of 190–260 nm, in a 1-mm path-length quartz 
cuvette, using a Jasco J-815 spectropolarimeter. Each scan was acquired at a rate of 
20 nm·min-1, under controlled T conditions (20 ºC) and represents the average of 3 
accumulations. Raw ellipticity values (mdeg) were converted to molar ellipticity (Mol. Ellip.; 
degcm2dmol-1) using a previously described methodology (Fears et al. 2013). 
2.5. Fourier Transformed Infrared Spectroscopy (FTIR) studies 
The samples concerning functionalized MNPs were prepared as previously described 
in the section 2.3. A sample of MNPs conjugated with BSA, the MNPs before 
functionalization, and a BSA sample were prepared. All the samples were dried, at 37 ºC, 
overnight. Potassium bromide was used as reference material for the FTIR analysis. The 
IR spectra (1800–400 cm-1) were collected in transmission mode using a Nicolet 6700 
spectrometer (Thermo Scientific).  
2.6. In vitro magnetic hyperthermia treatments in two cancer cell models 
LN229 cells were detached using trypsin, while Jurkat cells were kept in suspension; 
both cell lines were washed with the appropriate cell culture medium, and the cell density 
and viability was counted in a haemocytometer using trypan blue exclusion method. Cells 
(2–2.5106 per test condition) were incubated with MNPs (functionalized or not with 
antibodies), to a final concentration of magnetite of 0.2 or 0.5 g·L-1, for 1 h, at 37 ºC, under 
constant shaking. A centrifugation step (125 g, 5 min, RT) was performed to separate the 
free MNPs from the mixture, and the samples were then recovered in 1 mL of cell culture 
medium. All samples were transferred to glass vials and placed at the mid-point of a 
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water-cooled copper coil of a DM 100 system (nB nanoScale Biomagnetics). Each 
sample’s temperature was recorded using an optical-fibre-based thermometer. 
2.7. Cytotoxicity evaluation after MHT 
2.7.1. Presto Blue metabolization 
After AMF application to the cell samples, Presto Blue reagent (PB) was added at a 
1:10 dilution, following the manufacturer’s instructions. Following exposure for 30–60 min, 
the samples were centrifuged at 850 g, for 5 min, at 4 ºC, to collect the supernatant, 
whose fluorescence was measured, at 590 nm emission and 560 nm excitation 
wavelengths, in a microplate reader (Synergy H1, BioTek Instruments). 
2.7.2. Laser scanning confocal microscopy 
After MHT application, cells were seeded in 8-well -dishes with treated surface for 
adherent cells (Ibidi, Martinsried, Germany) and incubated at 37 °C, 5 % CO2 and 
humidified atmosphere for 24 h. Prior to live cell imaging, samples were labelled with 
phycoerythrin (PE)-labelled Annexin-V (2 L of stock solution), during 30 min, and 
counterstained with Hoechst 33342 (final concentration1 g·mL-1), during 10 min, at 37 °C. 
Samples were then washed with Hanks Balanced Saline Solution with calcium and 
magnesium salts (HBSS +/+) before imaging. Fluorescence images were collected using 
a laser scanning confocal microscope (LSM 780, Carl Zeiss) simultaneously using 405 
(for Hoechst 33342) and 561 nm (for PE) excitation lasers. 
 
3. Results and discussion 
3.1. Selection of the magnetic nanoparticle formulation 
Three distinct MNP dispersions, different in capping/stabilizing agent and/or 
synthesis method—PAA-CP, PAA-HT (Kolen’ko et al. 2014) and PAA-HT-Na—were 
compared regarding their MHT performance to select the most appropriate to proceed for 
the functionalization studies. Figure 2a shows the curves of T versus time for each of the 
three MNPs’ formulations when diluted to the same final magnetite concentration (0.5 g·L-
1) and exposed to the same AMF. The equipment used for the AMF application (Figure 
2b) is composed of an applicator module, holding a water-cooled copper coil with the 
centred sample holder and the optical fibre T-probe, and a controller module for the 
selection of the AMF parameters, and the monitoring and analysis of the experiments. 
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Figure 2 - Magnetic hyperthermia performance of different PAA-coated MNPs.  
Samples diluted to 0.5 g/L [magnetite] in cell culture medium were submitted to AMF (869 kHz, 
18 kA/m) for 15 min, using the equipment in b). The detail shows a transverse section of the 
sample holder. The samples’ T at each minute was collected using an optical T probe. SAR values 
for each sample are provided in the table. Adapted from (Biomagnetics) 
 
Sample PAA-HT presented the best performance in heating ability at the tested 
magnetite concentration, increasing the medium’s T to 46 ºC in less than 15 min (Figure 
2a). Accordingly, this sample exhibited the highest SAR value, as denoted in Figure 2a, 
which was 3–4 bigger than the ones calculated for the other samples. This distinctive 
performance of PAA-HT sample for MHT purposes led to its selection for further 
optimization of the functionalization. Therefore, all the other tests further presented in this 
work were performed using PAA-HT MNPs, also simply called MNPs hereinafter. 
3.2. MNPs’ functionalization 
The widely used EDC-Sulfo-NHS crosslinking chemistry was optimized for the 
functionalization of the MNPs with biomolecules. This chemistry takes advantage on the 
carboxylic groups (–COOH) provided by the PAA-coating of the MNPs to activate and 
bind them to the amine groups (–NH2) of proteins (Sperling and Parak 2010). The 
collection of samples for the evaluation of the functionalization efficiency was described in 
the Methods section and summarized in Figure 1. 
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3.2.1. Optimization with Bovine Serum Albumin 
Due to its abundance and low price, BSA was used as a model protein for the 
optimization procedure. This protein has been described to increase the stability and 
biocompatibility of nanoparticles tested as drug carriers for biomedical applications (Jenita 
et al. 2014). The theoretical number of BSA molecules that fits the surface of 18-nm-core 
MNPs was calculated to be 40 BSA molecules per MNP (as described in supplementary 
data, taking into account the biomolecule’s parking area, but not steric or electrostatic 
interactions). We started by testing different concentrations of EDC and Sulfo-NHS to 
select the one that would be efficient without appreciably affecting the stability of the 
MNPs (Figure 3). 
  
Figure 3 - Dependence of BSA immobilization on EDC-Sulfo-NHS concentration. 
Different concentrations of EDC-Sulfo-NHS were tested for BSA immobilization on MNPs. a) The 
estimated number of BSA per MNP, quantified with Coomassie Plus reagent, was plotted for each 
EDC-Sulfo-NHS concentration. b) Representative optical micrographs (100 magnification) of the 
as-obtained MNPs showing that when using higher EDC-Sulfo-NHS more (and bigger) MNP 
aggregates are observed. 
 
The lowest tested concentration of EDC-Sulfo-NHS resulted in less efficient protein 
immobilization (~5 BSA per MNP) than the higher concentrations, which reached average 
levels of 20 BSA per MNP. Others have previously achieved efficient BSA immobilization 
on bare iron oxide MNPs using EDC as coupling agent (Mehta et al. 1997). When the 
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reagents were not used, no BSA binding was observed. Achieving similar protein binding 
efficiencies, the concentrations of 1.2 and 3.3 mgmL-1 were chosen due to the resulting 
higher stability and lower MNPs’ aggregation (Figure 3b). Similar dependency of MNPs’ 
aggregation on the EDC concentration has been previously reported (Wang and Lee 
2003). The concentration of BSA to be incubated with the activated MNPs also influenced 
the immobilization efficiency, with higher concentration resulting in higher amount of 
protein immobilization (Figure 4). While increasing surface coverage of 47, 78 and 184 % 
(taken the theoretical estimation as 100 %) were observed with increasing initial BSA 
concentrations, the highest tested concentration in this study resulted in more than 70 
BSA molecules per MNP, which far overcomes the calculated theoretical value of 40 BSA 
per MNP, suggesting the formation of additional protein layers. Wang et al. used similar 
EDC concentrations (2 mM  1.3 mgmL-1) for the efficient immobilization of avidin, 
quantifying the unreacted protein using a Bradford protein assay. These authors also 
reported a dependency of the immobilization efficiency on the protein concentration 
(Wang and Lee 2003). Nevertheless, in the reports by Wang et al. and Mehta et al. the 
number of biomolecules per MNP was not calculated (Mehta et al. 1997, Wang and Lee 
2003), preventing conclusions regarding the formation of extra layers of biomolecules.  
  
Figure 4 - Dependence of BSA immobilization on BSA initial concentration.  
The estimated number of BSA per MNP was plotted for each initial BSA concentration (dashed line 
represents the theoretical value calculated for BSA fitting on 18-nm-MNPs). 
 
BSA isoelectric point has been reported to be ca. 4.9 (Galisteo-Gonzalez and Molina-
Bolivar 2014); therefore, the use of a buffer with a pH slightly below BSA’s isoelectric point 
would favour the initial interaction of the protein with the carboxylic groups of the MNPs 
due to the overall net positive charge. Therefore, BSA immobilization was also tested 
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using SA buffers at pH=4.5 and pH=4.0 as coupling buffers, but the observed binding 
efficiency was lower than when using ultrapure water as vehicle (data not shown).  
The MNPs samples were analysed before and after BSA immobilization using FTIR, 
and the obtained spectra are shown in Figure 5. 
  
Figure 5 – Fourier transformed infrared spectra of PAA-MNPs before and after BSA 
immobilization.  
Red spectrum – PAA–HT; blue spectrum – PAA–HT–BSA. 
 
The FTIR data supported the interaction of PAA with the iron oxide nanoparticles (red 
bands at 583.5 and 444 cm-1), despite the presence of a small amount of free PAA, i.e., 
not interacting with the magnetite core (red band at 1703.9 cm-1) (Lin et al. 2005). 
Furthermore, the effective interaction between BSA and the carboxylic groups from PAA 
was confirmed, due to the  appearance  of amide bonds (blue bands at 1641 and 
1543 cm-1) different from the ones found in the spectra of HT–PAA (red bands at 1630 
and 1562 cm-1) and BSA-only (1648 and 1540 cm-1 (Peng et al. 2004)).  
3.2.2. MNPs functionalization with streptavidin, protein A or antibodies 
Using the optimized settings for functionalization of MNPs, the process was repeated 
for STR, PA and pAb, and the relative efficiency was calculated quantifying the free 
protein (Figure 6). In particular, a Bradford assay (Coomassie Plus reagent) was used for 
the estimation of STR and pAb, and for PA the quantification was performed using circular 
dichroism (CD). The theoretical values calculated for the fitting of STR, PA and pAb 
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molecules were 44, 192 and 27, respectively (see supplementary data) and the observed 
estimated protein immobilization values were 30.43.6, 161.060.3 and 25.74.0 
molecules per MNP, respectively, suggesting satisfying MNP-surface coverage with the 
proteins. These values represent 69, 84 and 95 % surface coverage, respectively, for STR, 
PA and pAb (Figure 6). 
  
Figure 6 – Efficiency of PAA–HT MNPs’ functionalization with Streptavidin, Protein A, or 
polyclonal antibody.  
For STR and pAb, the free protein collected from the MNPs (in the supernatants and washing 
steps) was quantified using Coomassie Plus reagent. PA was quantified by circular dichroism. The 
number of protein molecules immobilized per MNP was estimated and compared with the 
maximum theoretical values. 
 
STR and PA are interesting proteins that enable the binding of antibodies with high 
affinity to obtain targeted MNPs. In particular, STR binds with elevated affinity to biotin, 
which in turn can be linked to antibodies. This is considered the strongest non-covalent 
biological interaction known, being widely used for a number of different cellular and 
molecular assays (Holmberg et al. 2005). We tested the ability of the as-STR-
functionalized MNPs to bind a biotin-conjugated polyclonal antibody (pAb) and estimated 
an average of 30 pAb per MNP, which corresponds to ca. 1 pAb per STR (data not 
shown). Interestingly, when not using the EDC-Sulfo-NHS reagents for the 
functionalization, a residual amount of 10 STR per MNP was found, contrarily to BSA that 
would not bind at all. Adding fluorescein isothiocyanate (FITC)-labelled biotin (Biotin-FITC) 
to these samples resulted in a calculated average 4–5 biotin molecules per STR in the 
MNPs’ samples (data not shown). The fact that the four biotin-binding sites in these STR 
molecules are available for interaction with biotin shows that the STR’s functionality is 
retained after immobilization, but is also suggestive of weak interaction between the STR 
and the MNPs. 
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Regarding PA, curiously, the protein failed to react with the Coomassie Plus reagent 
and it was not possible to establish a proper calibration curve (Figure S1). When using the 
micro-BCA (bicinchoninic acid) protein assay a standard curve was obtained (Figure S1, 
R2=0.9962), but interferences were found when reading the S samples, possibly due to 
contaminating and residual nanoparticles contributing for the absorbance readings. 
Proteins are known to absorb at the 280 nm and, less commonly, in the far ultraviolet (UV), 
at 195–205 nm (Kelly et al. 2005, Fears et al. 2013). Particularly, the immobilization of PA 
on the surface of MNPs has been previously quantified by measuring the absorbance at 
280 nm (Mu et al. 2015). However, for the work described herein, the measurements at 
280 nm performed on a NanoDrop spectrophotometer encountered similar challenges as 
for the micro-BCA assay: a standard curve was obtained (Figure S1, R2=0.9925) and the 
PS sample’s concentration could be estimated but significant interferences were found for 
the S samples. 
As previously referred, another standard, though not so common, method for protein 
quantification is protein absorbance in the far UV, at 195 nm. As for the previous methods, 
a linear correlation was found for the standards (Figure 7a), but real samples may have 
some interference at this wavelength. Therefore, a more protein-specific method, i.e., 
circular dichroism (CD), was necessary, as it can be related to the protein’s structure, 
concentration, etc. In fact, measurements of CD signals in the far UV can give quantitative 
estimates of secondary structure (-helix and -sheet conformations) comparable to those 
obtained with X-ray crystallography or NMR (Kelly et al. 2005). Previous studies on the 
PA’s CD spectrum have estimated that PA contains nearly 50 % -helix structure and 10–
20 % -sheet structures (Sjoholm 1975). The peak positions and shapes within the CD 
spectra for PA were conserved among the standards and samples, allowing an 
extrapolation of the sample’s concentration from the standard curve. In particular, the 
signal at 208 nm, correspondent to PA’s -helix structure, in the CD spectrum seemed a 
convenient feature, as it was not affected by the solvent (water) or by residual amounts of 
MNPs that may be contaminating in the S samples (Figure 7b). This signal has been 
previously recommended for the estimation of the -helical content of proteins (Kelly et al. 
2005), but to the best of the authors’ knowledge, it's the first time it has been used to 
estimate the efficiency of PA immobilization on MNPs. 
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Figure 7 - Protein A quantification in standards and samples after MNPs functionalization.  
a) A linear correlation was found between PA concentration and the absorbance at 195 nm. b) 
Circular dichroism spectrum of PA did not suffer interference from water or from traces of MNPs 
that could be present after MNPs functionalization (S samples). c) The similar and almost 
superimposing molecular ellipticity curves showed no significant concentration-dependent changes 
in the protein structure, in particular, at the CD wavelength selected for protein quantification 
(208 nm). d) The measured absorbance at 195 nm linearly correlated with the CD signal at 208 nm, 
allowing estimation of PA concentration.  
 
Furthermore, the CD 208 nm signal did not relate to any concentration-dependent 
structure alteration, as shown by the nearly superimposing molecular ellipticity curves 
(Figure 7c). A linear correlation was found between the CD 208 nm signal and the 
absorbance at 195 nm obtained in the same CD spectrometer (Figure 7d), which finally 
allowed the interpolation of the samples’ (PS and S) PA concentration. The results 
indicated a satisfactory coverage of the MNPs surface with an average 161 PA molecules 
per MNP (Figure 6), corresponding to 84 % of surface coverage with protein, which can 
further bind the Fc region of IgG, leaving the Fab free for antigen recognition. 
The optimized functionalization strategy successfully allowed the immobilization of a 
polyclonal antibody directly at the MNPs surface (Figure 6, pAb). This direct 
immobilization of antibodies on MNPs has the advantage of being simple and fast, and 
readily applicable to polyclonal antibodies, dramatically cheaper than their monoclonal 
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counterparts. For monoclonal antibodies, however, this approach can become nearly 
unaffordable due to the excess of protein required to favour the coupling chemistry. 
Moreover, the random orientation of the antibody molecules landing on the MNP’s surface, 
and the use of relatively aggressive reagents, may hamper the antibodies’ functionality to 
some extent (Peluso et al. 2003). Whenever direct immobilization is not an option, the 
antibody immobilization via STR or PA affinity may be favourable as it requires less 
amount of antibody. 
3.3. Assessing protein functionality after immobilization using magnetic 
hyperthermia experiments in cancer cells 
As an example of a biomedical application, the STR–MNPs were conjugated with a 
biotinylated-anti-CXCR4 antibody, simply by adding the IgG solution to the STR-MNPs, at 
a ratio of 3 IgG/MNP, and tested in MHT experiments with cancer cells. In fact, CXCR4 is 
a chemokine receptor that is overexpressed in many types of cancer cells, being therefore 
an interesting target for cancer diagnosis and treatment (Zlotnik 2006). For these tests a 
human glioblastoma cell line, LN229, was used in which CXCR4 overexpression was 
confirmed (Manuscript 3). The conditions to be used for the MHT experiments were 
selected on the basis of the heating performance of the unconjugated MNPs and the 
respective outcome in another human glioblastoma cell line (Manuscript 2, supplementary 
data). Cells in suspension were incubated with the obtained CXCR4–STR–MNPs at a final 
magnetite concentration of 0.2 g·L-1 and then centrifuged to remove the excess of free 
MNPs. The T profile of these samples during AMF application (2 cycles, 499 kHz, 24 
kA·m-1, 1h each) is shown in Figure 8a. The T profile of samples containing LN229 cells 
incubated with CXCR4–STR–MNPs were clearly distinguishable from the ones containing 
MNPs without antibody, due to the higher T reached during MHT. This fact is a strong 
indicator that the linker protein retained its functionality after immobilization (Jung et al. 
2008), binding to the antibody that, in turn, recognised and bound to cells. Although the T 
did not rise above 37 ºC in any case, surprisingly, some decreases in the metabolic rate of 
the cells (Presto Blue, Figure 8b) were observed for the samples containing MNPs 
without antibody, particularly after MHT.  
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Figure 8 – Magnetic hyperthermia experiment using LN229 cells incubated with MNPs, or 
STR–MNPs, or CXCR4–STR–MNPs.  
a) Heating profiles. b) The effects on cell viability were evaluated using PrestoBlue reagent, right 
after AMF application. Laser scanning confocal microscopy images showing Hoechst 33342 
labelling of the nucleus (blue) and Annexin-V staining (yellow) in cells-only (c), cells with MNPs (d), 
cells with STR–MNPs (e), and cells with CXCR4–STR–MNPs (f), 24 h after MHT. 
 
Hypothesizing that this decreased metabolic rate could be a transitory effect of the 
MHT protocol, as these samples were kept at T bellow the physiological ones, the 
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samples were imaged the following day, with laser scanning confocal microscopy (LSCM), 
to check for apoptosis signals, using Annexin-V (Figure 8c–f). Annexin-V binds to the 
phosphatidylserine residues that translocate to the outer leaflet of the cell membrane at 
the onset of apoptosis (Koopman et al. 1994). The cells exhibited a normal shape, at this 
time-point, indicating that the results of PB after MHT were not due to an irreversible 
cytotoxic effect. The levels of Annexin-V staining did not vary significantly between 
samples (Figure 8c–f, yellow staining), indicating that the different treatments did not 
produce significant toxicity in LN229 cells. 
Subsequently, we compared the efficiency of the STR–MNPs to the PA–MNPs, 
conjugated with anti-CXCR4 antibody, in MHT experiments with Jurkat cells. This in vitro 
model of acute lymphoblastic leukaemia is widely used for mechanistic studies due to its 
easy manipulation, and it widely expresses CXCR4 (Baribaud et al. 2001). As control 
samples, an isotype control antibody (i.e., an antibody from the same host and IgG 
subtype) was used instead of the anti-CXCR4 antibody used for the test samples. Unlike 
the previous MHT experiments, AMF parameters were adjusted so that the samples heat 
to the maximum possible T within the first half (30 min) of the treatment, then keeping this 
T during the second half (Manuscript 2). The heating profiles varied principally according 
to the linker protein used for antibody’s attachment to the MNPs, i.e., STR or PA. In this 
sense, the samples with STR–MNPs, overall heated more than the ones with PA–MNPs 
with the same antibody, but PA–MNPs allowed a clearer distinction between the T curves 
of the control and test samples (Figure 9a), also providing evidence on the maintenance 
of PA’s (and antibody’s) functionality after immobilization. In agreement with the observed 
T profiles, the cell viability levels 24 and 72 h after MHT were considerably lower when 
STR was used as the linker biomolecule, resulting in less than 10 % viable cells 72 h after 
MHT (Figure 9b).  
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Figure 9 – Comparing MHT efficiency using STR– or PA–MNPs further conjugated with an 
anti-CXCR4 antibody, in Jurkat cells.  
a) Heating profiles b) Cellular metabolic rate 24 and 72 h after MHT. Samples bearing STR–MNPs 
(c) or PA–MNPs (d) were imaged 72 h after MHT using optical microscopy, under a 100 
magnification.  
 
The optical microscopy images collected 72 h after MHT show noteworthy 
aggregation of STR–MNPs, mostly with the isotype control antibody, but also with anti-
CXCR4 antibody (Figure 9c). The PA–MNPs also display some aggregation but to a 
relatively lower extent (Figure 9d). Knowing that antibodies may have more than one 
biotin per antibody molecule, and that each STR can bind more than one biotin molecule, 
crossed interactions may occur in which the same antibody molecule may be shared 
between different STR–MNPs, resulting in big agglomerates of MNPs (Garanger et al. 
2009) (Figure 10). In order to avoid this effect an excess of antibodies should be added to 
conjugate with the STR immobilized in the MNPs surface, meaning a high cost of the 
functionalization and preventing its use. In the case of PA–MNPs, however, such 
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aggregation was not observed, probably due to the oriented binding of the antibody, 
through its Fc region, to the PA on the MNPs (Figure 10).  
 
 
Figure 10 – Schematic representation of magnetic nanoparticle’s functionalization with 
antibodies, using streptavidin (STR) or Protein A (PA) as linker proteins. 
 
Overall, the obtained results indicate that, despite the lower T reached when using 
PA–MNPs, using PA as the linker protein for antibody attachment is a strategy less prone 
to MNPs’ aggregation, and consequently, with less risk of unspecific binding and toxicity. 
We believe that the MHT efficiency of this strategy may be improved by using bigger 
MNPs that are magnetically more efficient (higher saturation magnetization). 
 
4. Conclusions 
This work describes the challenges of the optimization of protein binding to MNPs. 
Successful immobilization of distinct proteins was accomplished, reaching satisfactory 
levels of biomolecules per MNP. The immobilized proteins retained functionality, as 
supported by the in vitro experiments on magnetic hyperthermia using cancer cells. These 
experiments showed that the higher level of aggregation of STR–MNPs might be 
contributing for the observed higher temperatures, and consequent low cell viability levels, 
in particular in the control samples. On the other hand, PA–MNPs appear to be more 
stable and, therefore, more suitable for biomedical applications.  
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Supplementary data 
Protein A quantification – unsuitable methodologies  
  
Figure S 1 – Different protein quantification methods tested for PA quantification. Coomassie 
Plus reagent failed to react with PA and a proper calibration curve could not be established. 
Although it was possible to establish a calibration curve using Micro BCA (bicinchoninic acid) and 
protein absorbance at 280 nm (using a NanoDrop spectrophotometer), interferences were detected 
in the S samples that prevented PA quantification. 
 
Calculation of protein fitting on MNPs surface 
The number of protein molecules per unit volume was calculated: 
ܲݎ݋ݐ	݉݋݈݁ܿ	݌݁ݎ	ܮ ൌ ݉ܥ ൈ ௔ܰܯ  
where ݉ܥ is the mass concentration (g·L-1), ௔ܰ is the Avogadro constant and ܯ is the 
molecular weight (g·moL-1). 
The mass, in grams, of each MNP can be calculated: 
݉ ൌ ߩ ൈ 43ߨݎ
ଷ 
where  is the density (g·cm-3) and ݎ is the radius of the MNP (cm). Knowing the 
magnetite concentration (ܨ݁ଷ ସܱ݉ܥ , g·L-1) of the MNPs, the number of MNPs per unit 
volume can be roughly estimated: 
ܯܰܲ	݌݁ݎ	ܮ ൌ ܨ݁ଷ ସܱ݉ܥ݉  
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The number of protein molecules that fit the surface of a MNP was calculated 
considering the average diameter of the protein and the surface area of the MNP as 
follows: 
ܲݎ݋ݐ	݌݁ݎ	ܯܰܲ ൌ 4ߨݎଵ
ଶ
ߨݎଶଶ  
where ݎଵ corresponds to the MNPs’ radius and ݎଶ is the average protein radius. 
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Abstract: 
We describe an in vitro anti-cancer treatment strategy that uses a combination of 
targeted and non-targeted magnetic (nano)particles to kill Jurkat cells via magnetically-
induced hyperthermia. Jurkat cells are an in vitro model of human acute T-cell leukaemia, 
a hematopoietic cancer that kills around 65 % of the affected adults. Cells are incubated 
with (non-targeted) poly(acrylic acid)-coated magnetic nanoparticles, followed by 
incubation with magnetic particles functionalized with anti-CXCR4 antibody, to target the 
CXCR4 receptor that is highly expressed in these cells. After removing the excess of free 
(non-interacting) particles, an alternating magnetic field (AMF) is applied to produce 
magnetic hyperthermia treatment (MHT). This study shows that complete cancer cell 
death is achieved only when a necrotic, rather than apoptotic, pathway is followed. As 
expected in this strategy of using two particle populations, this lethal MHT outcome could 
only be attributed to the combined iron loading resulting from both specific (targeted) and 
nonspecific (non-targeted) particle populations. This controlled strategy is a rare example 
of using MHT in a mono-therapeutic context to achieve complete cell death after a 1-h 
exposure to AMF, making it a promising approach for leukaemia treatment that minimizes 
potential side effects. 
 
Keywords: magnetic hyperthermia; CXCR4; nanoparticles; cancer treatment; 
leukaemia 
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1. Introduction 
Susceptibility of cancer cells to different drugs or treatments is commonly evaluated 
using Jurkat cells as in vitro models (Finlay et al. 1993, Black et al. 2016, Daglioglu and 
Okutucu 2016). These easily handled suspension cells are particularly appropriate models 
for studies of targeted treatments because Jurkat cells are immortalized T-lymphocytes 
collected from a patient with Acute Lymphoblastic Leukaemia (ALL), which in clinical 
oncology typically requires long and aggressive treatments (Inaba et al. 2013). After 
successful experimental treatments, the Fas-receptor up-regulation in Jurkat cells can be 
readily exploited to provide a positive control for apoptotic cell death pathway (Kolenko et 
al. 1999). 
The chemokine receptor CXCR4 is a natural choice for targeting Jurkat cells that are 
known to overexpress it (Crazzolara et al. 2001). The specificity and effectiveness of 
targeting CXCR4 in ALL cells has been demonstrated using its antagonist AMD3100, 
which reduced the growth and proliferation of ALL, while having no impact on normal 
haematopoiesis (Juarez et al. 2007). Potential clinical significance of targeting CXCR4 is 
emphasized by its association with greater invasive potential and organ infiltration in 
childhood ALL (Crazzolara et al. 2001). In a more general context, CXCR4 is highly 
expressed in many other types of tumour cells (Zlotnik 2006), opening possibilities for 
extending CXCR4-targeting treatments developed using Jurkat cells to other types of 
cancer. 
Magnetic hyperthermia treatment (MHT) is a cancer therapy (Banobre-Lopez et al. 
2013) which is currently under phase II clinical trials for glioblastoma treatment (MagForce 
2016). MHT exploits the local heat generated by magnetic nanoparticles (MNPs) under an 
external alternating magnetic field (AMF). Phase I clinical trials showed MHT to be well 
tolerated with moderate side effects (Wust et al. 2006, Johannsen et al. 2007), and the 
results collected from the phase II clinical trials on glioblastoma patients were encouraging, 
leading to a 7.2 to 8.6 months increase in overall survival (Maier-Hauff et al. 2011). 
Targeting strategies with functionalized nanoparticles, e.g. with antibodies (Zhang et al. 
2011) or peptides (Sadhukha et al. 2013), have been proposed in order to improve MHT 
outcome (Sadhukha et al. 2013, Kruse et al. 2014, Liao et al. 2015, Sadhasivam et al. 
2015). Our work pursues a similar volumetric targeting concept, whereby the targeted 
particles are preferentially retained in the volume with high concentration of cancerous 
cells. 
Mono-therapeutic apoptotic MHT has been characterized in a recent review as 
“basically ineffective” and “insufficient for cancer treatment” (Lee et al. 2015). The 
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apparent practical limit on the effectiveness of MHT is encountered despite highly efficient 
targeting, whether evaluated by the fraction of retained particles or by the concentration of 
particles associated with individual targeted cells. Accordingly, MHT has been typically 
used in combination with other therapies (Shah et al. 2014, Yin et al. 2014, Yuan et al. 
2014, Espinosa et al. 2016, Hervault et al. 2016), including stereotactic radiotherapy 
(Maier-Hauff et al. 2011), or anticancer drugs (Kim et al. 2015, Quinto et al. 2015). We 
hypothesize that instead of supplementing MHT by other therapies it may be possible to 
enhance the effectiveness of a “pure” MHT strategy by further increasing the total iron 
loading, which would increase the temperature achieved during MHT and result in 100 % 
lethal outcome for cancer cells in the targeted volume. Given the apparent limit on iron 
loading that can be achieved using a single population of targeted (specific) particles, we 
propose to augment the iron loading by adding a second non-targeted (nonspecific) 
particle population. As an example, this work describes the development of a therapeutic 
strategy based on the combined use of both CXCR4-targeted (specific) and non-targeted 
(nonspecific) magnetic nanoparticles to produce cytotoxic magnetic hyperthermia in 
leukaemia cells in a mono-therapeutic context, by ensuring that lethal temperatures are 
reached under an AMF. 
 
2. Materials and Methods 
2.1. Reagents 
All reagents used in this study were of analytical grade or of the highest grade 
available. Fetal bovine serum (FBS) was purchased from HyClone UK, Ltd, 
Northumberland, England, UK. Penicillin (10,000 U·mL-1) and streptomycin 
(10,000 μg·mL-1), herein referred to as Pen-Strep, RPMI-1640 cell culture medium, 
sodium pyruvate, nicotinamide adenine dinucleotide reduced form (NADH), triton x-100, 
caspase-3 fluorimetric substrate N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin 
(Ac-DEVD-AMC), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 3-[(3-
cholamidopropyl)dimethylammonio]-1-propane-sulfonate hydrate (CHAPS), dithiothreitol 
(DTT), ethylenediaminetetraacetic acid (EDTA), KH2PO4, K2HPO4.3H2O, CaCl2, NaCl, 
glycerol, staurosporine (STS) from Streptomyces sp., propidium iodide (Pi), 
glutaraldehyde solution (25 % in water), hydrochloric acid, sodium cacodylate trihydrate, 
calcein-AM solution and bovine serum albumin (BSA) were purchased from Sigma-Aldrich, 
Inc. (St. Louis, MO USA). BD Pharmingen™ FITC labelled Annexin-V (AnV–FITC) was 
purchased from BD Biosciences (USA). Anti-human CXCR4, clone 12G5, low endotoxin, 
azide-free monoclonal antibody produced in mouse, and its matched isotype-control, 
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mouse anti-human monoclonal IgG2a were purchased from BioLegend Inc. (San Diego, 
CA, USA). 
2.2. Cell culture 
Human acute T-cell leukaemia cell line Jurkat, clone E6.1, (ATCC® TIB-152™) was 
purchased from the American Type Culture Collection (Manassas, VA, USA). This cell line 
was grown in RPMI-1640 medium supplemented with 10 % FBS, 1 % Pen-Strep and 
maintained in a controlled atmosphere at 37 ºC and 5 % CO2.  
2.3. Incubation of cells with nanoparticles for in vitro magnetic 
hyperthermia 
Poly(acrylic acid)-coated magnetic nanoparticles (SPION), with an average iron-oxide 
core diameter of 17.9 ± 4.4 nm were synthesized and characterized as previously 
described (Kolen’ko et al. 2014). Two million cells per test condition were resuspended in 
1 mL of a 0.362 g·L-1 [Fe] SPION suspension in cell culture medium (final sample volume 
1 mL), for 2 h, with mild agitation. Samples were then centrifuged at 125 g for 5 min and 
resuspended in 1 mL of a 0.264 g·L-1 [Fe] suspension of dextran-coated 250 nm magnetic 
particles (09-20-252 Nanomag®-D, Micromod Partikeltechnologie GmbH, Rostock, 
Germany), in 2 % BSA, for 1 h, at 37 ºC, with mild agitation (final sample volume 1 mL). 
These particles have covalently bound protein-A at their surface, and were previously 
incubated with CXCR4 or IC antibodies, for 1 h, at 37 ºC, with agitation, to obtain 
functionalized particles (MP–CXCR4 or MP–IC, respectively). Samples were then 
centrifuged at 125 g for 5 min, washed with cell culture medium, centrifuged again, 
recovered in 1 mL cell culture medium and transferred to glass vials, previously blocked 
with BSA, for the MHT experiments. Incubations using only SPION (2 h, 37 ºC, in cell 
culture medium) or only MP–CXCR4 (1 h, 37 ºC, in 2 % BSA) were also performed. 
2.4. Magnetic hyperthermia treatment  
The application of the alternating magnetic field (AMF) to the samples described in 
the preceding section was performed using a magnetic field generator (DM 100, nB 
nanoScale Biomagnetics, Zaragoza, Spain) operating at 869 kHz and 20 kA·m-1 for 
30 min, followed by another 30 min period at 554 kHz and 24 kA·m-1. The temperature (T) 
of the suspension was measured using an optical temperature probe included in the 
equipment and the average constant T reached in the second step of AMF was called Tc. 
For SAR determination, temperature increases under the same AMF conditions were 
recorded for suspensions of only SPIONs and only MP in cell culture medium, as 
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previously suggested (Wildeboer et al. 2014). After AMF application, cells were seeded 
and subsequently tested to determine the levels of cell viability at successive points in 
time.  
2.5. TEM for SPION uptake studies 
Samples were prepared following a previously established protocol (Fraga et al. 
2013). Briefly, JK cells with SPION were pelleted at 300 g for 5 min, fixed with 2.5 % 
glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4, for 2 h, and rinsed with 
cacodylate buffer 0.1 M. Samples were then post-fixed in 2 % osmium tetroxide, 
dehydrated with graded ethanol, embedded in Epon and further placed 2 to 3 days at 
60 ºC to promote resin polymerization. Ultrathin (100 nm) sections, contrasted with 
uranylacetate and lead citrate, were then prepared on cupper grids (300 Mesh) for TEM 
analysis (Zeiss EM10A, Carl Zeiss, Oberkochen, Germany). 
2.6. Confirming specific (targeted) interactions 
After incubating cells with MP–CXCR4 or MP–IC, samples were incubated with atto-
633 labelled anti-mouse antibody produced in goat (Sigma-Aldrich, Inc., St. Louis, MO 
USA), for 30 min, at 37 ºC. Samples were further incubated with calcein-AM 0.4 μM, for 
flow cytometry studies, or calcein-AM 1 μM and then seeded in 8-well μ-slide (Ibidi, 
Martinsried, Germany) for laser scanning confocal microscopy using a Zeiss LSM 780 
confocal microscope. For flow cytometry studies, a S3™ cell sorter (Bio-Rad Laboratories, 
Hercules, CA), equipped with 488 nm and 561 nm lasers, was used as a flow cytometer to 
acquire the fluorescence signals in logarithmic mode. JK cell population was defined 
setting a polygon gate according to their light scattering properties (forward vs. side 
scatter plot) excluding cell debris. Fluorescence due to calcein was followed in FL-1 
channel, and atto-633 fluorescence was collected in FL-4. FCS files were analysed using 
ProSort™ software. 
2.7. Iron quantification with inductively coupled plasma optical emission 
spectroscopy (ICP-EOS)  
Cells were incubated with SPION only, MP–CXCR4 only, SPION+MP–CXCR4 or 
SPION+MP–IC following the procedure and described in section 2.3. For the ICP 
measurements, samples were digested with 1 mL hydrochloric acid, for 24 h, and then 
diluted with milli-Q water (Millipore) to a final volume of 50 mL. Measurements were 
performed in triplicates, in an ICPE-9000 Multitype ICP Emission Spectrometer 
(Shimadzu). 
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2.8. Assessment of MHT-induced cytotoxicity  
The effects from the MHT were assessed by flow cytometry using Annexin-V (AnV–
FITC) and propidium iodide (Pi) labelling. Caspase-3 activity was assessed using a 
fluorimetric substrate. Cellular metabolic activity was estimated using PrestoBlue® 
reduction assay and membrane damage was evaluated through the LDH leakage assay. 
The anticancer drug staurosporine (STS) was used at 2.5 μM for 1 h as a positive control 
for apoptotic cell death. 
2.8.1. Annexin-V & propidium iodide labelling for flow cytometry 
The translocation of phosphatidylserine residues from the inner to the outer leaflet of 
the cell membrane is considered one of the earliest events of apoptosis (Koopman et al. 
1994). A previously described protocol was used with minor modifications (Valente et al. 
2012). Briefly, two hours after MHT, 2105 cells were collected in cell culture medium, 
washed with PBS and resuspended in 200 μL of Annexin-V binding buffer (diluted from 
the 10x stock solution: 0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM CaCl2) in 2 % BSA, with 
or without 5 μL of FITC-labelled Annexin-V (AnV–FITC), and kept for 20 min, at room 
temperature, in the dark. Cells were centrifuged at 210 g, 5 min, at 4 ºC and immediately 
analysed. Propidium iodide (Pi, 1 μg·mL-1) was used to detect membrane damage in 
these samples.  
Flow cytometry parameters were set as described in section 2.6, using positive and 
negative controls. Fluorescence collected in FL-1 channel (green fluorescence from AnV–
FITC) was plotted vs. the one collected in FL-3 channel (red fluorescence from Pi), and 
the percentage of positive cells for each channel (or both) estimated after establishing the 
quadrants based on the controls. For each sample, at least 15,000 gated events were 
counted and distinguished as living cells (AnV–FITC-/Pi-, lower left quadrant); apoptotic 
cells (AnV–FITC+/Pi-, upper left quadrant); late stage apoptosis or necrotic cells (AnV–
FITC+/Pi+, upper right quadrant), and necrotic cells (AnV–FITC-/Pi+, lower right quadrant). 
2.8.2. Caspase-3 activity assay 
After MHT, at least 1106 cells per well were seeded in 6-well plates and incubated at 
37º C with a controlled atmosphere with 5 % CO2. Cells were collected 24 h after AMF 
application to check the activation status of caspase-3 protein. Cells were collected on ice, 
centrifuged at 850 g, for 5 min, at 4 ºC, washed with PBS and resuspended in 35 μL of a 
lysis buffer (50 mM HEPES, 0.1 mM EDTA, 1.63 mM CHAPS supplemented with 1 mM 
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DTT before using). After vigorously vortexing the samples, these were kept at -80 ºC until 
analysis.  
On the day of analysis, samples were thawed on ice, vortexed and left to equilibrate 
for 10 min on ice before centrifugation at 16,000 g, for 10 min, at 4 ºC. The supernatant 
was collected to new tubes and the pellet was discarded. For each assay, 10 μL of this 
supernatant were mixed with 90 μL of an assay buffer (50 mM HEPES, 100 mM NaCl, 
1 mM EDTA, 1.63 mM CHAPS, 10 % glycerol supplemented with 10 mM DTT before 
using), containing 14.8 μM fluorimetric substrate (Ac-DEVD-AMC), and the kinetic reading 
was immediately started. A Synergy H1 microplate reader (BioTek Instruments, Bad 
Friedrichshall, Germany) was used to perform the kinetic readings (at 37 ºC; excitation at 
380 nm, emission at 460 nm), which lasted for 3 h with successive readings at each 
10 min. The amount of protein loaded per well was estimated using Coomassie Plus 
(Bradford) Protein kit (Thermo Fisher Scientific, Inc., Rockford, IL USA) following 
manufacturer’s instructions. Caspase-3 activity was expressed as the slope of the curve 
obtained plotting the protein corrected-fluorescence signals vs. time (RFU·μg-1·min-1). 
2.8.3. Metabolic rate assay 
After MHT, cells were seeded in 96-well plates (15,000 cells per well) and cell viability 
was assessed 24 and 72 h after AMF application by the addition of 10 μL PrestoBlue® 
cell viability reagent (Molecular Probes™, Carlsbad, CA) to each well. After incubation at 
37 ºC for 3 h, fluorescence signals were collected using a microplate reader (Synergy H1, 
BioTek Instruments) with excitation wavelength at 560 nm and emission wavelength at 
590 nm. 
2.8.4. Lactate dehydrogenase (LDH) leakage assay 
LDH activity in the cell culture medium was assessed spectrophotometrically 
following the decrease in absorbance of nicotinamide adenine dinucleotide reduced form 
(NADH) during the reduction of pyruvate to lactate, as an indicator of membrane 
disruption, i.e., cell death. A previously described protocol was used with minor 
modifications (Barbosa et al. 2014). Briefly, after MHT, 20,000 cells were seeded per well 
in 96-well plates and LDH leakage was assessed 24 and 72 h after AMF application. 
Fifty μL of cell culture medium were collected per well (to measure extracellular LDH 
content) and replaced by 50 μL of a 0.5 % triton X-100 solution in cell culture medium (to 
induce cell lysis). After incubating for 1 h, at 37 ºC, 25 μL of cell culture medium were 
collected to a new plate, for LDH measurements after the full kill. The collected medium 
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was mixed with 200 μL of reagent solution containing 0.21 mM NADH, dissolved in LDH 
buffer (33.3 mM KH2PO4 and 66.7 mM K2HPO4.3H2O, pH 7.4). The reaction was started 
with 25 μL sodium pyruvate (22.7 mM, prepared in LDH buffer) and the kinetic conversion 
of NADH into NAD+ was followed for 5 min, at 340 nm, in a microplate reader (Synergy H1, 
Bio-Tek Instruments). The final volume of reaction in each well was previously set to 
275 μL with LDH buffer. Final results of LDH released into the extracellular medium (LDH 
leakage), were expressed as cell death values calculated as previously described 
(Barbosa et al. 2014). 
2.9. Statistical analysis 
All data are presented as mean±standard deviation (SD), except when stated 
otherwise, of at least three independent experiments performed in triplicate whenever 
possible. Normality of the data distribution was assessed applying three tests: KS 
normality test, D’Agostino and Pearson omnibus normality test and Shapiro-Wilk normality 
test. Differences between the average Tc were estimated using ordinary two-way ANOVA 
followed by Dunnett’s multiple comparisons post test. In the AnV–FITC/ Pi double staining, 
PrestoBlue® and LDH experiments, differences between controls and treatments at each 
time-point were estimated using ordinary two-way ANOVA followed by Tukey’s multiple 
comparisons test. For the caspase-3 activity experiments, the change of the protein 
corrected-fluorescence signal with incubation time (RFU·μg-1·min-1) was determined by 
linear regression analysis for each control or treatment and plotted as caspase-3 activity 
values. Differences in caspase-3 activity values were estimated using one-way ANOVA 
(Kruskall-Wallis) followed by Dunn’s multiple comparisons test. P values under 0.05 were 
considered statistically significant. 
 
3. Results and discussion  
3.1. Selecting AMF parameters 
For practical implementation of the strategy where each of the two nanoparticle 
populations controls one of the factors contributing to the overall MHT efficiency, it is 
critical to ensure that neither population alone produces lethal heating under AMF (Figure 
1). 
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Figure 1 – Heating profiles of Jurkat cells incubated with SPION and/or antibody-
functionalized MPs.  
The samples were submitted to an alternating magnetic field for 1 h, as outlined in the graph, until 
a constant temperature (Tc) was reached. The graph shows an initial sample’s chilling due to lack 
of thermal insulating system (Tdec), followed by a T increase after the thermal barrier is overcome (Tinc), and a final stabilization phase for the last 30 min of MHT (Tc). When a combination of SPION and CXCR4-functionalized MPs were used, average Tc of 42.7 or 45.2 ºC were observed. The 
curves represent the mean±SD of two to four independent experiments. Differences between the 
average Tc were estimated using ordinary two-way ANOVA followed by Dunnett’s multiple 
comparisons test. **p<0.01 JK+SPION+MP–CXCR4+AMF Tc=45.2ºC vs. JK+SPION+MP–
CXCR4+AMF Tc=42.7ºC; ****p<0.0001 JK+SPION+MP–CXCR4+AMF Tc=45.2ºC vs. any of the 
other tested conditions.  
 
After an optimization of AMF parameters (Figures S1 and S2 in SI†), the heating 
profile in our experiments matched that recommended in a recent review for optimal MHT 
(Dutz and Hergt 2014). AMF was applied following a two-step process, whereby 
temperature (T) mainly rises during the first AMF step (30 min, 869 kHz, 20 kA·m-1) (Tinc) 
and stabilizes in the second AMF step (30 min, 554 kHz, 24 kA·m-1) at a constant 
temperature (Tc) that depends on the particles used and their functionalization. 
A minor artefact related to a limitation of our equipment, during the initial phase, a 
decrease of temperature can be observed for all samples (Tdec), due to the time needed 
for the heating to be effective after placing the samples, pre-incubated at 37 ºC, inside the 
coil. This artefact would not be applicable in a living organism. 
3.2. Two nanoparticle populations 
The two independent particle populations of our MHT strategy were implemented by 
design to have specific (targeted) and nonspecific (non-targeted) interactions, respectively, 
with cancer cells.  
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For the specifically interacting population, we functionalized protein-A-modified 
250 nm magnetic particles with an anti-CXCR4 antibody (MP–CXCR4) that is able to 
recognize and target the highly overexpressed CXCR4 in JK cells (Figure S3 in SI†). 
Although some nonspecific retention of particles was observed, the surface targeting of JK 
cells with these functionalized particles (JK+MP–CXCR4) was confirmed by flow 
cytometry and laser scanning confocal microscopy, whereby antibodies attached to the 
MPs were labelled with fluorescent secondary antibodies (Figure 2). 
	 
Figure 2 – Studying the interaction between SPIONs, MPs and cells.  
a) Transmission Electron Microscopy (TEM) micrograph showing Jurkat cells (JK) with SPION 
internalized in endosomal compartments (white arrows) or adherent to the cell membrane (black 
arrows). Scale bar is 200 nm. JK cells labelled with calcein-AM were incubated with IC- or CXCR4-
functionalized particles and analysed using b) flow cytometry and c) laser scanning confocal 
fluorescence microscopy. A fluorescently labelled secondary antibody (atto-633 IgG) was used to 
detect the antibodies attached to the particles. Flow cytometry measurements (b) show an increase 
in the mean fluorescence intensity emitted by JK cells (selected as calcein-positive events) on the 
atto-633 detection channel (FL4) when using CXCR4-functionalized particles, indicating these 
particles are recognising and binding to these cells. These results were further confirmed by laser 
scanning confocal fluorescence microscopy (c), which showed JK cells (staining green) surrounded 
by CXCR4-functionalized particles (staining red, right panel). Scale bar is 10 µm The insert shows 
a zoomed 3D detail of the selected area, with reversed colouring for better visualization. 
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Both techniques (Figure 2b and c) showed increased fluorescence in cells targeted 
with MP–CXCR4 in comparison to cells only (JK) and cells with MP–IC (MPs 
functionalized with an isotype control antibody, IC). The complex 3D microstructures 
formed by agglomerates of fluorescently labelled MP–CXCR4 particles around the JK 
cells are highlighted in the 3D view inset (Figure 2c, right panel). This targeted association 
of MP–CXCR4 particles with JK cells was further corroborated by ICP-OES results (Table 
1) that showed retention of 92.4 % of the MP–CXCR4 particles by JK cells, after 
incubation followed by removal of free particles. 
As the nonspecifically interacting population, 18-nm-core super-paramagnetic iron 
oxide nanoparticles (SPIONs) were used in this work because of their efficient heating 
ability. SPIONs were synthesized and characterized as previously reported (Kolen’ko et al. 
2014). Unlike the specific MP–CXCR4 particles, only 2.4 % of these nonspecific SPIONs 
become associated with JK cells after incubation followed by removal of free particles 
(Table 1). This modest uptake is corroborated by TEM imaging that shows only a minimal 
number of SPIONs associated with the cell membrane (Figure 2a, black arrows), in 
contrast to the extensive adsorption and agglomeration of MP–CXCR4 particles at JK cell 
surfaces (Figure 2c, right panel). Uptake of some SPIONs into endosomal compartments 
in JK cells is also evident in the TEM image (Figure 2a, white arrows). 
For either particle population independently, the Tc reached under AMF was 
relatively low: 34.5 ºC for the JK+SPIONs and 40.5 ºC for the JK+MP–CXCR4 samples 
(Figure 1). The MHT treatment did not induce perceptible cytotoxicity in the presence of 
SPIONs alone (Figure S4 in SI†). The higher Tc reached for JK+MP–CXCR4 samples 
lead to an increase of caspase-3 activity, however it did not produce a significant effect on 
viability of targeted cells (Figure S4 in SI†). Given the >90 % retention of the MP–CXCR4 
particles by JK cells, further optimization of the targeting is unlikely to increase the iron 
loading sufficiently to produce significant cytotoxicity in targeted cells. Conversely, 
supplementing the specific MP–CXCR4 particles with a second (nonspecific) SPION 
population opens the possibility for a more substantial increase in iron loading and the 
associated effectiveness of MHT. The high SAR of our SPIONs (261 W·g-1 vs. 220 W·g-1 
for MP–CXCR4 particles), under the AMF conditions used in this work, further supports 
the practicality of the two-population strategy. 
3.3. Sequential incubation with two nanoparticle populations 
The incubation procedure involved four steps: first, a 2 h-incubation of cells with 
SPIONs (0.362 g·L-1 Fe); second, removing the excess of free SPIONs; third, a 1 h-
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incubation with MP–CXCR4 (0.264 g·L-1 Fe); and fourth, removing the excess of free MPs. 
Following the two washing steps, the total iron concentration during AMF application was 
measured using ICP-OES and calculated to be 0.309 g·L-1 ( 5.5 mM) in the 
JK+SPION+MP–CXCR4 samples and 0.168 g·L-1 ( 3.0 mM) in the JK+SPION+MP–IC 
samples (Table 1). This represents nearly 50 and 27 %, respectively, of the total initial iron 
amount these samples were exposed to (0.626 g·L-1,  11.2 mM, Table 1). 
Table 1 – Iron quantification by Inductively Coupled Plasma - Optical Emission 
Spectrometry 
Sample Initial Fe [g·L-1] 
Average Fe/ sample 
[g·L-1] % particle retention
a 
JK+SPION 0.362 0.0087±0.0043 2.4 
JK+MP-CXCR4 0.264 0.2440±0.0254 92.4 
JK+SPION+MP-CXCR4 0.626 0.3090±0.0042 49.4 
JK+SPION+MP-IC 0.626 0.1680±0.0212 26.8 
aThe percentage of particle retention was calculated as 100 ratio between the average Fe/ sample and the respective initial 
Fe, for each sample. Results are meanSD of two independent experiments. 
 
Flow cytometry data obtained after co-incubation of cells and nanoparticles (Figure 3) 
indicate that both particle populations interact with the cells, showing different light 
scattering properties (in forward scatter, FSC, and side scatter, SSC, detectors) 
depending on the type of particles. Similar data have been previously interpreted as a 
proof of cell-particle interactions (Poirier et al. 2014). 
Figure 3 clearly shows the movement of the gated events up on the SSC-Height axis, 
related to cell granularity or internal complexity, from a JK cells-only sample (31.1 ± 4.9) to 
JK+SPIONs (73.4 ± 0.6; p<0.0001), and then to JK+MP–CXCR4 (135.0 ± 7.6; p<0.0001). 
When a combination of both particles was used, features of both scattering patterns of 
cell-particle events were observed, reaching an intermediate SSC value (90.1 ± 11.8; 
p<0.0001 vs. JK+MP–CXCR4). Observing evidence of interactions with both types of 
particles, in particular, indicates that SPIONs associated with the cells during the first step 
do not block the subsequent MP–CXCR4 interaction with the cell surface. 
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Figure 3 – Light scattering properties of Jurkat cells incubated with SPION and/or antibody-
functionalized MPs.  
Flow cytometry data showing changes in light scattering properties due to the presence of different 
nanoparticles, alone or in combination, an indication of interaction between particles and cells. The 
mean±SD values collected by the forward and side scatter detectors, from three independent 
experiments, are presented in the table. Differences were estimated using ordinary two-way 
ANOVA followed by Tukey’s multiple comparisons test. ****p<0.0001 vs. JK cells only or the 
selected sample  
	
3.4. MHT outcome  
As expected, the cytotoxic effects of MHT were observed only after cells were treated 
with a combination of both nanoparticle populations (Figures 4 and 5). In other words, a 
lethal MHT outcome could only be attributed to the combined iron loading resulting from 
both specific and nonspecific interactions. This exclusive attribution is supported by the 
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absence of significant cytotoxicity in all negative controls (Figures 4 and 5): whenever 
AMF was not applied (JK+SPION+MP–IC and JK+SPION+MP–CXCR4 samples) or the 
matched IC antibody was used (JK+SPION+MP–IC+AMF samples). In particular, no 
significant effects on cell viability were observed in all the negative controls that included 
only the putatively nonspecific SPIONs (Figure S4). As a positive control, STS, yielded 
apoptotic signatures in the assays, in agreement with previous reports (Ullal and Pisetsky 
2010). Given the complexity of the samples systematically compared in these 
measurements, we have to evaluate the results based on the aggregate parameters, such 
as heating curves, Tc values, and cell death outcomes. 
3.5. Apoptotic vs. necrotic outcome 
Serendipitously, after MHT experiments we observed both apoptotic and necrotic 
outcomes that strongly correlated with the average reached Tc: 42.7 ºC and 45.2 ºC, 
respectively (Figure 1, purple curves). 
In the first outcome group (n=4, Tc=42.7 ºC), results suggest the cell death pathway 
to be predominantly apoptotic, as caspase-3 activity was significantly induced (Figure 4a, 
p<0.05). Unexpectedly for a classical apoptotic pathway, we found only low levels of AnV+ 
cells for JK+SPION+MP–CXCR4+AMF Tc=42.7ºC samples (Figure 4b), which could be 
related to an interference of the MNPs with the standard AnV assay. The positive control 
for an apoptotic cell death, STS, clearly increased the number of AnV+ cells, representing 
the apoptotic pathway (Figure 4b and c). 
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Figure 4 – Apoptosis-induction studies after MHT.  
a) An induction of caspase-3 activity was observed in JK+SPION+MP–CXCR4+AMF samples 
when Tc was 42.7 ºC and in the tested positive control for apoptosis, staurosporine (STS). Differences between each treatment and untreated control were estimated using ordinary two-way 
ANOVA followed by Tukey’s multiple comparisons test.  b) and c) Incubation with AnV–FITC and 
Pi dyes was performed 2 h after AMF application. The percentage of cells staining positive for each 
dye individually or together are shown for each treatment/ control. A significant increase in Pi+ cells 
was observed in JK+SPION+MP–CXCR4+AMF samples, compared to all tested controls, 
independently of the average reached Tc. When an average 45.2 ºC were reached, a significant 
increase in the double stained events was also observed, showing a total of around 60% dead cells, 
as short as 2 h after MHT treatment. STS induced a significant increase in the percentage of AnV+ 
cells, as expected in an apoptotic cell death pathway. Values are mean+SD of at least three 
independent experiments. Differences were estimated using one-way ANOVA (Kruskal-Wallis) 
followed by Dunn’s multiple comparisons test. *p<0.05; **p<0.01, ***p<0.001 and ****p<0.0001 vs. 
untreated cells or vs. the referred control. 
 
In the second outcome group, for which Tc reached 45.2 ºC (n=4), a more destructive 
scenario was observed, as illustrated in Figure 4c by representative plots of AnV and Pi 
double staining to study apoptosis. In this outcome group, nearly 60 % of the cells stained 
either Pi or Pi and AnV double positive, as early as 2 h after MHT (Figure 4b and c), 
indicating cell membrane damage. These results, along with the lack of caspase-3 
activation, are indicative of a necrotic pathway for cell death. Furthermore, cell viability 
dropped to zero in these samples, 72 h after MHT (Figure 5), demonstrating the high 
effectiveness of the treatment. 
Notably, when an apoptotic pathway was activated (i.e. JK+STS and 
JK+SPION+MP–CXCR4+AMF Tc=42.7ºC samples) a slightly different outcome was 
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registered, as cell death was significant but not complete. This fact suggests treatments 
that induced necrotic pathway to be more effective than the apoptotic pathway, in terms of 
cancer cell death in the present study, in agreement with previous conclusions about 
insufficient effectiveness of apoptotic MHT (Lee et al. 2015). 
  
Figure 5 - Cell viability and cell death rates after AMF application.  
a) PrestoBlue® reagent was used to measure cellular metabolic activity after AMF application and 
the emitted fluorescence was compared as a measure of cell viability. Clearly significant 
differences in cell viability were observed for the JK+SPION+MP–CXCR4+AMF samples when 
compared to all the tested controls, in both studied time-points (24 and 72 h post-MHT), and 
independently of the reached Tc. Cell viability values after 72 h drastically dropped to zero when 
the highest Tc was achieved. (b) Accordingly, the LDH leakage assay results showed a significant 
increase in cell death levels in JK+SPION+MP–CXCR4+AMF samples. Results are mean+SD of at 
least four independent experiments performed in triplicate. Differences were estimated using 
ordinary two-way ANOVA, followed by Tukey’s multiple comparison post test. *p<0.05; **p<0.01; 
***p<0.001 and ****p<0.0001 vs. untreated cells or vs. the referred sample. 
 
Observing different outcomes under identical initial conditions may seem 
counterintuitive, however, as previously reported (Guardia et al. 2012), the natural 
variability of the cell-nanoparticle system, including differences between batches of 
particles and antibodies, can lead to different plateau T. This natural variability highlights a 
speculative advantage of using two independent particle populations, whereby insufficient 
specific iron loading could be augmented by the nonspecific population as necessary. 
3.6. Comparative MHT efficiency  
Despite the extensive literature on MHT, none could be directly compared to our work 
because, first, only a few reports refer to the use of MHT in leukaemia cells (Giustini et al. 
2011, Ren et al. 2012), and second, CXCR4-targeting MNPs have only been previously 
reported as MRI contrast agents for pancreatic cancer, i.e., in a context of cancer 
diagnostics (He et al. 2012, Zevon et al. 2015). Accordingly, the following discussion will 
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rely on comparisons to studies that used cell lines, targeting and operating conditions 
different from ours. 
The variety of criteria to evaluate the practicality and efficiency of the proposed MHT 
notwithstanding, we find that our treatment compares very favourably to those reported in 
the literature. For example, in vitro MHT studies using CREKA-functionalized MNPs 
reported a 60 % decrease in cell viability under AMF conditions similar to ours (Kruse et al. 
2014). Considering the required iron concentration provides an insightful context for this 
impressive result. In our work AMF was applied after removing the excess free particles 
that are not associated with the cells. We note that in reference (Kruse et al. 2014) the 
AMF was applied without removing the excess of free particles and, thus, the total iron 
concentration was more than 7 higher than that used in our work (2.2 vs. 0.3 g·L-1, 
respectively). Other studies using functionalized MNPs observed similar MHT efficiency 
outcomes, however, a quantitative comparison in terms of iron concentration is not 
possible because only overall mass-concentration of nanoparticles was reported (Liao et 
al. 2015, Sadhasivam et al. 2015). 
In an example using non-targeted nanoparticles, Guardia and co-authors reported a 
50–100 % decrease in cell viability in vitro in an experiment using magnetic nanocubes 
(Guardia et al. 2012). The heating power provides an important basis for the comparison 
of different AMF protocols for MHT. Specifically, the heating power is an increasing 
function of the product of the field amplitude H and the frequency f (H·f product), which 
therefore provides a quantitative index of the heating power for a given AMF protocol. In 
terms of the overall heating efficiency, in both reference (Guardia et al. 2012) and our 
work, samples reached 43 ºC after a 1 h AMF application. This suggests an approximately 
linear effect of both AMF power and iron concentration on the heating efficiency, as we 
used 8 higher H·f product (the maximum of 17.4 x 109 vs. 2.2 x 109 A·m-1·s-1) and a 6.5–
13 lower iron concentration (0.309 vs. 2.0–4.0 g·L-1 Fe, respectively) to achieve a similar 
Tc. In terms of the cell death outcome, in our strategy decreasing cell viability from ca. 
15 % to ca. 0 % (after 72 h) required an increase of T of only 2.5 ºC, whereas with 
magnetic nanocubes a T increase of 22 ºC (up to 65 ºC), and a concomitant increase in 
iron concentration to 5 g·L-1 (16 higher than the one used in this work), was reported for 
reaching 100 % cell death (Guardia et al. 2012). In our approach, a shorter incubation 
time (3 h vs. 24 h) was sufficient to reach this outcome. Another previous study that 
reported SAR values comparable to ours while using AMF with a lower H·f product 
similarly relied on a proportionally higher total iron concentration (Hayashi et al. 2013). 
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We find the outlook for our strategy of combining specific and nonspecific populations 
of nanoparticles for MHT to be promising both in terms of efficiency and the potential 
range of applications. As discussed above, the efficiency of MHT—evaluated via either 
heating or cell death outcome—achieved in our strategy favourably compares to those 
reported in the literature (Giustini et al. 2011, Guardia et al. 2012, Kruse et al. 2014). 
Furthermore, our strategy could enhance other implementations of MNP-based cancer 
therapies. First, it provides a straightforward approach to reaching cytotoxic magnetic 
hyperthermia whenever specific (targeted) iron content alone is insufficient, particularly in 
a mono-therapeutic regimen. Second, it suggests the possibility of a broader (e.g., tissue-
wide or even systemic) application of non-targeted nanoparticles, combined with a more 
localized and/or targeted strategy. Crucially, the localization of cytotoxic MHT under this 
strategy remains defined by the specific (targeted) particles, i.e., unaffected by the 
supplemental nonspecific particle population. Furthermore, a lower (and more easily 
manageable) concentration of each component would be required. Finally, our strategy 
can directly benefit from all the enhancements of MHT that have been proposed in the 
literature, including a combination of hyperthermia with chemotherapy agents (Kim et al. 
2015, Quinto et al. 2015), or with photothermal therapy (by taking advantage of both 
magnetic and photothermal properties of iron oxide nanoparticles) (Espinosa et al. 2016), 
or by confining the MHT region using a static magnetic field (Ma et al. 2015). 
 
4. Conclusions 
This work describes an efficient in vitro magnetic hyperthermia methodology to 
achieve complete death of Jurkat cells using a combination of CXCR4-targeted and non-
targeted magnetic nanoparticles. As expected in our strategy, this lethal MHT outcome 
could only be attributed to the combined iron loading resulting from both specific 
(targeted) and nonspecific (non-targeted) particle populations. This controlled strategy is a 
rare example of using MHT in a mono-therapeutic context to achieve complete cell death 
after a 1-h exposure to AMF, therefore proving its promise for future in vivo evaluations. 
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Combining the Iron Loading of CXCR4-Targeted and Non-Targeted 
Nanoparticles to Efficiently Kill Jurkat Cells via Unassisted Magnetically-Induced 
Hyperthermia 
 
Vânia Vilas-Boas*, Begoña Espiña, Yury V. Kolen’ko, Manuel Bañobre-Lopez, José 
Alberto Duarte, Verónica Martins, Dmitri Y. Petrovykh, Paulo Freitas and Félix D. 
Carvalho* 
 
Optimization of AMF parameters 
The MHT experiments were performed using a DM 100 nB nanoScale Biomagnetics 
AMF applicator equipped with an optical temperature probe. The influence of the different 
combinations of AMF parameters on cell viability was initially studied in order to select the 
conditions that would lead to higher MHT efficiency. To do so, U87MG cells (ATCC® 
HTB-14™, cultivated in a controlled atmosphere containing 5 % CO2, at 37 ºC, in Eagle's 
Minimum Essential Medium + 10 % Hyclone FBS) were detached using trypsin, incubated 
with SPIONs and submitted to different combinations of frequency and field amplitude, as 
shown in Figure S1. These preliminary results suggested that submitting the samples to 
temperatures (T) above 40 ºC for longer periods increased MHT efficiency. Cell viability 
data were obtained using PrestoBlue® cell viability reagent.  
  
Figure S1 – Optimization of AMF parameters for efficient MHT. a) Different AMF parameters 
were tested to evaluate the most efficient MHT conditions to be applied in our study. b) Viability 
tests indicate that submitting the samples to T above 40 ºC for longer period of time (red and blue 
curves) leads to more significant reductions in cell viability, to around 50 %. The AMF (688 kHz, 
20 kA·m-1) or the SPIONs-only did not significantly impair cell viability. Differences were estimated 
using one-way ANOVA (Kruskal-Wallis test) followed by a Dunn’s multiple comparisons test. 
***p<0.001 and ****p<0.0001 vs. untreated cells (100% line in the graph). 
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Based in the preliminary results reported above, further tests were performed to 
select the final conditions to be used in the work herein presented. Our in vitro model of T-
cell leukaemia, Jurkat cells (JK), was used for these optimization studies. Two different 
protocols were established using a two-step procedure: A - 869 kHz, 20 kA·m-1, 30 min + 
554 kHz, 24 kA·m-1, 30 min, or B – 554 kHz, 24 kA·m-1, 30 min + 869 kHz, 20 kA·m-1, 
30 min. Figure S2 shows the heating profiles obtained when applying protocols A or B to 
JK cells previously incubated for 1 h, with MP–CXCR4, after removing the excess of free 
MPs by centrifugation (125 g, 5 min).  
  
Figure S2 – Selection of AMF parameters for efficient MHT on Jurkat cells. Two different 1 h 
AMF protocols were tested: protocol-A – 30 min at 554 kHz, 24 kA·m-1, followed by 30 min at 
869 kHz, 20 kA·m-1; protocol-B – 30 min at 554 kHz, 24 kA·m-1, followed by 30 min at 869 kHz, 
20 kA·m-1. In protocol-A 40 ºC are reached in 25 min and T is kept above this level throughout the 
rest of the protocol. Protocol-B needed more time to reach 40 ºC (40 min), which may limit the 
exposure time to high and damaging T. 
 
The heating curve from protocol-A shows that a high T (above 40 ºC) is reached in 
the first half of the protocol, which is kept in the second half of the AMF application as a 
consequence of a decrease in the overall AMF power. Following protocol-B, in turn, leads 
to a lower T (than protocol-A) in the end of the first half of the procedure, which further 
increases in the second half of the protocol due to the overall increase AMF power. 
Although a higher absolute T is reached at the end of protocol-B application, protocol-A 
reached 40 ºC in 25 min and the T was kept above this threshold for efficient MHT for at 
least 35 min. These findings suggest protocol-A to be the most suitable, amongst the 
tested, to be applied in the subsequent work. 
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CXCR4 expression in Jurkat cells 
Surface expression of CXCR4 receptor in JK cells was assessed by flow cytometry 
after incubating ca. 2.5×105 cells with 5 μL PE-conjugated mouse anti-human monoclonal 
CXCR4 antibody (clone 44717, R&D Systems, Abingdon, UK) for 30 min, at 37 ºC, in the 
dark, in 2 % BSA. In parallel, samples with the matched isotype control (IC) antibody (PE-
conjugated mouse anti-human monoclonal IgG2b, ImmunoTools GmbH, Friesoythe, 
Germany) were prepared to depict unspecific staining. After this incubation period, cells 
were washed with cold PBS and kept on ice, in the dark, until flow cytometry analysis. 
Flow cytometry parameters were set as described in section 2.6 of the main text. 
Fluorescence due to CXCR4–PE was followed in FL-2 channel, and 7-AAD’s (BD 
Pharmingen™, BD Biosciences, USA) fluorescence (followed on FL-4 channel) was used 
to exclude dead cells from the analysis. FCS files were analysed using ProSort™ software. 
The results confirmed that, as expected, Jurkat cells are highly CXCR4 expressing cells 
(Figure S3). 
  
Figure S3 – Overexpression of CXCR4 in Jurkat cells.  
The expression of CXCR4 in JK cells was assessed by flow cytometry using a PE-labelled anti-
CXCR4 antibody. The results were plotted against a PE-labelled isotype control (IC) antibody 
histogram to better demonstrate the high expression levels of the receptor in this cell line. 
 
Figure S4 presents the kinetic readings of caspase-3 activity and cell viability levels 
for Jurkat cells with the each particle population independently, after exposure to the 
selected AMF conditions (protocol-A, Figure S2). As stated in the main text of this work, 
MHT performed on JK+SPION+AMF samples did not produce cytotoxicity signatures. For 
the JK+MP–CXCR4+AMF samples, caspase-3 activity was significantly induced (p<0.01, 
Figure S4) but failed to produce a significant reduction in cell viability levels. 
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Figure S4 - Caspase-3 and cell viability assays after MHT application when only one type of 
particles was used.  
When using SPION only, average Tc was kept around 34.5 ºC (see Figure 1), which is not 
expected to affect cell viability. Indeed, caspase-3 activity did not significantly change, and cell 
viability was not significantly impaired, comparing to cells-only control (100 % dashed line). When 
using only MP–CXCR4, the average Tc was 40.5 ºC (see Figure 1), which could yield some toxicity 
in cancer cells. An evident increase in caspase-3 activity was observed in this case (**p<0.01 vs. 
untreated cells), but cell viability did not decrease more than 35 %. Differences between the 
observed caspase-3 slopes were estimated using repeated measures two-way ANOVA followed by 
Dunnett’s multiple comparisons test; differences between treated and untreated cell viability rates 
in both time-points were estimated using ordinary two-way ANOVA followed by Dunnett’s multiple 
comparisons test. 
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Abbreviations: 
7-AAD – 7-aminoactinomycin D 
AMF – Alternating magnetic field 
AnV–PE – Annexin-V labelled with phycoerythrin 
BSA – Bovine serum albumin 
DMEM – Dulbecco’s modified essential medium 
DMEM/ F-12 – Dulbecco’s modified Eagle’s medium with nutrient mixture F-12 
EDTA - ethylenediaminetetraacetic acid 
FBS – Fetal bovine serum  
GBM – Glioblastoma multiforme 
HEPES – 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIV – Human Immunodeficiency Virus 
HBSS – Hanks balanced saline solution with (+/+) or without (-/-) calcium and magnesium 
ions 
IC – Isotype control 
ICP-OES – Inductively-Coupled-Plasma – Optical Emission Spectrometry 
LDH – Lactate dehydrogenase 
MHT – Magnetic hyperthermia 
MNP – Magnetic nanoparticle 
MP – Magnetic particle 
PBS – Phosphate buffer saline solution 
RIPA – Radioimmunoprecipitation assay 
RT – Room temperature 
SD – standard deviation 
T – Temperature 
Tc – Constant temperature 
TEM – Transmission electron microscopy 
Tmax – Maximum temperature 
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Abstract: 
The cell-surface expression levels of a selected target often hamper the development of 
an efficient targeted strategy to treat cancer. In the case of magnetic hyperthermia (MHT) 
treatments, this phenomenon limits the accumulation of magnetic material by cancer cells, 
which is crucial for the achievement of lethal temperatures and, therefore, treatment 
effectiveness. Herein, we describe the optimization of a highly effective MHT treatment, 
combining targeted and non-targeted nanoparticles, applied to an in vitro model of 
glioblastoma multiforme (GBM) expressing intermediate levels of a selected surface target, 
the chemokine receptor, CXCR4. 
The CXCR4 at the surface of LN229 cells (in vitro model of human GBM) was targeted 
using immuno-modified magnetic particles, after a boost of magnetic material was provided 
to cells using non-functionalized nanoparticles. Under specific alternating magnetic field 
conditions the sample’s temperature increased, leading to cell death. A model of human 
kidney normal cells (HK-2) was used as control. 
MHT treatment resulted in significantly different temperature profiles between GBM and 
normal cells, leading to extensive levels of cancer cell death as briefly as 2 h after MHT. HK-
2 cells were kept practically undamaged during the same procedure. Using an isotype 
control antibody attached to the particles, instead of anti-CXCR4, further confirmed the role 
of the targeting system in this strategy. 
The proposed methodology was highly effective in killing GBM cells, following a necrotic 
pathway. The dramatic difference between the outcomes for cancer and normal cells, 
treated under the same conditions, suggests that undesirable side effects could be 
minimized in future applications for GBM treatment. 
 
Keywords: cancer treatment; glioblastoma; nanoparticles; magnetic hyperthermia; 
CXCR4  
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1. Introduction 
Glioblastoma multiforme (GBM) is a tumour of the brain that arises from astrocytes, 
being the most frequent (around 52% of all primary brains tumours) (AANS 2015) and 
aggressive type of brain tumours. Despite the therapeutic efforts to overcome it (surgery, 
chemotherapy and radiotherapy), 95 % of the patients die within 12 to 15 months after 
diagnosis (Bleeker et al. 2012). This very poor prognosis for GBM patients highlights the 
need for more efficient and safer treatments. 
Nearly twenty years have passed since CXCR4, a chemokine receptor known to be a 
co-receptor for Human Immunodeficiency Virus (HIV) infection of CD4 cells (Feng et al. 
1996), was found to be overexpressed in GBM, compared to normal brain tissue (Sehgal et 
al. 1998). An association was established between CXCR4 expression and tumour 
proliferation, aggressiveness, metastatic ability and resistance to chemotherapy (Rempel et 
al. 2000, Rubin et al. 2003, Ehtesham et al. 2006, Redjal et al. 2006, Zagzag et al. 2006). 
These facts make CXCR4 an appealing target to be used in cancer treatment. Initially 
developed to prevent HIV from infecting susceptible cells, the CXCR4 antagonist, AMD3100 
(Plerixafor), prevented tumour recurrence in a mouse model of xenografted GBM (Kioi et al. 
2010), and was recently suggested to be included in the adjuvant treatment of GBM in 
association with other drugs (Rios et al. 2016). 
The local heat generated by magnetic nanoparticles (MNPs) under an external 
alternating magnetic field (AMF), called magnetic hyperthermia (MHT), is currently being 
exploited to destroy cancer cells or sensitize them to other treatments, such as radiation 
(MagForce 2016). MHT treatment of a number of different cancer types showed to be well 
tolerated, with moderate side effects, in phase I clinical trials (Wust et al. 2006, Johannsen 
et al. 2007). Phase II clinical trials in GBM patients were encouraging, showing a 7.2 to 
8.6 month increase in overall survival (Maier-Hauff et al. 2011), but there’s still margin for 
treatment improvement. Until now, literature on this topic mostly suggests MHT as a 
sensitizing therapy in combination with stereotactic radiotherapy (Maier-Hauff et al. 2011), 
with chemotherapy (Kim et al. 2015, Quinto et al. 2015), or other therapies (Yin et al. 2014, 
Yuan et al. 2014, Di Corato et al. 2015), which is mostly due to insufficient effectiveness of 
MHT in a mono-therapeutic context. The use of functionalized nanomaterials, often with 
monoclonal antibodies (Zhang et al. 2011), that can target specific molecules at the cancer 
cell membrane has been regarded as a means to improve MHT outcome and safety profile. 
As previously discussed by our group (Manuscript 2), this targeted MHT strategy is 
dependent on the amount of target molecule available at the cell surface (limiting the 
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targeted binding of functionalized MNPs), as well as on the cell’s iron loading (limiting MHT 
efficiency). 
This work describes the optimization and application of an MHT therapeutic strategy 
based on the combined use of both CXCR4-targeted and non-targeted magnetic 
nanoparticles to kill glioblastoma cells expressing intermediate levels of CXCR4. 
 
2. Materials and methods 
2.1. Reagents 
All reagents used in this study were of analytical grade or of the highest grade available. 
Fetal bovine serum (FBS) was purchased from HyClone UK, Ltd, Northumberland, England, 
UK. Penicillin (10,000 U·mL-1) and streptomycin (10,000 μg·mL-1), herein referred to as Pen-
Strep, Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g·L-1 glucose, sodium pyruvate, 
nicotinamide adenine dinucleotide reduced form (NADH), triton x-100, 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), ethylenediaminetetraacetic acid 
(EDTA), KH2PO4, K2HPO4.3H2O, CaCl2, NaCl, glycerol, and bovine serum albumin (BSA) 
were purchased from Sigma Inc., St. Louis, MO USA. Dulbecco’s modified Eagle’s medium 
with nutrient mixture F-12 (DMEM/ F-12) and GlutaMAX™, trypsin 0.25 %-EDTA, fungizone 
(250 μg·mL-1) and human transferrin (4 mg·mL-1) were purchased from Gibco Laboratories 
(Lenexa, KS, USA). Anti-mouse IgG-peroxidase polyclonal antibody was purchased from 
Amersham Pharmacia Biotech (Buckinghamshire, United Kingdom). BD Pharmingen™ 
Phycoerythrin (PE)-labelled Annexin-V (AnV-PE) and 7-aminoactinomycin D (7-AAD) were 
purchased from BD Biosciences, USA. Anti-human CXCR4, clone 12G5, low endotoxin, 
azide-free monoclonal antibody produced in mouse, and its matched isotype-control, mouse 
anti-human monoclonal IgG2a (IC) were purchased from BioLegend Inc., San Diego, CA, 
USA.  
2.2. Cell culture 
Human cell lines from glioblastoma (LN229, ATCC® CRL-2611™) and normal kidney 
(HK-2, ATCC® CRL-2190™) were purchased from the American Type Culture Collection 
(Manassas, VA, USA). LN229 cells were grown in DMEM (high glucose) medium 
supplemented with 10 % FBS and 1 % Pen-Strep, and HK-2 cells were grown in DMEM/F12 
Glutamax™, supplemented with 10 % FBS, 1 % Pen-Strep, 2.5 μg·mL-1 fungizone and 
5 μg·mL-1 human transferrin. Both cell lines were maintained at 37 ºC, in a controlled 
atmosphere of 5 % CO2.  
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2.3. CXCR4 expression in LN229 and HK-2 cells assessed by western blot 
Approximately 1.0106 per well were seeded in 6-well plates and grown for 24 h before 
being scraped (2 wells per condition) in 1 mL ice-cold PBS and centrifuged at 3,000 rpm, for 
5 min, at 4 ºC. Cells were then lysed using ice-cold RIPA buffer (50 mM Tris-HCl pH 8, 
150 mM NaCl, 1 % Triton X-100, 0.5 % sodium deoxycholate, 0.1 % SDS, 5 mM EDTA) with 
1 % (v/v) protease (cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail, Roche) and 
phosphatase (1 mM Na3VO4, 1 mM NaF) inhibitors for 30 min at 4 ºC, and centrifuged at 
13,000 rpm, 10 min, at 4 ºC. Protein content in the supernatant was quantified using 
Coomassie Plus (Bradford) Protein kit (Thermo Fisher Scientific, Inc., Rockford, IL USA) and 
25 μg of protein were diluted 1:1 in 2 x Laemmli buffer with 5 % β-mercaptoethanol, and 
heated at 95 ºC, for 5 min. Samples were kept at -20 ºC until analysis.  
Samples were loaded in a 4–15 % Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-
Rad Laboratories, Hercules, CA, USA) and electrophoretically separated at a constant 
voltage of 75 V using a Tris-glycine running buffer [25 mM Tris base, 192 mM glycine, and 
0.1 % SDS (w/v), pH 8.3]. Proteins were then transferred to a nitrocellulose membrane using 
a transfer buffer [20 % methanol (v/v) in 25 mM Tris base and 192 mM glycine, pH 8.3] at a 
constant voltage of 100 V, for 3 h. A Mini-PROTEAN Tetra cell system (Bio-Rad 
Laboratories, Hercules, CA, USA) was used for the electrophoresis and transfer. 
Membranes were rinsed in Tris-buffered saline solution [TBS: 20 mM Tris base, 300 mM 
NaCl, pH 8.0], blocked for 2 h, at room temperature (RT), in blocking buffer [5 % non-fat 
powdered skim milk (w/v) in Tris-buffered saline solution with 0.05 % Tween 20 (v/v) (TBS-
T)] and then incubated overnight, at 4 ºC, with a mouse monoclonal anti-human-CXCR4 
antibody (clone 44717, R&D Systems, Abingdon, UK) or an anti-α-tubulin in a 1:2,000 
dilution in blocking buffer. After incubation with the primary antibody, membranes were 
washed three times (10 min each) with TBS-T and incubated with the secondary antibody 
[anti-mouse IgG peroxidase polyclonal antibody (1:5,000 in blocking buffer)], for 1 h, at RT. 
Following two more washes in TBS-T (10 min each), bands were revealed using ECL Prime 
chemiluminescence reagents (Amersham Pharmacia Biotech, Buckinghamshire, United 
Kingdom), according to the supplier’s instructions, and visualized using a G:Box Chemi XT4 
(Syngene, Cambridge, UK). Quantification of band intensity was performed using Image J 
analysis software (NIH, USA). Final results, collected from three independent experiments, 
represent the ratio between CXCR4 and α-tubulin band intensities.  
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2.4. Incubation of cells with magnetic nanoparticles 
A previously developed protocol was used (Manuscript 2), with some modifications. 
Three million cells per T25 culture flask were incubated with increasing concentrations of 
poly(acrylic acid)-coated superparamagnetic nanoparticles (SPIONs), synthesized and 
characterized by our group (Kolen’ko et al. 2014), in cell culture medium, for 150 min, at 
37 ºC. The total initial iron concentration of those SPIONs was 0.176, 0.195, 0.217 or 
0.260 g·L-1 [Fe]. Excess of free SPIONs was then removed and the cellular monolayer was 
washed with HBSS (+/+). Concurrently, 250 nm composite dextran iron oxide particles (09-
20-252 Nanomag®-D, Micromod Partikeltechnologie GmbH, Rostock, Germany), with 
protein-A at the surface, were incubated (30 min, at RT, with agitation) with CXCR4 antibody 
or an isotype control (IC) antibody to obtain functionalized particles designated herein as 
MP–CXCR4 or MP–IC, respectively. Cells were further incubated with these functionalized 
particles at 0.264 g·L-1 [Fe], in 2 % BSA, for 70 min, at 37 ºC, with mild agitation. Excess of 
free, functionalized MPs was removed and the cellular monolayer was washed with HBSS (-
/-) prior to detachment with trypsin-EDTA solution. Samples containing an average 6106 
cells were then centrifuged at 125 g, for 5 min, recovered in 1 mL cell culture medium and 
transferred to glass vials previously blocked with 2 % BSA.  
2.5. Magnetic hyperthermia treatment (MHT)  
The application of AMF to samples prepared in the previous step was performed using 
a magnetic field generator (DM 100, nB nanoScale Biomagnetics, Zaragoza, Spain) 
operating at 869 kHz and 250 Oe (≈ 20 kA·m-1) for the first 30 min of the experiment, 
followed by another 30 min at 554 kHz and 300 Oe (≈ 24 kA·m-1). The temperature (T) of the 
suspension was measured using an optical temperature probe included in the equipment 
and the maximum T reached at the end of the first step of AMF was called Tmax and the 
average T kept thereafter was called Tc (from “constant T”). After AMF application, cells 
were kept in suspension for the flow cytometry studies or seeded for the subsequent tests. 
2.6. Studying the interaction of cells with nanoparticles 
2.6.1. Transmission electron microscopy (TEM) 
Cells (2106) were incubated with 0.217 g·L-1 [Fe] of SPION for 150 min, washed, 
trypsinized and collected. TEM samples were prepared following the protocol described in 
Manuscript 2. Briefly, cells were pelleted at 1,000 g, for 5 min, at 4 ºC, fixed with 2.5 % 
glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4 for 2 h, and rinsed with cacodylate 
buffer 0.1 M. Samples were then post-fixed using 2 % osmium tetroxide, dehydrated with 
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graded ethanol, embedded in Epon and further placed 2 to 3 days at 60 ºC to promote resin 
polymerization. Ultrathin (100 nm) sections, contrasted with uranylacetate and lead citrate, 
were prepared on cupper grids (300 Mesh) for TEM analysis (Zeiss EM10A, Carl Zeiss, 
Oberkochen, Germany). 
2.6.2. Immunostaining for optical microscopy 
To study the interaction between cells and antibody-functionalized MPs, 2106 cells 
were incubated with 0.264 g·L-1 [Fe] MP–IC or MP–CXCR4 for 70 min, at 37 ºC, and then 
washed, trypsinized and collected. Cells were then pelleted at 125 g, for 5 min, at RT, and 
fixed with paraformaldehyde 4 % in PBS 0.1 M, pH 7.2–7.4, during 24 h. Samples were 
subsequently dehydrated in graded ethanol, cleared with xylene, and embedded in paraffin 
following routine procedures. A microtome (Leica Microsystems, Model RM2125) with a 
disposable stainless steel blade (Leica Microsystems, Model 819) was used to cut 5 μm 
sections from paraffin blocks. These sections were then floated onto warm water (42–44 ºC), 
and mounted on silane-coated slides (Sigma, S4651-72EA). After dewaxing with xylene and 
rehydration with graded alcohol, slides were placed in 10 mM citrate buffer in a pressure 
cooker during 10 min for antigen retrieval, and subsequently placed in a blocking solution of 
3 % BSA during 30 min. The endogenous peroxidases were further blocked with a solution 
of methanol and hydrogen peroxidase during 30 min. After washing, sections were 
incubated for 2 h with a sheep anti-mouse antibody conjugated with horseradish peroxidase 
(Amersham Pharmacia Biotech). SIGMAFAST® DAB with Metal Enhancer Tablets (D0426-
50SET, Sigma) was used as substrate during 3 min, according to manufacturer's instructions, 
and the sections were further counterstained with Mayer's haematoxylin. Optical images 
were collected using an Inverted Wide-Field Microscope Eclipse Ti-E, Nikon. 
2.7. Inductively-Coupled-Plasma–Optical Emission Spectrometry (ICP-OES) 
for iron quantification 
To measure the amount of iron in each sample, after MHT, samples were digested in 
1 mL HCl 37 %, at RT, for 72 h, and then analysed by ICP-OES, using an ICPE-9000 
Multitype ICP Emission Spectrometer (Shimadzu). Three repeated measurements per 
sample were performed. 
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2.8. Assessment of cell viability after MHT 
2.8.1. Annexin-V & 7-AAD labelling for flow cytometry and fluorescence 
microscopy 
Double staining with AnV–PE and 7-AAD was performed 2 h after MHT treatment, for 
flow cytometry, and 20 h after MHT for laser scanning confocal microscopy. For flow 
cytometry studies, 2x105 cells in 50 μL of Annexin-V-binding buffer (diluted from the 10 x 
stock solution: 0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM CaCl2), were incubated with or 
without 2 μL of AnV–PE, and kept for 30 min, at RT, in the dark. Cells were centrifuged at 
210 g, 5 min, at 4 ºC and immediately analysed. 7-AAD was used to detect membrane 
damage in these samples. Fluorescence collected in FL2 channel (fluorescence from AnV–
PE) was plotted vs. the one collected in FL4 channel (fluorescence from 7-AAD), and the 
percentage of positive cells for each channel (or both) was estimated after establishing the 
quadrants based on the controls. For each sample, at least 10,000-gated events were 
collected.  
For the laser scanning confocal microscopy (LSCM) studies, after MHT application, 
cells were seeded in 8-well micro-slides with tissue culture treated surface (μ-slide 8-well 
ibiTreat, Ibidi, Martinsried, Germany), in 200 μL of cell culture medium, and incubated for 
20 h to allow attachment. Two μL of AnV–PE in 18 μL of 10 concentrated AnV-binding 
buffer (0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM CaCl2) were added to the 200 μL of 
medium in each well and incubated for 30 min at 37 ºC, in the dark. Two μL of 7-AAD were 
added to each well and incubated for 10 min, in the same conditions. The medium (with 
excess of dyes) was removed and the cells were fixed with 4 % paraformaldehyde in PBS, 
for 15 min, at RT, after which each well was washed twice with HBSS (+/+). The samples 
were imaged using a laser scanning confocal microscope (LSM 780, Carl Zeiss) using 488 
and 514 nm excitation lasers. 
2.8.2. Lactate dehydrogenase (LDH) leakage assay 
LDH leakage from cells is a consequence of membrane disruption, so LDH activity in 
the cell culture medium is used as a measure of cell death. A previously described protocol 
(Manuscript 2) was used. Results from the LDH released into the extracellular medium (LDH 
leakage) were expressed as cell death values calculated according to a previously described 
methodology (Barbosa et al. 2014). Cell death from untreated controls was then subtracted 
so that the presented cell death values translate solely the effects of the treatment. 
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2.8.3. Metabolic rate assay 
Around 15,000 cells per well were seeded in 96-well and cell viability was assessed 24 
and 72 h after MHT application by the addition of 10 μL PrestoBlue® cell viability reagent 
(Molecular Probes™, Carlsbad, CA) to each well. After incubation at 37 ºC for 1 h, 
fluorescence signals were collected using a microplate reader (Synergy H1, BioTek 
Instruments) with excitation wavelength at 560 nm and emission wavelength at 590 nm. 
2.9. Statistical analysis 
All data are presented as mean ± standard deviation (SD), except when stated 
otherwise, of at least two independent experiments. Normality of the data distribution was 
assessed applying three tests: KS normality test, D’Agostino and Pearson omnibus 
normality test and Shapiro-Wilk normality test. Differences on the Tmax and iron content 
between tested conditions were estimated using two-way ANOVA followed by Tukey’s 
multiple comparisons test. Multivariate linear regression models were used to estimate the 
dependence of Tmax on the initial iron amount. Whenever singular values of two variables 
were plotted, Spearman’s rank correlation was estimated to evaluate the magnitude of the 
association between those variables (Tmax and iron loading per sample (mg Fe·mL-1), Tmax 
and cell death levels 2 and 24 h after MHT, and between iron loading per sample and cell 
death levels after 24 h). Correlations were considered significant for r>0.6 and p<0.05.  
All statistical analysis was carried out using GraphPad Prism software v6 (San Diego, 
CA). P values under 0.05 were considered statistically significant. 
 
3. Results and discussion  
This work describes the optimization and application of a MHT-based strategy to kill 
GBM cells that express intermediate levels of cancer biomarkers. The overexpression of 
such cancer biomarkers is often sufficient for discrimination from normal cells in a diagnostic 
context; however, those expression levels may be insufficient for successful targeting in 
therapeutic context. Our group has previously attempted to kill Jurkat cells, an in vitro model 
of leukaemia expressing high levels of CXCR4, with magnetic hyperthermia using a purely 
targeted system (anti-CXCR4-functionalized particles). We found that an independent 
magnetic boost was necessary to reach temperatures that could significantly reduce cell 
viability; a second population of non-targeted nanoparticles was then successfully used to 
provide the magnetic boost. In this work we propose the use of a similar strategy applied to 
GBM cells that express lower levels of that same target receptor. 
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3.1. Assessing CXCR4 expression levels 
CXCR4 expression in LN229 and HK-2 cells was assessed by western blot (Figure 1), 
using Jurkat cells as a positive control (high expression of CXCR4). As expected, Jurkat 
clearly presented the highest levels of CXCR4, while LN229 cells expressed intermediate 
levels of the target receptor, and HK-2 cells (normal cells) presented the lowest levels 
(Figure 1).  
  
Figure 1 –CXCR4 expression in LN229 and HK-2 cells.  
Jurkat cells were used as a positive control of high CXCR4 expression. LN229 cells expressed 
intermediate CXCR4 levels while HK-2 cells exhibited the lowest levels of that chemokine receptor.  
 
3.2. Magnetically-induced hyperthermia 
The optimization and fine-tuning of the hyperthermia strategy presented herein was 
intended to find the most appropriate conditions to efficiently kill cancer cells. The 
concentration of MP-CXCR4, the time of incubation of cells with particles, and the number of 
cells per experiment, had an impact on the observed heating and MHT outcome (Figure S1). 
Experiments with normal cells were carried in parallel, under the same conditions, to monitor 
the potential occurrence of side effects in normal cells. Different starting amounts of iron 
were tested, by changing the amount of the non-targeted (unspecific) nanoparticles, while 
keeping constant the amount of functionalized nanoparticles. The total iron concentration in 
all cases was such that the temperature (T) reached during MHT could affect LN229 cells 
but not HK-2 cells. After removing the excess of free nanoparticles by rinsing the monolayer, 
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cells were detached and submitted to a biphasic AMF, which has been previously tested and 
optimized to kill Jurkat cells (Manuscript 2). This biphasic AMF consists of a 30 min period at 
869 kHz, 20 kA·m-1, after which the maximum T (Figure 2, Tmax) of the MHT is reached, 
followed by another 30 min period at 554 kHz; 24 kA·m-1 that keeps the T constant (Figure 2, 
Tc) for enough time to produce cytotoxicity (Falk and Issels 2001, Taratula et al. 2013). The 
heating profiles obtained for the different amounts of SPIONs are presented in Figure 2, 
independently for each cell type and particle functionalization. 
  
Figure 2 – Heating profiles of LN229 and HK-2 cells when exposed to different concentrations 
of SPIONs (0.176–0.260 g·L-1 Fe) and to CXCR4- or IC-functionalized MPs (0.264 g·L-1 Fe).  
The dotted line marks 41 ºC, the maximum temperature reached by normal (HK-2) cells, to facilitate 
comparisons between the cell types or different particle functionalization. Tmax points the T reached at the end of the first heating step. Tc refers to the average T kept thereafter. Results are mean+SD of 
at least two independent experiments per condition. 
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The differences in the heating profiles of LN229 (cancer) and HK-2 (normal) cells treated under 
the same conditions were evident. All HK-2 heating curves reached no more than 41 ºC, considered a 
safe temperature for normal cells, during the entire AMF application period (30+30 min), 
independently of the initial amount of SPIONs. For the similarly treated LN229 samples, all the curves 
clearly overcame this threshold T in less than 25 min, and the samples’ T was kept above this 
threshold until the end of AMF application. As expected, LN229 samples reached lower T when the 
functionalized particles had the IC antibody, instead of anti-CXCR4. The average maximum 
temperature (Tmax) reached for each condition, at the end of the first 30 min, was used for comparison 
between the experiments and was compiled in Table 1. 
 
Table 1 – Average maximum temperature (Tmax) reached in MHT experiments using increasing initial iron amounts. 
 Initial [Fe] (g·L-1)   
Treatment 0.176+0.264 0.195+0.264 0.217+0.264 0.260+0.264 slope r2 
LN229+SPION+MP–CXCR4 42.4±0.5 42.3±1.8 45.8±0.6 46.9±0.8 10.28 0.84 
LN229+SPION+MP–IC 41.9±1.3 40.7±1.8 43.4±2.3 43.4±1.9 * 4.32 0.49 
HK-2+SPION+MP–CXCR4 40.7±0.5 40.9±0.4 40.0±0.6 *** 41.2±0.2 *** 0.72 0.09 
Results are mean±SD of at least two independent experiments. Differences were estimated using regular two-way ANOVA 
followed by Tukey’s multiple comparisons post test. *p<0.05 and ***p<0.001 vs. LN229+SPION+MP–CXCR4 for the same 
initial iron amount. The slopes obtained from linear regression fitting are also presented along with the goodness of this fit, r2, 
which indicates the nearly linear variation between the reached Tmax and the initial iron amount for the LN229+SPION+MP–
CXCR4 samples. 
 
Analysing the slope of the dependence of Tmax on the initial concentration of the 
SPIONs indicates three clearly different regimes for the three treatments in Table 1: the 
strongest dependence (r2=0.84) was observed for the LN229+SPION+MP–CXCR4 samples, 
a much weaker dependence (r2=0.49) for the LN229+SPION+MP–IC, and no dependence 
(r2=0.09) for the HK-2+SPION+MP–CXCR4 samples. 
For the highest tested iron loading, the Tmax observed for LN229+SPION+MP–CXCR4 
significantly differed from the samples using MP–IC, instead of MP–CXCR4 (Table 1, 
p<0.05). The mean Tmax obtained for LN229 cells with MP–CXCR4 was higher than the ones 
obtained for HK-2 cells under the same conditions, nevertheless, they only reached 
statistical significance for the two highest tested initial iron amounts (Table 1, p<0.001).  
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3.3. Interaction of particles with cells 
The uptake of SPIONs by both cell lines was confirmed by TEM, as exemplified by the 
micrographs of LN229+SPIONs or HK-2+SPIONs showing SPIONs internalized in 
endosomal compartments (Figure 3, red arrows), and not in other organelles or free in the 
cytoplasm, in both cells lines. Quantification of iron levels in these samples by ICP-OES 
showed increased uptake for LN229 compared to HK-2 cells (88.27 vs. 55.78 pg Fe/cell, 
respectively), contributing to the observed differences in the reached Tmax. This intriguing 
difference in the uptake between a cancer and a normal cell line has been observed and 
reported before (Rago et al. 2011, Prijic et al. 2012, Sims et al. 2016). Differences in the 
composition of the cell membrane are believed to play a role in this regard (Rago et al. 
2011). Further studies should be conducted to understand whether normal cells, in general, 
incorporate less non-targeted nanoparticles than cancer cells, as this could indicate a 
“targeting” system per se. 
  
Figure 3 – Uptake of SPION by LN229 and HK-2 cells.  
Transmission electron micrographs showing that both LN229 (a) and HK-2 (b) cells uptake SPIONs to 
endosomal compartments (red arrows). Scale bar is 200 nm. 
 
Using an HRP-labelled secondary antibody, which targets the primary antibody 
attached to MPs, a bigger amount of MP–CXCR4 was detected interacting with LN229 
(Figure 4a) than with HK-2 cells (Figure 4c). These particles were found surrounding the 
LN229 cell membrane (detail in Figure 4a), almost depicting the shape of the cells, while for 
the HK-2 cells they distributed randomly and in much less quantity (Figure 4c). 
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Figure 4 – Interaction of functionalized MPs with LN229 and HK-2 cells.  
LN229 cells interact to a bigger extent with (a) CXCR4-targeting than with IC-functionalized (b) 
particles. Also, LN229 cells (a) interact more than HK-2 cells (c) with CXCR4-targeting nanoparticles. 
Scale bar is 20 µm. The inserts show details of each picture for better visualization. Iron quantification 
using ICP-OES (d) confirmed the results obtained using immunocytochemistry.  
 
It was also possible to see some unspecific retention of MP–IC particles in LN229 cells 
(Figure 4b), which also contributes for the intermediate Tmax observed for these samples 
(Table 1). The ability of the targeting particles (MP–CXCR4) to distinguish both cell types 
was confirmed by the ICP-OES quantification of the iron levels in these samples, which 
further supported the observed results (Figure 4d). In fact, LN229 cells retained at least the 
double amount of particles of HK-2 cells. Although these high sensitivity techniques could 
detect these differences, the temperature profiles of LN229 or HK-2 cells containing only 
MP–CXCR4 were similar (Figure S2). 
Table 2 shows the average calculated iron content per cell in each sample, depending 
on the initial iron concentration, when using both particle populations. 
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Table 2 – Average iron content per cell (pg Fe/cell) with increasing initial iron amounts. 
 Initial [Fe] (g·L-1) 
Treatment 0.176+0.264 0.195+0.264 0.217+0.264 0.260+0.264 
LN229+SPION+MP–CXCR4 90.0±4.0 61.7±6.3 106.4±16.5 108.0±28.7 
LN229+SPION+MP–IC 80.4±35.8 53.5±0.7 97.7±37.3 77.7±4.2 
HK-2+SPION+MP–CXCR4 44.5±16.6 * 53.3±3.6 41.6±13.3 ** 38.0±10.2 ** 
Results are mean±SD of at least two independent experiments. Differences were estimated using regular two-way ANOVA 
followed by Tukey’s multiple comparisons post test. *p<0.05 and **p<0.01 vs. LN229+SPION+MP–CXCR4 for the same initial 
iron concentration. 
 
In agreement with the observed Tmax results, LN229+SPION+MP–CXCR4 incorporated 
significantly more iron per cell than HK-2 samples (Table 2, p<0.05). For the highest tested 
initial iron amount, these samples accumulated nearly 110 pg Fe/cell to reach a Tmax of 
46.9 ºC (Table 1). These values are in line with a previous work by Gupta and co-authors 
that reported 150 pg Fe/cell in their experiments with folic acid-conjugated nanoparticles for 
MHT, after a 3 h incubation with DU145 prostate cancer cells (Gupta et al. 2016). Oh et al. 
also reported similar values for MDA-MB-231 breast cancer cells after a long 48-h incubation 
with non-targeted, chitosan-coated, magnetic particles (Oh et al. 2016). In agreement with 
the obtained T curves (Figure 2), the iron content in HK-2+SPION+MP–CXCR4 samples did 
not increase as a consequence of increased initial iron amount from either source, almost 
suggesting that a saturation level for the incorporation of nanoparticles was reached in this 
cell line. 
Interestingly, correlation studies show that the iron content retained by each sample 
(measured by ICP-OES) positively and significantly correlated with the reached Tmax 
(Spearman r0.74, p0.0128), for the LN229+SPION+MP–CXCR4 (Figure 5), which was not 
observed for the control samples. 
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Figure 5 – Iron content per sample and its correlation with Tmax and cell death after MHT.  The amount of iron in each sample was quantified by ICP-OES. Spearman r correlation coefficients 
and their p-values, for each group of variables, are provided at the top of the respective graph. A 
significant positive correlation was found between the iron content and the reached Tmax (a), and the levels of cell death (b), in LN229+SPION+MP–CXCR4 samples. 
 
3.4. Cytotoxic outcome 
The cytotoxic effects of MHT on LN229 and HK-2 cells were analysed at different time-
points after AMF application. These results are shown in Figure 6. 
Two hours after MHT, samples were analysed by flow cytometry (Figure 6a) to study 
the possibility of apoptotic/necrotic pathways being triggered by MHT. Samples were 
incubated with AnV–PE and 7-AAD and the amount of cells showing positivity for one or 
both labels was counted. Contrary to what could be expected for the samples reaching 
apoptotic temperatures (≈41–43 ºC), our samples exhibited only very low levels of AnV+-only 
or double-stained cells, the 7-AAD being the main marker for positivity, whenever the T 
would destroy the membrane and allow this dye to enter the cell. A possible explanation for 
this observation, is the time-point at which the assessment was performed being too early 
for this apoptotic marker to be detected, as laser scanning confocal microscopy images 
taken 24 h after MHT showed increased double positive, round and detached cells for 
LN229+SPION+MP–CXCR4 compared to HK-2+SPION+MP–CXCR4 samples (Figure 6d). 
In the absence of a truly apoptotic signature, the events showing positivity were summed 
and presented as “percentage of dying cells” (Figure 6a), which strongly correlated with the 
Tmax for the LN229+SPION+MP–CXCR4 samples (Spearman r0.96, p0.0028). For most of 
these samples, more than 25 % (dashed horizontal line, Figure 6a) of the cells stained 
positive for both labels, while for the control conditions (LN229+SPION+MP–IC and HK-
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2+SPION+MP–CXCR4) remained below this level. A representative dot plot of the event 
distribution of a LN229+SPION+MP–CXCR4 sample is provided in Figure 6b in comparison 
with untreated control cells. 
  
Figure 6 – Individual analysis of cell death/ viability after MHT.  
a) Two h after AMF application, samples were stained with Annexin-V and 7-AAD and analysed using 
flow cytometry. Results are expressed as percentage (%) of dying cells, when positive for any or both 
fluorescence labellings, are shown for the diverse treatments; LN229+SPION+MP-CXCR4 (violet 
dots), LN229+SPION+MP-IC (green dots) and HK2+SPION+MP-CXCR4 (orange dots). b) Dot plot of 
the ★ sample is shown in comparison with untreated cells. “+“ represents the mean. c) LDH leakage 
was evaluated 24 h after MHT as a measure of cell death. Spearman r values with the respective p 
values are provided for correlation studies. d) Laser scanning confocal micrographs of AnV and 7-
AAD labelling of LN229 or HK-2 untreated cells, and 20 h after MHT with SPIONs and MP–CXCR4. 
Scale bar is 20 m. 
 
The leakage of lactate dehydrogenase (LDH) to the extracellular medium is a sign of 
membrane disruption and, consequently, effective cell death. LDH leakage levels were 
measured 24 h after MHT (Figure 6c), using 0.5 % Triton X-100 as a positive control 
(92.39.1 % cell death for HK-2 cells and 99.36.2 % cell death for LN229 cells). In 
accordance with the percentage of dying cells, cell death levels were equal to or greater 
★ 
★ 
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than 25 % for all the LN229+SPION+MP–CXCR4 samples and significantly and positively 
correlated with the observed Tmax (Figure 6c, Spearman r=0.71, p=0.0268). On the other 
hand, cell death was always kept below 20 % for all the HK-2+SPION+MP–CXCR4 samples 
(Figure 6c). 
Although cell death levels never reached 100 %, cell viability experiments after MHT, 
using a metabolic rate assay, showed that LN229+SPION+MP–CXCR4 samples, treated 
with the highest initial concentration of SPIONs, have significantly less viable cells than the 
HK-2 samples treated similarly, exhibiting less than 10 % viable cells 24 h after MHT and 
practically no viable cells 72 h after MHT (purple bars, Figure 7). This outcome was mainly 
dependent on the increase in T, as the used particles alone did not produce significant 
toxicity in any of the cell lines (black and grey bars, Figure 7). The AMF alone (i.e. applied to 
cells without nanoparticles) also did not affect cell viability (Figure S3). These results further 
support the elevated efficiency and overall safety of our strategy. 
  
Figure 7 - Cell viability levels after MHT when using the highest tested amount of iron.  
LN229 cells targeted with CXCR4-functionalized particles showed significantly lower cell viability than 
the HK-2 cells treated similarly. No viable cells were observed 72 h after MHT in LN229+SPION+MP–
CXCR4 samples. The particles used for the experiments did not significantly affect LN229 and HK-2 
cell viability (grey and black bars, respectively). Results are mean+SD. Differences were estimated 
using regular two-way ANOVA followed by Tukey’s multiple comparisons post test. ****p<0.0001 vs. 
untreated cells (dashed line); **p<0.01 and ***p<0.001 vs. the referred sample, for the same end-point. 
 
3.5. Comparative MHT outcome 
One of the main purposes of this work was showing that the developed strategy may be 
applied to cells that expressed intermediate levels of the selected target but also, that it may, 
under similar conditions, differently affect cancer and normal cells. The results now obtained 
show that the proposed treatment (+SPION+MP–CXCR4) reached higher T in cancer than 
Manuscript III 
128 
in normal cells, in particular at the two highest tested initial iron concentrations (Table 1, 
Figure 2), because cancer cells accumulated more iron, both from non-targeted and from 
targeted origin, than normal cells (Table 2, Figure 4). The observed increased heating due to 
MHT lead to significantly increased cell death levels in cancer cells, showing these 
parameters positively correlated (Figures 5–7). The experiments performed in LN229 using 
IC-functionalized particles, further supported the role of MP–CXCR4 in the present strategy. 
The observed differences in cell viability at longer end-points definitely establish this strategy 
as highly efficient in killing cancer cells, while safe for normal cells. 
There are only a few reports in the literature on in vitro targeted MHT in a mono-
therapeutic context (Liao et al. 2015, Thomas et al. 2015). As an example, Thomas and co-
workers, incubated cancer (CD44+) vs. normal (CD44-) cells from mouse, during 1 h, with 
hyaluronic-acid-conjugated particles (to target CD44 antigen) to perform in vitro MHT 
(Thomas et al. 2015). Even though the observed T was not specified, these authors reported 
cell viability levels of ca. 30 % for the cancer cells, without damaging normal cells. In another 
study, Liao et al. targeted liver cancer cells with galactosamine-conjugated nanoparticles to 
perform targeted in vitro MHT (780 kHz, 19 kA·m-1, 20 min), reaching desirably low viability 
levels of liver cancer cells as the ones reported herein (Liao et al. 2015). The application of 
this approach may be limited by the wide expression of asialoglycoprotein receptors, to 
which galactosamine binds to, in normal hepatocyte cells, as well (Shi et al. 2013). 
In fact, most of the reports on targeted MHT in the literature refer to works in which this 
strategy was insufficient to kill cancer cells, therefore mainly being used in combination with 
chemotherapy agents (Mi et al. 2012, Kruse et al. 2014, Gupta et al. 2016). For example, Mi 
and co-workers developed Herceptin-conjugated nanoparticles and tested their MHT 
potential in breast cancer cells. The MHT efficiency of these particles, when submitted to 
AMF, was low (a 40 % reduction in cell viability) and a multimodality nanoparticle system, 
integrating nanoparticles and docetaxel in a copolymer matrix conjugated with Herceptin, 
was then proposed with very promising results. The synergistic effects of chemotherapy and 
targeted MHT lead to cell viability levels similar (lower than 20 % cell viability) to the ones 
reported herein obtained in a pure MHT context (Mi et al. 2012). 
Using AMF parameters very similar to the ones used in this study, Kruse et al. 
described the use of CREKA-functionalized nanoparticles for targeted MHT in a lung cancer 
cell line. Considerably high initial magnetite concentration (3 mg Fe3O4·mL-1  
2.17 mg Fe·mL-1) was necessary to reach T from 41–45 ºC during 20 min, which reduced 
cell viability to 50 %. The MHT strategy was, in the end, improved by an additive effect of 
cisplatin (Kruse et al. 2014). Another work using folate-conjugated nanoparticles for in vitro 
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targeted MHT reported a 35 % decrease in cell viability 24 h, after application of a 265 kHz 
and 27 kA·m-1 AMF during 10 min. These authors have chosen to use this targeted MHT 
strategy to sensitize cancer cells for chemotherapy with doxorubicin, further decreasing cell 
viability levels to around 10 % (Gupta et al. 2016). Combining two different populations of 
magnetic nanoparticles, the strategy proposed herein reached similar results in a mono-
therapy context, and a single MHT session, without the need of using highly cytotoxic, non-
selective, chemotherapeutic agents. 
 
4. Conclusions 
This work shows a successful application of a combination of non-targeted and targeted 
nanoparticles to kill glioblastoma cells, expressing intermediate levels of CXCR4, via 
magnetic hyperthermia, in a mono-therapeutic context. This treatment has proven to be safe 
for normal cells, which express even lower levels of the selected target, providing a 
promising strategy to be used in other types of cancer with similar levels of the same, or 
other, cancer biomarker. 
 
5. Acknowledgements 
V. V.-B. acknowledges FCT (Portugal) for her PhD fellowship (grant 
SFRH/BD/82556/2011). This work received financial support from the European Union 
(FEDER funds through COMPETE) and National Funds (FCT) through project Pest-
C/EQB/LA0006/2013. This work is a result of the project Nanotechnology Based Functional 
Solutions (NORTE-01-0145-FEDER-000019), supported by Norte Portugal Regional 
Operational Programme (NORTE2020), under the PORTUGAL 2020 Partnership Agreement, 
through the European Regional Development Fund (ERDF). 
 
6. Conflict of interest 
The authors declare that they have no competing interests. 
 
 
Manuscript III 
130 
7. References 
American Association of Neurological Surgeons. (October 2015). "Glioblastoma multiforme." 
Retrieved December 2016, from http://www.aans.org/patient information/conditions and 
treatments/glioblastoma multiforme.aspx. 
Barbosa DJ, Capela JP, Silva R, Vilas-Boas V, Ferreira LM, Branco PS, Fernandes E, 
Bastos Mde L and Carvalho F. 2014. The mixture of "ecstasy" and its metabolites is toxic to 
human SH-SY5Y differentiated cells at in vivo relevant concentrations. Arch Toxicol 88(2): 
455-473. 
Bleeker FE, Molenaar RJ and Leenstra S. 2012. Recent advances in the molecular 
understanding of glioblastoma. J Neurooncol 108(1): 11-27. 
Di Corato R, Bealle G, Kolosnjaj-Tabi J, Espinosa A, Clement O, Silva AK, Menager C and 
Wilhelm C. 2015. Combining magnetic hyperthermia and photodynamic therapy for tumor 
ablation with photoresponsive magnetic liposomes. ACS Nano 9(3): 2904-2916. 
Ehtesham M, Winston JA, Kabos P and Thompson RC. 2006. CXCR4 expression mediates 
glioma cell invasiveness. Oncogene 25(19): 2801-2806. 
Falk MH and Issels RD. 2001. Hyperthermia in oncology. International Journal of 
Hyperthermia 17(1): 1-18. 
Feng Y, Broder CC, Kennedy PE and Berger EA. 1996. HIV-1 entry cofactor: Functional 
cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272(5263): 
872-877. 
Gupta J, Mohapatra J, Bhargava P and Bahadur D. 2016. A pH-responsive folate 
conjugated magnetic nanoparticle for targeted chemo-thermal therapy and MRI diagnosis. 
Dalton Trans 45(6): 2454-2461. 
Johannsen M, Gneveckow U, Taymoorian K, Thiesen B, Waldofner N, Scholz R, Jung K, 
Jordan A, Wust P and Loening SA. 2007. Morbidity and quality of life during thermotherapy 
using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective 
phase I trial. Int J Hyperthermia 23(3): 315-323. 
Kim HC, Kim E, Jeong SW, Ha TL, Park SI, Lee SG, Lee SJ and Lee SW. 2015. Magnetic 
nanoparticle-conjugated polymeric micelles for combined hyperthermia and chemotherapy. 
Nanoscale 7(39): 16470-16480. 
Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR and Brown JM. 2010. Inhibition of 
vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after 
irradiation in mice. J Clin Invest 120(3): 694-705. 
Kolen’ko YV, Bañobre-López M, Rodríguez-Abreu C, Carbó-Argibay E, Sailsman A, Piñeiro-
Redondo Y, Cerqueira MF, Petrovykh DY, Kovnir K, Lebedev OI and Rivas J. 2014. Large-
scale synthesis of colloidal Fe3O4 nanoparticles exhibiting high heating efficiency in 
magnetic hyperthermia. The Journal of Physical Chemistry C 118(16): 8691-8701. 
Kruse AM, Meenach SA, Anderson KW and Hilt JZ. 2014. Synthesis and characterization of 
CREKA-conjugated iron oxide nanoparticles for hyperthermia applications. Acta Biomater 
10(6): 2622-2629. 
Manuscript III 
131 
Liao SH, Liu CH, Bastakoti BP, Suzuki N, Chang Y, Yamauchi Y, Lin FH and Wu KC. 2015. 
Functionalized magnetic iron oxide/alginate core-shell nanoparticles for targeting 
hyperthermia. Int J Nanomedicine 10: 3315-3328. 
MagForce. (2016). "Nanotherm® therapy information for the treatment of brain tumors." 
Retrieved December 2016, from http://www.magforce.de/en/patienten/beschreibung-der-
therapie.html. 
Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V and 
Jordan A. 2011. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide 
nanoparticles combined with external beam radiotherapy on patients with recurrent 
glioblastoma multiforme. J Neurooncol 103(2): 317-324. 
Mi Y, Liu X, Zhao J, Ding J and Feng SS. 2012. Multimodality treatment of cancer with 
herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of 
biodegradable polymers. Biomaterials 33(30): 7519-7529. 
Oh Y, Lee N, Kang HW and Oh J. 2016. In vitro study on apoptotic cell death by effective 
magnetic hyperthermia with chitosan-coated MnFe2O4. Nanotechnology 27(11): 115101. 
Prijic S, Prosen L, Cemazar M, Scancar J, Romih R, Lavrencak J, Bregar VB, Coer A, Krzan 
M, Znidarsic A and Sersa G. 2012. Surface modified magnetic nanoparticles for immuno-
gene therapy of murine mammary adenocarcinoma. Biomaterials 33(17): 4379-4391. 
Quinto CA, Mohindra P, Tong S and Bao G. 2015. Multifunctional superparamagnetic iron 
oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment. 
Nanoscale. 
Rago G, Bauer B, Svedberg F, Gunnarsson L, Ericson MB, Bonn M and Enejder A. 2011. 
Uptake of gold nanoparticles in healthy and tumor cells visualized by nonlinear optical 
microscopy. Journal of Physical Chemistry B 115(17): 5008-5016. 
Redjal N, Chan JA, Segal RA and Kung AL. 2006. CXCR4 inhibition synergizes with 
cytotoxic chemotherapy in gliomas. Clin Cancer Res 12(22): 6765-6771. 
Rempel SA, Dudas S, Ge S and Gutierrez JA. 2000. Identification and localization of the 
cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and 
angiogenesis in human glioblastoma. Clin Cancer Res 6(1): 102-111. 
Rios A, Hsu SH, Blanco A, Buryanek J, Day AL, McGuire MF and Brown RE. 2016. Durable 
response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose 
of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and 
niacinamide. Oncoscience 3(5-6): 156-163. 
Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD and Segal 
RA. 2003. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary 
brain tumors. Proc Natl Acad Sci U S A 100(23): 13513-13518. 
Sehgal A, Keener C, Boynton AL, Warrick J and Murphy GP. 1998. CXCR-4, a chemokine 
receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J 
Surg Oncol 69(2): 99-104. 
Shi B, Abrams M and Sepp-Lorenzino L. 2013. Expression of asialoglycoprotein receptor 1 
in human hepatocellular carcinoma. J Histochem Cytochem 61(12): 901-909. 
Manuscript III 
132 
Sims LB, Curtis LT, Frieboes HB and Steinbach-Rankins JM. 2016. Enhanced uptake and 
transport of PLGA-modified nanoparticles in cervical cancer. Journal of Nanobiotechnology 
14. 
Taratula O, Dani RK, Schumann C, Xu H, Wang A, Song H, Dhagat P and Taratula O. 2013. 
Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs 
and mild hyperthermia to ovarian cancer cells. Int J Pharm 458(1): 169-180. 
Thomas RG, Moon MJ, Lee H, Sasikala AR, Kim CS, Park IK and Jeong YY. 2015. 
Hyaluronic acid conjugated superparamagnetic iron oxide nanoparticle for cancer diagnosis 
and hyperthermia therapy. Carbohydr Polym 131: 439-446. 
Wust P, Gneveckow U, Johannsen M, Bohmer D, Henkel T, Kahmann F, Sehouli J, Felix R, 
Ricke J and Jordan A. 2006. Magnetic nanoparticles for interstitial thermotherapy - feasibility, 
tolerance and achieved temperatures. Int J Hyperthermia 22(8): 673-685. 
Yin PT, Shah BP and Lee KB. 2014. Combined magnetic nanoparticle-based microRNA and 
hyperthermia therapy to enhance apoptosis in brain cancer cells. Small 10(20): 4106-4112. 
Yuan C, An Y, Zhang J, Li H, Zhang H, Wang L and Zhang D. 2014. Magnetic nanoparticles 
for targeted therapeutic gene delivery and magnetic-inducing heating on hepatoma. 
Nanotechnology 25(34): 345101. 
Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB and 
Newcomb EW. 2006. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in 
glioblastoma: Implications for angiogenesis and glioma cell invasion. Lab Invest 86(12): 
1221-1232. 
Zhang J, Dewilde AH, Chinn P, Foreman A, Barry S, Kanne D and Braunhut SJ. 2011. 
Herceptin-directed nanoparticles activated by an alternating magnetic field selectively kill 
HER-2 positive human breast cells in vitro via hyperthermia. Int J Hyperthermia 27(7): 682-
697. 
 
Manuscript III 
133 
Supplementary data 
  
Figure S1 – Different parameters affecting the heating profile and MHT outcome on LN229 
cells.  
The optimization of the conditions to be used in our experiments indicated a dependence of the 
heating profile and the MHT outcome (cell viability) on the a) concentration of MP–CXCR4, b) the 
duration of the incubation period of cells with particles, and c) with the number of cells used per 
experiments. In every case, the same of amount of SPIONs was used (0.176 g Fe/L). Each 
comparison is made for experiments in which the only variable is the one referred. 
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Figure S2 - Heating profile of LN229 and HK-2 cells with targeting particles (MP–CXCR4).  
No differences between both cell lines were detected in the temperature profile, when using 2106 
cells per condition, despite the increased iron content of LN229 compared to HK-2 cells (Figure 4d 
of the man text). Results are mean+SD of two independent experiments. 
 
  
Figure S3 – Applying AMF to cells without magnetic nanoparticles.  
Cells without magnetic particles were submitted to AMF (a) and to viability tests after that 
procedure (b). Results indicate that the used AMF conditions did not produce significant heating 
and did not significantly affect cell viability of neither cell line.  
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Figure S4 – Overview of MHT efficiency.  
Disregarding the different initial concentrations of SPIONs tested in our studies, i.e., considering 
the results as only being dependent on cell type or particle functionalization, shows that, overall, 
this strategy produced significantly higher MHT temperatures (a), and significantly increased iron 
content (b) in cancer cells treated with the SPION and CXCR4-functionalized particles 
(LN229+SPION+MP–CXCR4), as compared with normal cells subjected to the same treatment 
(HK-2+SPION+MP–CXCR4). Results are min to max (“+” represents the mean). Differences were 
estimated using ordinary one-way ANOVA followed by Holm-Sidak’s multiple comparisons post 
test (a) or one-way ANOVA (Kruskal-Wallis) followed by Dunn’s multiple comparison post test (b). 
Similarly, cell death levels (c) were significantly higher for LN229+SPION+MP–CXCR4 samples 
than the HK-2+SPION+MP–CXCR4 samples, a result corroborated by the significantly lower cell 
viability levels (d) observed for LN229 cells compared to HK-2 treated similarly. Results are 
mean+SEM of at least six independent experiments. Differences were estimated using two-way 
ANOVA followed by Tukey’s multiple comparisons post test (c and d). **p<0.01 and ****p<0.0001 
vs. LN229+SPION+MP–CXCR4 samples. 
 
Interestingly, even when disregarding the differences in the initial SPIONs 
concentration, the differences between cancer (LN229) and normal (HK-2) cells were 
evident. Significantly elevated temperatures, higher iron content, increased cell death and 
lower cell viability were found after MHT was performed in LN229 cells with SPIONs and 
targeted particles (MP–CXCR4), as compared to the same treatment applied to normal 
cells. This observation further highlights the elevated efficiency and safety of the proposed 
MHT strategy. 
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Integrated Discussion 
This work was devoted to the development of a targeted anticancer therapy based on 
MHT. Therefore, the workflow of these studies consisted in: first, optimizing the 
functionalization of the magnetic agents to be used for the MHT studies; second, selecting 
the cancer target; third, tuning the MHT conditions for optimized heating; and fourth, 
performing MHT studies with targeted MNPs in in vitro cancer models. In this sense, the 
following discussion will roughly address these issues and integrate the observed results, 
without the need to strictly follow the mentioned order of events.  
1. Functionalization of the MNPs for MHT studies 
The attachment of biomolecules to nanomaterials is an important step towards their 
increased stability, biocompatibility and targeting ability for the MHT studies. The 
immobilization strategy is selected according to the functional groups present on the 
particle’s surface (Martins et al. 2012). Particularly for this work, we optimized a coupling 
methodology that takes advantage of the carboxylic groups from the PAA-coated MNPs to 
covalently bind free amine groups from proteins, known as EDC-Sulfo-NHS coupling 
chemistry. The protein BSA was used as a model biomolecule due to its low price and its 
known enhancement of the MNPs’ stability and biocompatibility (Jenita et al. 2014). We 
have previously accomplished direct physisorption of BSA on oleic acid-coated MNPs, 
which are only soluble in non-polar organic solvents, after promoting their phase transfer 
to an aqueous solution (Appendix) (Vilas-Boas et al. 2015). Specifically, the phase 
transfer to aqueous solvents enables the biomedical use of those MNPs, while the BSA 
further promotes their stability and biocompatibility. Mehta and co-workers were the first to 
report direct binding of BSA to bare MNPs, reaching high immobilization rates (Mehta et al. 
1997), i.e., nearly all the initial amount of BSA was immobilized in the MNPs. Similarly, in 
their work, Wang et al. observed increased efficiency of avidin immobilization for higher 
initial concentrations of protein, immobilizing nearly 100 % of the initial amount of protein 
(Wang and Lee 2003). Nevertheless, the rough number of biomolecules per surface area 
of MNPs was not calculated in these two studies and, therefore, the surface coverage 
efficiency could not be estimated. In fact, while high protein content may reflect the 
formation of various protein layers at the MNPs surface (Martins et al. 2012) —which may 
unnecessarily contribute to loss of functionality with time and increased cost of the 
process, particularly for expensive biomolecules—low surface coverage may hamper the 
stability of the MNPs. Therefore, reporting the functionalization efficiency in terms of 
number of biomolecules per MNP, allows estimating the probability of having successive 
layers of proteins or low number of immobilized biomolecules. For this purpose, the 
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available surface area in each nanoparticle was compared to the area that each protein 
molecule would occupy (parking area). Thus, the number of biomolecules that physically 
fit each MNP was estimated, similarly to a previous report (Hung et al. 2008). While 
increasing the initial protein concentration led to increased final amount of protein 
interacting with the MNPs, as seen by others (Wang and Lee 2003, Mu et al. 2015), these 
biomolecules were probably forming a double layer around the MNPs at the highest tested 
initial concentration. Reports on the formation of a double protein layer in the available 
literature are scarce (Martins et al. 2012).  
We observed a dependency of the functionalization efficiency on the coupling agents’ 
(EDC and Sulfo-NHS) concentration (Figure 3, Manuscript 1). While the lowest tested 
concentration resulted in very low immobilization efficiency, increasing the concentrations 
of coupling agents led to increasing efficiencies, however accompanied by increased 
MNPs’ aggregation. Using avidin as protein model, Wang and co-workers also observed 
MNPs’ agglomeration and precipitation when using high concentrations of coupling agents 
(Wang and Lee 2003). The observed agglomeration prohibits the use of these MNPs for 
biomedical purposes. With this in mind, the selected concentration of coupling agents to 
be used in further procedures was the one yielding better overall MNPs’ stability while 
keeping satisfactory surface coverage with the protein. 
The attachment of antibodies (the targeting agents in this work) to MNPs may be 
achieved either by direct immobilization of the antibodies through their functional groups, 
or by using a linker protein such as STR or PA, which allows further high affinity binding of 
antibodies (respectively, biotinylated or not). The direct immobilization of antibodies is 
possible for polyclonal antibodies (pAb) but practically unaffordable for many expensive 
monoclonal antibodies, due to the excess of biomolecule required to favour the 
directionality of the coupling chemistry. Furthermore, the random immobilization of the 
antibody molecules may hamper the antibody’s ability to recognize its target, an issue that 
is also raised when using STR to bind biotinylated antibodies. In fact, we observed 
considerable aggregation of the STR–MNPs after addition of biotinylated antibodies 
(Figure 9, Manuscript 1). The tetravalent nature of STR regarding its high affinity ligand, 
biotin, and the presence of two (or more) biotin molecules per (biotinylated) antibody may 
lead to cross-interaction between MNPs that can, therefore, share the same antibody 
molecules (Figure 10, Manuscript 1). Moreover, the presence of biotin in random parts of 
the antibody may hamper their functionality, particularly if present at the fragment 
responsible for antigen binding (Fab). These issues are unlikely to occur in PA–MNPs, 
where the interaction between the antibody and the PA is oriented through the Fc region 
of the antibody, while keeping the Fab free for antigen recognition and binding (Figure 10, 
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Manuscript 1). No significant MNPs aggregation was observed for PA–MNPs after 
antibody immobilization (Figure 9d, Manuscript 1). 
Of note, the estimation of PA immobilization was peculiar and rather challenging. 
While others have previously estimated PA immobilization on MNPs measuring its 
absorbance at 280 nm (Mu et al. 2015), in this work we noticed some interference, 
probably arising from the contact with the MNPs, which prevented the used of this 
methodology. Therefore, PA quantification on the supernatants collected after protein 
immobilization was performed using CD signal at 208 nm (Figure 7, Manuscript 1). A 
linear correlation between this signal and the sample’s absorbance in the far UV spectrum 
(at 195 nm) was initially assured, as previously recommended for other proteins (Kelly et 
al. 2005, Fears et al. 2013). We believe this to be the first report in which the efficiency of 
PA immobilization on MNPs was assessed using CD.  
The reached levels of surface coverage for STR, PA and pAb were very satisfactory 
(69, 84 and 95 %, respectively), suggesting a broad and immediate applicability of the 
immobilization strategy optimized in this work to other proteins, resulting in sufficient 
coverage of the MNPs’ surface.  
After the immobilization of antibodies, a high degree of aggregation was observed for 
the STR–MNPs but not for the PA–MNPs, suggesting higher stability of the latter 
functionalized MNPs. This fact, along with the clear separation between the heating 
curves of the CXCR4–PA–MNPs and the respective isotype control MNPs, suggests that 
PA–MNPs are more suitable for biomedical applications, namely MHT, than the STR–
MNPs. However, the results suggested that the amount of CXCR4–PA–MNPs that 
interacted with the cells was insufficient to produce cytotoxicity. Therefore, bigger MNPs, 
with higher magnetic susceptibility, were used in the subsequent experiments to further 
increase the heating ability of this targeted strategy. 
2. CXCR4 as target for specific MHT of cancer cells  
The CXCR4 is a chemokine receptor overexpressed in many types of cancer cells 
that has been used as part of lymphoma and multiple myeloma treatment (Jagirdar et al. 
2015). It has recently been suggested as a target for the treatment of ALL (de Lourdes 
Perim et al. 2015) and GBM (Terasaki et al. 2011), and its antagonist has been 
successfully used as an adjuvant in GBM treatment (Rios et al. 2016). Although CXCR4-
targeting MNPs have been tested for diagnostic purposes, particularly for magnetic 
resonance imaging (He et al. 2012, Zevon et al. 2015), using CXCR4-targeted MNPs for 
MHT cancer treatment has never been proposed or developed to date. Furthermore, the 
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MHT strategies clinically available so far are limited to the local injection of non-targeted 
MNPs, resulting in inhomogeneous MNPs’ distribution within the tumour and, 
consequently, variable intratumoural heating. Therefore, many of the studies on targeted 
MHT show lack of efficiency, which is normally increased by combining chemotherapeutic 
drugs (Mi et al. 2012, Sivakumar et al. 2013, Taratula et al. 2013, Kruse et al. 2014, Gupta 
et al. 2016). This combined strategy often results in unwanted side effects of these non-
selective drugs. For those reasons, the development of an efficient anti-cancer pure MHT 
strategy based on CXCR4-targeting would be a significant refinement of the available 
treatment. 
Contrary to the endocytosis of non-targeted MNPs, the magnetic content that cells 
can bear at their surface is, in theory, limited by the number of surface receptors available 
for interaction with targeted-MNPs. We chose a widely used in vitro model of ALL, Jurkat 
cells, for the set-up of our MHT strategy due to the elevated expression of that surface 
receptor in this cell line (Figure S3, Manuscript 2 and (Huang et al. 2014)). For the 
following studies on adherent cells, a GBM in vitro model (LN229 cells) was selected, 
exhibiting lower levels of surface receptor, but still higher than negative control cell line, 
the HK-2 cells (Figure 1, Manuscript 3), an in vitro model of proximal tubular cells from 
normal kidney. In this context, CXCR4 expression in LN229 cells was, therefore, 
categorized as intermediate. 
Following the results of the functionalization experiments (Manuscript 1), for our MHT 
studies, we selected the commercially available dextran composite particles with a 
diameter of 250 nm (Rudershausen et al. 2002) for further attachment of anti-CXCR4 
monoclonal antibodies. These particles are, magnetic beads, also known as cluster-type 
particles, composed of smaller IONPs embedded in a dextran matrix, with PA covalently 
bound to their surface. Compared to the previously functionalized MNPs (Manuscript 1), 
the increased magnetite content of these MPs makes them suitable for experiments that 
highly depend in the magnetic amount, like MRI and MHT studies (Wabler et al. 2014). In 
addition, the relative cost of these PA modified MPs was far lower than performing the 
modification of the 18 nm MNPs used for the functionalization studies. 
3. Setting up the MHT conditions  
The preliminary tests on the optimization of the MHT conditions [the AMF power, 
which is proportional to the product of the field amplitude H and the frequency f (H·f 
product), and the time of exposure] indicated that sustaining the T above 40 ºC for periods 
longer than 30 min resulted in decreased cell viability (Figure S1, Manuscript 2). These 
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results are in line with previous publications in which MHT efficiency was enhanced by 
prolonging the period of exposure to higher T (Levi-Polyachenko and Stewart 2011, 
Taratula et al. 2013). According to these preliminary results, the conditions were tuned to 
produce a rapid initial increase in the sample’s T, reaching a maximum T at the midterm of 
the treatment, and then keeping this high T for the second half of the treatment (Figure S2, 
Manuscript 2). Although there are examples in the literature of tuning the AMF power 
during the experiment to limit the observed Tmax (Alvarez-Berrios et al. 2014, Oh et al. 
2016), we believe this is the first use of a pre-established, two-step, AMF application. 
When using CXCR4-targeted MPs only, in Jurkat cells, significant, though insufficient, 
heating was observed (red, Figure 1, Manuscript 2). Further studies revealed that more 
than 90 % of the targeted MPs were kept in these samples (Table 1, Manuscript 2), 
suggesting that an increment of the cell population would not result in increased heating 
unless simultaneously accompanied by an increase in the amount of targeted MPs. 
A boost of magnetic material was then provided to cells to produce increased and, 
therefore, more efficient, heating, preserving a pure MHT strategy, an approach that had 
never been tested before. This boost was provided by 18 nm core iron oxide nanoparticles 
synthesized and fully characterized in house (Kolen’ko et al. 2014). These MNPs were 
coated with PAA and were used without any other modification, being described herein as 
non-targeted MNPs or SPIONs. PAA is a hydrophilic polymer that has gained recent 
interest as coating agent for MNPs due to the presence of many functional groups and the 
stability it brings to the MNPs’ systems (Lin et al. 2005). Although only a few studies 
addressed the biocompatibility and biodistribution of PAA–MNPs, they interestingly report 
effects deriving from relevant doses used as contrast agents for imaging procedures 
(Couto et al. 2016) or in MHT clinical studies (Iversen et al. 2013). These reports 
consensually showed enhanced accumulation of MNPs mainly in immune cells of the RES 
of the liver and spleen (Prijic et al. 2012, Couto et al. 2016), but also in the kidneys 
(Iversen et al. 2013), after intraperitoneal or IV administration. Ding and co-workers 
studied the continuous biodistribution of gelatin-PAA nanoparticles (ca. 100 nm) loaded 
with cisplatin (developed for targeted drug release), at different time-points after IV 
injection. Similar to the previous studies, the nanoparticles accumulated in the spleen, 
liver and femur (bone marrow) as a consequence of RES clearance. Interestingly, after 
22 h, the nanoparticles accumulated in the tumour, as a consequence of the EPR effect 
(Ding et al. 2012). The EPR effect is a characteristic of solid tumours that derives from the 
combined hyper-permeability of tumour vasculature, exhibiting pores that may be 
hundreds of nanometers in size, along with the lack of functional lymphatics that favours 
nanoparticles’ retention (Iyer et al. 2006). This has practical implications since 
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nanoparticles with sizes above 10 nm (the regular pore size of normal vasculature) 
extravasate to the tumour but not to the normal tissues, providing a natural, passive 
targeting, system.  
Similarly unanimous is the reported overall biocompatibility of PAA coated 
nanoparticles (Prijic et al. 2012, Couto et al. 2016), only producing temporary effects in 
the blood pressure (Iversen et al. 2013), although the triggering of an inflammatory 
response has also been reported (Couto et al. 2016). At a cellular level, and similar to our 
findings, PAA–MNPs (i.e., SPIONs) have been found internalized in endosomes (Iversen 
et al. 2013). The internalization of complexes of PAA–MNPs (200–400 nm) has also been 
reported, although the bigger size of these complexes suggests that these particles were, 
most probably, phagocytized (Prijic et al. 2012). 
The specific interaction of the targeted MPs with cells was confirmed by flow 
cytometry and laser scanning confocal microscopy, using a fluorescently labelled 
secondary antibody targeting the monoclonal antibody of the targeted MPs (Figure 2, 
Manuscript 2). Interestingly, the interaction of particles with cells induced light scattering 
changes that could be followed by flow cytometry through the significant differences in the 
inner complexity (side scatter, SSC, signal) of the analysed events (Figure 3, Manuscript 
2). Poirier and co-workers found similar increments in the inner complexity of the cells, 
which they related to internalization of 20 nm silver nanoparticles (Poirier et al. 2014). 
Later, a comparable increase in SSC signal was correlated with the iron content of cells, 
suggesting that flow cytometry studies may be performed to estimate the uptake of 
SPIONs by mammalian cells (Friedrich et al. 2015). We observed increased inner 
complexity signals of cells incubated with both types of particles, independently or 
together, which is a sign of particle internalization in our studies. Even though the 
threshold size for endocytosis to occur is not perfectly established, there seems to be 
consensus around the 500 nm upper limit (Rejman et al. 2004, Bychkova et al. 2012). We 
could not precisely determine whether, in our studies, the CXCR4-targeted MPs were 
internalized or not by the cells, due to lack of resolution of the light microscopy studies. 
However, the short time-period of incubation in our study (240–280 min) seems 
insufficient for the slower rate of internalization of larger particles (dos Santos et al. 2011). 
Although the internalization of the CXCR4-targeted MPs cannot be excluded in our 
studies, we believe that the presence of the MPs at the cell surface enhances the 
roughness of the cell membrane, therefore, producing increased light scattering 
interpreted as increased inner complexity. 
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4. The proof of concept: targeted MHT against leukaemia cells  
The combination of both non-targeted SPIONs and CXCR4-targeted MPs, in 
consecutive incubations, and the optimized AMF treatment, resulted in sufficient heating 
to induce death in Jurkat cells. Noteworthy, in our MHT experiments, the excess of free 
particles was always removed in every incubation step, to guarantee that only the uptaken 
SPIONs or interacting MPs would contribute to the observed heating effect. This important 
step is often missing in many in vitro MHT studies (Mi et al. 2012, Sivakumar et al. 2013, 
Kruse et al. 2014, Sadhasivam et al. 2015, Thomas et al. 2015), which prevents the 
attribution of the observed effects to the targeting system.  
Two distinct outcomes were observed according to the reached T (purple, Figure 1, 
Manuscript 2), which triggered distinct cell death pathways. The activation of apoptosis for 
T up to 43 ºC is a well-known fact, as well as the appearance of necrotic features for 
higher T (Hildebrandt et al. 2002). Although rather unexpected, these distinct T profiles 
may be a result of using different batches of antibodies and particles (Guardia et al. 2012), 
and even different cell passages. 
Interestingly, for the T range achieved in our work (42.5–47 ºC), it has been 
established that a drop of 1 ºC in the T can only be compensated by doubling the 
exposure time to reach similar efficiency. For T below this range, the exposure time needs 
to be multiplied by a factor of 4 (Hildebrandt et al. 2002). These facts demonstrate the 
importance of using MNPs with increased heating performance for the MHT experiments, 
which is often measured in terms of SAR values. The MNPs used in our work exhibited 
high SAR values in our experimental conditions, assuring effective heating and proving 
appropriate for the MHT tests. Still, comparing these values with the ones reported in the 
literature is limited by the considerable dependence of SAR values on the equipment and 
the AMF parameters used for the experiments (Vallejo-Fernandez et al. 2013). The 
development of a standardized procedure to measure the heating ability of the MNPs 
could help surpassing this limitation. 
Notwithstanding the low levels of Annexin-V positive cells in the samples reaching 
apoptotic T (Tc=42.7 ºC), the cystein protease, caspase-3, was significantly activated 
(Figure 4, Manuscript 2), supporting the triggering of an apoptotic pathway in these 
conditions. On the other hand, the elevated levels of cells with disrupted membrane (Pi 
and double positive cells) and the absence of caspase-3 activation (Figure 4, Manuscript 
2) provide clear indication of necrotic cell death in the samples reaching higher T 
(Tc=45.2 ºC). Both pathways led to a drastic decline in cell viability and extensive cell 
death (Figure 5, Manuscript 2), denoting the elevated efficiency of the proposed strategy. 
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Of note, while the activation of a necrotic pathway resulted in long-term, complete loss of 
cell viability after MHT, a slight recovery was observed when the apoptotic pathway was 
triggered, at the later time-point after MHT (Figure 5, Manuscript 2). To overcome this 
limitation of apoptotic MHT, which has been previously observed (Lee et al. 2015), a 
second AMF cycle could be performed in an attempt to kill the surviving cells, as done by 
Ito and co-workers (Ito et al. 2004). These authors observed cell viability recovery after 
apoptotic MHT in breast cancer cells and could prolong the low cell viability levels when a 
second AMF cycle was applied 24 h after the first treatment. This approach is also 
commonly used in an in vivo context (some examples in Table 4, General Introduction). 
Our results suggest the necrotic pathway to be a more effective cell death 
mechanism than the apoptotic pathway, and are supportive of previous conclusions on the 
insufficient efficiency of apoptotic MHT (Lee et al. 2015), particularly in a mono-
therapeutic context. There is a wide discussion on whether apoptotic or necrotic pathways 
should be preferred for cancer treatment (de Bruin and Medema 2008). While apoptosis is 
considered a more natural process that can be cleaned up by macrophages, the main 
feature of necrosis is the inflammatory response that normally arises from the spill of the 
intracellular contents to the extracellular medium through the damaged cell membrane 
(Proskuryakov et al. 2003). Using an apoptosis-inducing agent to treat cancer may, 
therefore, seem debatable, and even counterproductive, due to the characteristic 
apoptosis-resistance of many cancer cells, particularly in solid tumours (de Bruin and 
Medema 2008). For such approach to be effective, this mechanism of cell death must be 
restored in these cells, which represents one of the major aims of anti-cancer therapy 
nowadays (Indran et al. 2011). In fact, the frequent tumour recurrence observed following 
treatment with an apoptosis-inducing agent led to the search for treatments in which 
necrosis is induced instead, as a strategy to increase the efficiency of the treatment 
(Proskuryakov et al. 2003). Particularly for MHT, it is known that reaching T above 43 ºC 
greatly enhances the treatment’s efficiency, possibly due to activation of the necrotic 
pathways (Hildebrandt et al. 2002). Therefore, it is our conviction that the methodology 
proposed herein provides strong evidence for the implementation of the concept, 
demonstrating all the requisites to proceed to further studies in in vivo models.  
The importance of CXCR4-targeting in the presented strategy was supported by the 
absence of significant heating of samples in which the CXCR4-targeted MPs were 
replaced by their IC counterparts (Figure 1, Manuscript 2). In fact, only when the CXCR4-
targeted MPs were used, in combination with the non-targeted MNPs, and the AMF was 
applied, a significant cytotoxic effect was observed (Figure 5, Manuscript 2). Most studies 
concerning in vitro testing of targeted MHT strategies do not test this type of control 
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antibodies (or peptides), but the same MNPs without the targeting molecule (Mi et al. 
2012, Taratula et al. 2013, Kruse et al. 2014, Liao et al. 2015), which seems particularly 
relevant if simultaneously not testing normal cells. Although the IC antibody would not be 
used in a clinical situation, it is our conviction that using the MP–IC, instead of MPs 
without antibody, in parallel to the MP–CXCR4, ensures a more reliable control 
experiment. This way, the observed effects may be undoubtedly attributable to that 
particular test antibody, and not to the presence of any antibody that could unspecifically 
bind to the cells. 
5. Application of the developed strategy to adherent cell models 
The lower surface expression levels of CXCR4 in adherent cells as compared to 
Jurkat cells (Figure 1, Manuscript 3) implied the need for further optimization of the 
developed strategy to be applicable in those cellular models. The observed outcome 
strongly depended on the concentration of targeted and non-targeted MNPs, the duration 
of the incubation period, and the cell number to be used in the experiments (Figure S1, 
Manuscript 3).  
In parallel, the same procedure was tested in normal cells to monitor the occurrence 
of unwanted cytotoxic side effects. In this sense, the ability of MP–CXCR4 to preferentially 
accumulate in LN229, compared to normal cells, was evident, as suggested by the 
elevated iron amounts in cancer cells targeted with MP–CXCR4, and further corroborated 
by optical microscopy studies (Figure 4, Manuscript 3). However, similarly to Jurkat cells, 
MHT mediated solely by the CXCR4-targeted MPs was insufficient to produce significant 
elevation of the T, generating heating profiles very similar to the HK-2 ones (Figure S2, 
Manuscript 3). This fact suggested that, unlike Jurkat cells, SPIONs would have more 
impact than the MP–CXCR4 on the overall heating of GBM cells, due to limited CXCR4 
expression. Therefore, increasing amounts of SPIONs were then tested and a 
dependency of the reached Tmax on the initial concentration of SPIONs was observed 
(Figure 2 and Table 1, Manuscript 3). Interestingly, for the normal cell line, HK-2 cells, 
increasing the initial amount of SPIONs or the presence of the MP–CXCR4 did not 
produce differences in the observed T. Furthermore, cancer cells naturally internalized 
bigger amounts of SPIONs than normal cells, a fact already noticed by others (Rago et al. 
2011, Prijic et al. 2012, Sims et al. 2016). This fact may represent an important advantage 
if also occurring in an in vivo context, along with the EPR effect that also favours MNPs 
accumulation in tumour tissues (Iyer et al. 2006). These results suggested that, in our 
study conditions, normal cells might reach a saturation of their endocytic pathways at a 
faster rate than cancer cells. Differences in cell membrane dynamics and composition 
Integrated Discussion 
148 
between normal and cancer cells may be on the basis of this contrasting accumulation 
(Rago et al. 2011), along with their distinct cellular metabolic rate (Bychkova et al. 2012).  
Applying the optimized strategy to LN229 versus HK-2 cells resulted in very distinct 
heating profiles and, consequently, distinct MHT outcome, as expected. The Tmax 
exceeded 41 ºC in MP–CXCR4-treated cancer cells, independently of the initial amount of 
SPIONs. Particularly at the highest tested initial concentration of SPIONs, for which Tmax 
overreached 45 ºC, long-lasting and complete loss of cell viability was observed (Figure 7, 
Manuscript 3). Contrarily to cancer cells, in normal cells, Tmax remained below (or equal to) 
41 ºC, independently of the initial amount of SPIONs, producing limited cytotoxicity. Using 
MP–IC instead of the MP–CXCR4 in the LN229 cells further strengthened our findings, 
attributing a noteworthy role for CXCR4-targeting in the proposed methodology. 
Furthermore, the SPIONs, MPs, and the AMF conditions used in the experiments 
produced no significant cytotoxic effects by themselves (Figure 5, Manuscript 2; Figures 7 
and S3, Manuscript 3). 
6. Comparative MHT efficiency 
There are only a few studies reporting in vitro targeted MHT efficiency comparable to 
ours, in a mono-therapeutic context (Taratula et al. 2013, Liao et al. 2015). While Taratula 
et al. reported long-lasting decreased cell viability in cells that reached 44 ºC after MHT 
mediated by LHRH-targeted MNPs (Taratula et al. 2013), Liao et al. observed low cell 
viability levels before the population doubling time was complete, which may be 
misleading. The latter authors also did not report the achieved T and, therefore, we cannot 
predict if cellular recovery was expected or not (Liao et al. 2015). In any case, the results 
of our work suggest that the proposed strategy is amongst the most effective in vitro MHT 
procedures reported so far, using a mono-therapeutic MHT approach that requires lower 
concentration of magnetic material than previous works presenting similar outcomes 
(Guardia et al. 2012). Guardia and co-workers needed to increase the T to 65 ºC to 
observe complete cell death, which may be a dangerous T in a clinical context, especially 
if maintained during long periods (Guardia et al. 2012). The normal tissues surrounding 
the tumour may be damaged by the dissipation of heat from the tumour. In their in vivo 
studies, Huang et al. observed an increase in the tumour’s T to 60 ºC but it was limited to 
an interval of less than 5 min and, therefore, no significant adverse effects derived from it 
(Huang and Hainfeld 2013). Using non-targeted zinc and manganese-doped nanoclusters, 
Qu et al. reported comparably low levels of cell viability in their in vitro MHT studies with 
breast cancer cells (Qu et al. 2014).  
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Results similar to ours were observed if combining in vitro targeted MHT with 
doxorubicin (Gupta et al. 2016), docetaxel (Mi et al. 2012), or 5-fluorouracyl (Sivakumar et 
al. 2013). These chemotherapeutic agents, if not carried by the targeted MNPs, will 
inevitably produce cytotoxicity in normal cells. The effects of non-targeted MNPs for in 
vitro MHT have also been potentiated by the combination with other therapeutic modalities, 
this way reaching outcomes similar to ours. A group from the University Paris Diderot 
combined MHT with photodynamic (Di Corato et al. 2015) and photothermal (Espinosa et 
al. 2016) therapies for increased efficiency, resulting in cell viability levels similar to the 
ones observed with our strategy. The need for different equipment for the application of 
their combination approach (AMF applicator and laser system) may represent a 
disadvantage compared to a pure MHT strategy that only requires an AMF applicator.  
7. Potential applications of the developed methodology 
It is our conviction that the potential applications of the approach developed 
throughout this work go far beyond the models and targets evaluated herein. The 
overexpression of CXCR4 in many other cancer models, namely breast and prostate 
(Muller et al. 2001, Taichman et al. 2002), among others, suggest that this strategy may 
be successfully applied to those types of cancer. Similarly, choosing other target receptors, 
according to their overexpression, is another thrilling possibility that could be adapted 
individually to each type of cancer/ receptor overexpression, resembling a “personalized 
medicine” approach. Also exciting for further in vivo studies, is the possibility of allowing 
the targeted nanoparticles to chemotactically find their targets and accumulate at the 
tumour site after injection. In particular, for the in vitro models addressed in this work, in 
vivo studies shall establish the potential for further clinical developments, as addressed 
subsequently. 
The development of this strategy in an ALL cancer model was primarily a 
consequence of the overexpression of CXCR4 in that cellular model. Despite this 
overexpression, the distribution of cancer cells throughout the whole body in the clinical 
context makes the application of this strategy for leukaemia treatment a real challenge. 
However, one could take advantage of the magnetic loading of the targeted cells to 
concentrate the cells in various locations within the body using external magnets, as 
suggested by Ma et al. for hepatocellular carcinoma (Ma et al. 2015). This strategy would 
allow a localized application of the AMF. The size of the targeted particles would need to 
be tuned because particles sized above 200 nm are known to be rapidly taken up by 
phagocytes of the RES and accumulate in the liver and spleen, limiting their half-life in 
circulation (Bychkova et al. 2012). Similarly to PEG, dextran coating is known to increase 
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the circulation time of the coated nanoparticles, by surpassing opsonisation (Sharma et al. 
2012). Although this characteristic is not yet fully established for PAA coating, the 
biodegradable nature of that polymer and the presence of flexible hydrophilic chains 
suggest a prolonged residence time in blood to be possible. Additionally, the pro-apoptotic 
effects of PAA–MNPs on neutrophils might need to be considered (Couto et al. 2014), as 
well as the overall ability of the body to manage the iron stores, to avoid iron-related 
toxicity (Valdiglesias et al. 2016). 
Regarding the treatment of GBM, we expect the strategy described and developed 
herein to be safer than the currently available approach due to the selectivity of the 
targeted-MNPs. In normal conditions, cells from the nervous system recognizably resist to 
iron-induced cytotoxic effects by storing it intracellularly in iron-ferritin complexes 
(Valdiglesias et al. 2016). Therefore, iron-related cytotoxicity derived from the presence of 
the MNPs is not expected for normal cells. In fact, studies in normal astrocytes showed 
resistance to iron concentrations, supplied as IONPs, between 0.1 and 4.0 mM (Geppert 
et al. 2011), which fall within the range of concentrations used in this study. As an 
example, the possibilities offered by a targeted MHT approach could be explored after an 
intrathecal injection of the MNPs (Calias et al. 2014), instead of the direct IT injection used 
so far with non-targeted MNPs (MagForce 2016a). This administration route in the 
cerebrospinal fluid is already used for some chemotherapeutic drugs, particularly for the 
treatment of disorders of the central nervous system (Calias et al. 2014), and has been 
recently tested in vivo for the administration of lipid nanoparticles for genetic therapy in 
Friedreich’s ataxia (Nabhan et al. 2016). 
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Conclusions  
From the work performed under the scope of this dissertation some conclusions may 
be drawn: 
 Poly(acrylic acid)-coated iron-oxide nanoparticles synthesized in house could be 
efficiently functionalized with distinct proteins through the EDC-Sulfo-NHS coupling 
chemistry.  
 Staphylococcal Protein A proved to be a more suitable protein to mediate oriented 
immobilization of antibodies onto MNPs for biomedical purposes; 
 Total magnetic loading, time of exposure, alternating magnetic field parameters, and 
number of cells, are determining factors for the efficiency of an in vitro magnetic 
hyperthermia treatment; 
 A purely targeted MHT strategy to kill cancer cells in vitro was found to be poorly 
efficient. Such inefficiency was surpassed using a second population of non-targeted 
MNPs, preserving a mono-therapeutic approach; 
 The MHT strategy developed herein was further applied to other in vitro cell models, 
namely LN229 cells, with lower CXCR4-expression, reaching similarly high efficiency; 
 Sustained temperature raise above 41 ºC for at least 30 minutes induced cell death in 
Jurkat and LN229 cancer cells through apoptotic (T<43 ºC) or necrotic (T>43 ºC) 
pathways; 
 The triggering of a necrotic pathway was necessary to obtain 100 % loss of cell 
viability in Jurkat and LN229 cells, using one single application of the described 
magnetic hyperthermia treatment; 
 The MHT strategy described herein resulted in no relevant cytotoxicity in normal cells. 
As a final conclusion, we believe the strategy entirely developed through the course 
of this thesis represents an innovative way of increasing the efficiency of targeted MHT 
treatments with a boost of magnetic material of a non-targeted origin. This second 
population was similarly selective for cancer (versus normal) cells due to the higher rate of 
nanoparticles’ internalization by tumour cells, overall resulting in low toxicity in normal 
cells. The major advantage of our strategy is its elevated efficiency in a mono-therapeutic 
context, which prevents the need to further combine it with highly toxic chemotherapeutic 
drugs. Additionally, this work describes a set of new or improved methodologies for 
nanoparticles’ functionalization and characterization, and cell-nanoparticle interaction 
studies, which can help many other future studies in the emerging nanomedicine field of 
research. 
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We are confident that further in vivo studies will prove the vast potentiality of this 
strategy as a therapeutic approach for cancer treatment. 
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47954 | RSC Adv., 2015, 5, 47954–4795phase-transfer route to colloidal
iron oxide nanoparticles for protein
immobilization†
V. Vilas-Boas,a N. Guldris,b E. Carbo´-Argibay,b D. G. Stroppa,b M. F. Cerqueira,c
B. Espin˜a,b J. Rivas,d C. Rodr´ıguez-Abreub and Yu. V. Kolen'ko*bWe report for the ﬁrst time the eﬀective transfer of hydrophobic
oleate-capped iron oxide nanoparticles to an aqueous phase upon
treatment with a base bath cleaning solution. We discuss the mech-
anism of the phase transfer, which involves the elimination of the
organic capping agent followed by ionic stabilization of the nano-
particles due to negatively charged Fe–O surface species. The
resultant superparamagnetic aqueous nanocolloid shows excellent
protein immobilization capability.Iron oxide nanoparticles (NPs) are an important class of nano-
materials with useful magnetic properties, such as high Curie
temperature, high saturation magnetization, and many prac-
tical biomedical applications. For example, magnetite, Fe3O4,
and maghemite, g-Fe2O3, NPs are used in cancer therapy via
magnetic hyperthermia,1 drug and gene delivery,2,3 magnetic
separation and diagnostics,4,5 magnetic particle imaging,6 as
well as classical and multimodal magnetic resonance
imaging.7,8 From the perspective of biomedical applications,
iron oxide is preferred in the form of colloidally stable aqueous
dispersions of monodisperse NPs exhibiting high crystallinity
and high saturation magnetization. Control over particle size
and shape can be achieved by colloidal synthesis methods such
as thermal decomposition9,10 or hydrothermal/solvothermal
routes11,12 that typically employ readily available oleate (OL)
ligand as capping agent. Hence, various iron oxide NPs with
tunable size and morphology have been successfully prepared.
However, the drawback of the aforementioned colloidal
syntheses is that the resultant NPs are hydrophobic and can beology, Biological Sciences Department,
50-313 Porto, Portugal
ratory, 4715-330 Braga, Portugal. E-mail:
ga 4710-057, Portugal
of Santiago de Compostela, Santiago de
tion (ESI) available. See DOI:
8well dispersed only in apolar organic solvents. Obviously, such
NPs are not suitable for biomedical application, and proper
phase transfer into aqueous medium is required to render them
water-dispersible.
A variety of phase-transfer protocols have been developed,
which work based on electrostatic, steric, or electrosteric
repulsions.13 One strategy consists of ligand exchange, where
the hydrophobic surface ligand, typically oleate, is substituted
by amphiphilic polymers,14 surfactants,15 silica shell,16 or silane
molecules.17 Another interesting approach is coating hydro-
phobic NPs by amphiphilic polymers18,19 or bilayer shells,20 thus
rendering them dispersible in aqueous phase.
For instance, poly(ethylene glycol) (PEG) coated NPs are
colloidally very stable in aqueous medium against pH and ionic
strength changes, while heating of the dispersion results in NP
aggregation as a consequence of low solubility of PEG in water
at elevated temperatures.21,22 NPs transferred into water by
using poly(acrylic acid) polymer or tetramethylammonium
hydroxide surfactant are charged, whichmakes them very stable
against heating but quite sensitive to ionic strength and pH of
the medium. Additionally, polymers, silanes, and surfactants
used for phase transfer are expensive and sometimes toxic.
Hence, exploring and developing a novel, simple and low cost
route to transfer hydrophobic magnetic iron oxide NPs from
apolar organic solvent to aqueous medium is certainly required.
Our eﬀorts in phase transfer of monodisperse hydrophobic
iron oxide NPs have been directed toward eliminating all
organic capping ligands from the surface of the NPs. Speci-
cally, we considered the possibility that elimination of organic
capping ligands may be conveniently achieved through treat-
ment of hydrophobic nanocolloids by a base bath cleaning
solution, which is an inherent part of any chemical laboratory.
We envisioned that, in this way, water-dispersible iron oxide
NPs should be formed as a result of ionic stabilization.23 This
straightforward route oﬀers one principle advantage over a
traditional polymer and surfactant routes, namely, it produces a
nanocolloid free of organic coating, and thus results in a greater
content of magnetic material in the nal product. ToThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineunderstand the changes that the nanoparticles undergo during
base-bath-assisted phase transfer, we investigated the structure
and magnetic properties of the resultant water-dispersible
nanocolloids, which we detail in this communication.
OL-capped magnetite nanocolloid (entry OL-HT, Fig. S1a,
ESI†) was synthesized by hydrothermal method reported
elsewhere.24 As shown in Fig. 1a, the as-prepared nanocolloid
consists of highly crystalline NPs with an average particle
diameter of 10.5  5.2 nm with a 95.45% condence level, i.e.
2s. Treating this hydrophobic nanocolloid with KOH base
bath cleaning solution for 24 h at room temperature followed
by separation by centrifugation and purication by ethanol
provides a brown aqueous nanocolloid (entry OL-HT-BB,
Fig. S1b, ESI†) in nearly 70% isolated yield. High-angle
annular dark-eld scanning transmission electron micros-
copy (HAADF-STEM) images show that this phase-transfer
product consists of many highly crystalline NPs similar to
those in the initial OL-HT nanocolloid (Fig. 1b). Additionally,
no dramatic changes in particle size or shape are observed
with an average particle diameter of OL-HT-BB estimated to
be 11.1  5.2 nm. Notably, the NPs are not well separated
spatially from each other as in the case of OL-HT NPs,
which is most likely due to aggregation during the drying of
aqueous NP dispersion on the carbon-coated TEM grid.Fig. 1 Comparison of low-magniﬁcation, [110] high- and atomic-
resolution HAADF-STEM images together with the corresponding
structural models (Fe atoms ¼ yellow, O atoms ¼ red) for OL-HT (a, c
and e) and OL-HT-BB (b, d and f) nanocolloids. The indicated square
areas in (c) and (d) are shown enlarged in (e) and (f), respectively.
This journal is © The Royal Society of Chemistry 2015To test whether the atomic structure of the NPs is aﬀected
during phase transfer, we carried out a morphology character-
ization using atomic resolution STEM. Fig. 1b and c show a
comparison between the HAADF-STEM images of the NPs
before and aer phase transfer. These data conrm that the
atomic structures of the initial and the resultant NPs are
comparable. The NPs have cubic inverse-spinel structure type,
space group Fd3m (Fig. 1e and f). Notably, we cannot conclu-
sively distinguish between Fe3O4 and g-Fe2O3 iron oxide phases
using our atomic resolution TEM data, or even with electron
energy loss spectroscopy (EELS) studies.25 Specically, EELS
spectra from both OL-HT and OL-HT-BB NPs are extremely
similar and the changes in Fe L3/L2 ratio and in O proportion are
not signicant (Fig. S2, ESI†). Therefore, we conclude that Fe3O4
and g-Fe2O3 are indistinguishable by the used techniques. This is
most likely due to the isostructural nature of these two
compounds having similar cubic unit cell parameters (a¼ 8.396 A˚
for Fe3O4 and a ¼ 8.352 A˚ for g-Fe2O3), forming Fe3O4–g-Fe2O3
solid solutions.24
Next, we investigated the inuence of the developed phase-
transfer route on the structural properties of the resultant
iron oxide NPs. Powder X-ray diﬀraction (XRD) conrmed that
both OL-HT and OL-HT-BB samples have cubic inverse-spinel
structure (Fig. S3, ESI†). No remarkable changes are observed
aer phase transfer. Notably, we were not able to conclusively
distinguish between Fe3O4 and g-Fe2O3 using XRD, which is
consistent with the aforementioned electron microscopy study.
g-Fe2O3 and Fe3O4 have very similar crystal structures, and the
small size of the NPs results in very broad XRD peaks, rendering
phase-composition studies diﬃcult. In contrast to XRD, Raman
scattering can unambiguously detect the diﬀerent iron oxide
phases, because diﬀerent polymorphs show distinct Raman-
active phonon modes.26 The main diﬀerence between the
Raman spectra of Fe3O4 and g-Fe2O3 stems from the diﬀerent
position of the most intense A1g phononmodes.24 We compared
the ratio (R¼ I(666 cm1)/I(715 cm1)) of the intensity of the A1g
mode of Fe3O4 to the intensity of the A1g mode of g-Fe2O3. For
OL-HT NPs, R is 1.5, indicating the coexistence of both phases,
with Fe3O4 as the abundant one (Fig. S4a, ESI†). This is in good
agreement with our previous studies, wherein we determined
that the structure of hydrothermally-synthesized OL-HT NPs is
best understood as a Fe3O4–g-Fe2O3 solid solution.19 In contrast
to OL-HT, OL-HT-BB has a lower R value of 0.93 (Fig. S4b, ESI†).
These data suggest that base-bath-assisted phase transfer leads
to the slight oxidation of the initial Fe3O4–g-Fe2O3 solid solu-
tion NPs to one with large maghemite composition. We spec-
ulate that this oxidation within 24 h of the treatment is driven
by oxygen from air. It seems clear that the removal of the
protective OL capping ligands from the NPs results in direct
exposure of their surfaces to the oxidative base-bath conditions.
We employed vibrating samplemagnetometry (VSM) at room
temperature to investigate the magnetic eld dependence of
magnetization [M(H)] for the iron oxide NPs. The M(H) data in
Fig. 2 shows that both nanocolloids exhibit superparamagnetic
behaviour without any signature of coercivity, as manifested by
the lack of hysteresis loops. The saturation magnetization (Ms)
of OL-HT-BB is 72.7 emu g1, which is just slightly lower thanRSC Adv., 2015, 5, 47954–47958 | 47955
Fig. 2 Room-temperature M(H) plot for OL-HT and OL-HT-BB
nanocolloids.
Fig. 3 Comparison of BSA loading through physical adsorption on
OL-HT-BB NPs with a covalently bonded control OL-HT-COOH NPs
as reference, which indicates signiﬁcantly higher BSA immobilization in
the case of OL-HT-BB NPs (P < 0.05).
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View Article Onlinethat of the initial OL-HT (73.8 emu g1). These large Ms values
stem from the high crystallinity and increased particle size.19,24
The small decrease in Ms aer phase transfer correlates well
with the observed oxidation of Fe3O4–g-Fe2O3 OL-HT into
largely g-Fe2O3 OL-HT-BB, since bulk g-Fe2O3 (80 emu g
1)
exhibits lower Ms than bulk Fe3O4 (92 emu g
1).27 Nevertheless,
the Ms of hydrophilic OL-HT-BB obtained by our newly devel-
oped phase-transfer route is superior to that of other Fe3O4 or
Fe2O3 NPs synthesized by the majority of methods,28,29 and the
superparamagnetic state does not change with the phase
transfer.
Having investigated structural, microstructural, and
magnetic properties before and aer phase transfer, we further
probed NP capping with the aim of elucidating mechanistic
details of our phase-transfer protocol. Thermogravimetric and
diﬀerential scanning calorimetry analysis (TGA-DSC) of the
powdered OL-HT-BB demonstrates that the sample contains
only a small amount of organic phase, as shown by ca. 2%
weight loss between 300 and 750 C (Fig. S5, ESI†), the
temperature range of OL decomposition.19 Notably, this value is
signicantly lower compared to the theoretically calculated
ones of 9.6% and 18.3% assuming full OL coverage of 11.1 nm
iron oxide NPs (Fig. S6, ESI†), evidencing the loss of organic
phase. Signicant elimination of OL capping aer base-bath
treatment is also conrmed by Fourier transform infrared
spectroscopy (FTIR, Fig. S7, Table S1, ESI†). We presume that
the colloidal stability of OL-HT-BB results from the eﬀective
cleavage of the OL ligands by KOH from the NP surface in the
base bath followed by the formation of ionically-stabilized NPs
with negatively charged Fe–O surface species.23
We tested our hypothesis of the ionic stabilization by con-
ducting Zeta potential measurements at diﬀerent pH values.
OL-HT-BB displays negative Zeta potential of 89 mV at
pH 9, 10 mV in phosphate buﬀer pH 7.4, and +13 mV in MES
[(2-(N-morpholino)ethanesulfonic acid)] buﬀer pH 5.1. These
results corroborate that the mechanism of our convenient base-
bath-assisted phase transfer proceeds through the elimination
of the surface capping ligands followed by subsequent forma-
tion of negative-charge-surrounded iron oxide NPs.30 In water at
basic pH, the NPs exhibit electrostatic repulsions that render47956 | RSC Adv., 2015, 5, 47954–47958them colloidally stable (Fig. S1b, ESI†). Hence, as-prepared
aqueous nanocolloid is pH sensitive and has to be stored at
pH $ 8.
Aiming at employing magnetic OL-HT-BB for biomedical
applications, we examined the potential of our aqueous
nanocolloids for proteomic analysis.31 As a proof-of-concept,
we chose to study the immobilization of bovine serum
albumin (BSA) protein onto the magnetic NPs. For example,
crosslinked BSA-coated iron oxide contrast agents for MRI
visualization of intracranial glioma were realized with this
reasonably cheap and available protein.32 In addition, the
stability and biocompatibility of the NPs typically improve
when loaded with BSA.33
We expected our non-coated, charged OL-HT-BB NPs to be
suitable for eﬃcient anchoring of protein molecules, and
therefore, carried out BSA immobilization experiments. We
found that incubation of OL-HT-BB NPs in BSA solution for
3 h at 4 C (ESI†) led to protein loading of an average of 19 BSA
molecules per NP (Fig. 3). This value turned out to be slightly
lower than the theoretically estimated 27 BSA/NP assuming
monolayer coverage. To elucidate the eﬃciency of our loading
procedure, we also prepared BSA-bearing OL-HT NPs using
the known carbodiimide/N-hydroxysulfosuccinimide (EDC/
sulfo-NHS) method, where BSA is covalently bonded to the
NP surface (ESI†). We found that BSA loading using EDC/
sulfo-NHS method provides an average 8 BSA/NP (ESI†),
which is signicantly lower than in the case of OL-HT-BB
(Fig. 3).
To characterize BSA binding, we performed an FTIR study of
BSA, OL-HT-BB, and BSA-loaded OL-HT-BB samples lyophilized
from the respective aqueous dispersions (Fig. 4). The spectrum
of BSA-loaded OL-HT-BB features the characteristic amide I, II,
and III bands of BSA, as well as the Fe–O band for iron oxide
NPs, clearly conrming the presence of the protein on the NP
surface. We presume that BSA is physisorbed on the OL-HT-BB
NPs, most likely via Coulomb forces.34 Specically, incubation
of OL-HT-BB NPs in BSA solution is carried out in Millipore
water at pH 5.3 (ESI†). It is known that the isoelectric point ofThis journal is © The Royal Society of Chemistry 2015
Fig. 5 TEM images showing a series of control phase-transfer
experiments for monodisperse iron oxide NPs with sizes of 9.3  1.2
nm (a), 8.7  1.2 nm (b), 13.2  1.1 nm (c), 13.2  1.4 nm (d), 15.8  1.7
(e), and 14.8  1.7 nm (f) prepared by thermal decomposition of
Fe(OL)3. Left panels (a, c and e) demonstrate the initial hydrophobic
NPs, whereas right panels (b, d and f) show the respective NPs after
phase transfer to aqueous media using base-bath treatment. The
conﬁdence levels are 95.45%, i.e. 2s.
Fig. 4 Comparison of the FTIR spectra of lyophilized OL-HT-BB,
BSA-loaded OL-HT-BB and BSA (Table S1, ESI†).
This journal is © The Royal Society of Chemistry 2015
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View Article OnlineBSA is at pH ¼ 4.7,35,36 therefore at this slightly acidic pH of 5.3
the BSA molecules are negatively charged. In contrast, as shown
by the aforementioned Zeta potential measurements, the
OL-HT-BB NPs at pH 5.3 are positively charged. Consequently,
we propose that BSA-loaded iron oxide NPs are formed as a
result of electrostatic interactions.
Finally, to extend the use of our convenient phase-transfer
route to monodisperse magnetic NPs, we prepared a series of
iron oxide NPs using thermal decomposition of Fe(OL)3
complex (ESI†).9 Monodisperse hydrophobic NPs with average
diameters of 9.3  1.2 nm, 13.2  1.1 nm, and 15.8  1.7 nm
were synthesized and successfully transferred to aqueous
medium without apparent morphological or structural changes
(Fig. 5 and S8 (ESI†)). Obviously, our novel phase transfer can be
successfully employed to obtain aqueous monodisperse
magnetic nanocolloids. Hence, we expect this eﬃcient protocol
to nd broad application in phase transfer chemistry in the eld
of nanomedicine.
Conclusions
In summary, we have developed a novel convenient protocol
to transfer hydrophobic oleate-capped iron oxide NPs from
organic to aqueous phase. Our characterization data provide
general evidence of the eﬀective oleate-ligand removal
under base-bath conditions followed by formation of
ionically-stabilized NPs, rendering them dispersible in
aqueous medium. The outstanding physical adsorption of
protein by these hydrophilic NPs without the need for func-
tionalization highlights the potential of the system in sample
preparation for proteomics. This novel phase-transfer route
can be extended to obtain monodisperse aqueous nano-
colloids of various materials for further use in biomedical
applications.
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